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Over the last 40 years, little progress has been made in improving the treatment outcomes of 
pancreatic ductal adenocarcinoma (PDAC). The desmoplastic and hypo-vascular microenvironment of 
this cancer limits access to therapeutic strategies. Stellate cells, comprising the majority of stroma and 
secreting large amount of extracellular matrix (ECM), have been suggested to provide a supportive 
environment for pancreatic cancer whilst playing a suppressive role in cancer growth. In order to 
identify strategies capable of modulating pancreatic cancer stroma without promoting cancer growth, 
it is imperative to establish an in vitro human cancer model resembling the human cancer 
microenvironment.  
Conventional models of PDAC using 2D culture of human PDAC cells and mouse models have 
previously been useful to study PDAC biology. Unfortunately, the usage of such systems to screen 
potential therapeutic agents has not delivered significant improvements in the overall survival of 
patients with PDAC. 3D co-culture models of human PDAC cells, patient-derived stellate cells and ECM 
have been used to better recapitulate the human tumour microenvironment. Since mouse models 
and commercial matrices used in cancer models are expensive and variable between batches, it would 
be beneficial to explore other alternatives to reduce the cost and the variability of PDAC models. An 
inexpensive de-cellularized preparation termed Myogel can be produced in large quantities, providing 
a potential scaffold to recreate ECM in the human PDAC microenvironment. There are little data on 
using unmodified hyaluronic acid (HA), which is abundant in pancreatic cancer, to build the 3D co-
culture PDAC models. 
Yes-associated protein (YAP) is a transcriptional coactivator that can translocate between the 
cytoplasm and the nucleus. The expression and localisation of YAP is the key to YAP signalling, which 
functions to sense signals from external and internal changes in cells. Complex signalling networks 
have been elucidated that involve mechanisms of YAP signalling in the context of cancer. Cell 
junction/cell polarity, metabolic status, mechanical cues and G-protein-coupled receptors are 
regarded to affect YAP subcellular localisation, and thus its function. YAP signalling exerts significant 
impact on tumour initiation, progression, metastasis, malignancy and drug resistance in a number of 
cancers. YAP has been shown to position itself as an integral part in the crosstalk between various cell 
signalling pathways to promote cancer growth in solid tumour. Due to effects of the mechanical cues 
on YAP signalling, a realistic human PDAC model is required to recapitulate YAP signalling in the spatial 
manner. 
In the current study, an in vitro 3D fibrotic cancer model with human pancreatic cancer cells, ECM, 
and patient-derived stellate cells to recreate the human pancreatic cancer microenvironment in the 
liver and pancreas was established, suitable for high-throughput assay and examining YAP signalling.  
After identified that unmodified hyaluronic acid was biocompatible with cancer cells and could 
promote nuclear accumulation of YAP, mixing PDAC cells and stellate cells in a collagen I matrix with 
or without HA was performed, resulting in the formation of multiple cancer cells cores inside the 3D 
co-culture models that resemble the fibrotic cancer microenvironment in patients with advanced and 
metastatic PDAC. Dynamic YAP subcellular localisation is found in these 3D co-culture models of PDAC 
cells and stellate cells. Reduction of p53 expression correlates with YAP cytoplasmic localisation in 
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these 3D co-culture models of PDAC cells and stellate cells. Potential anti-cancer compounds 
Pseudopterosin A-D and Tylophorinine, derived from natural products, can reduce p53, Ki67 and YAP 
expression in these 3D co-culture models of PDAC cells and stellate cells. 
Future work could easily be built on choosing the high stellate cells to cancer cells ratio such as 5:1 or 
10:1 with HA and reduced collagen I to carry on refining the PDAC models. Imaging methods combining 
optical clearing with ethanol and BABB, Z-stack and Airyscan using the Zeiss LSM880 with a 10x 
objective lens are validated to be robust for future phenotypic analysis in thick cancer models with 
approximately 500 μm diameter without disturbing the samples, leading to higher efficiency 







ACE Automatic Component Extraction 
AJ  Adherens junction 
AMPK AMP-activated protein kinase  
APS Ammonium persulfate 
BABB  Benzyl alcohol: benzyl benzoate, 1:2 
BSA Bovine serum albumin 
CAFs Cancer-associated fibroblasts 
Cat. #  Catalogue number 
CDK Cyclin-dependent kinase 
CLSM Confocal laser scanning microscopy 
COL Collagen 
CTLA-4 Cytotoxic T lymphocyte-associated antigen - 4 
DAPI 4′,6-diamidino-2-phenylindole dihydrochloride 
DIC Differential interference contrast 
DMSO Dimethyl Sulfoxide 
EACA 6-aminocaproic acid  
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epithelial growth factor receptor  
EMT Epithelial to mesenchymal transition  
FAP Fibroblast activation protein 
FBS Fetal bovine serum 
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GEMMs Genetically engineered mouse models  
GPCRs G-protein-coupled receptors 
HA Hyaluronic acid 
HSCs Hepatic stellate cells 
KRAS Kirsten rat sarcoma oncogene homologue  
LATS1/2 Large Tumour Suppressor 1 and 2 kinases 
MDSCs Myeloid-derived suppressor cells 
MET Mesenchymal to epithelial transition 
MHCII Major histocompatibility class II  
miR MicroRNA 
MP Multiphoton 
MS/MS Tandem mass spectroscopy  
MST1/2 Mammalian Sterile 20-like 1 and 2 kinases  
Ocln Occludin  
P/S Penicillin and streptomycin 
PanIN Pancreatic intraepithelial neoplasia 
PBS Phosphate buffered saline 
PD-1 Programmed cell death protein - 1 
PDAC Pancreatic ductal adenocarcinoma  
PFA Paraformaldehyde 
PMSF Phenylmethylsulfonyl fluoride 
polyHEMA Poly(2-hydroxyethyl methacrylate) 
PSM Porcine skeletal muscle 
PsA-D Pseudopterosin A-D  
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PSCs Pancreatic stellate cells 
PSM Porcine skeletal muscle  
PVP Polyvinylpyrrolidone 
RIPA Radio-Immune Precipitation Assay 
SC Stellate cells 
SD standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SH3  Src homology domain 3 
SHH Sonic hedgehog (SHH)  
TAMs Tumour-associated macrophages 
TBS Tris Buffered Saline  
TBS-T Tris Buffered Saline and Tween® 20 
TEAD Transcription enhancer activator domain 
TEMED Tetramethylethylenediamine 
TGF-β Transforming growth factor- β 
TJ Tight junction  
TYLO Tylophorinine 
YAP  Yes-associated protein 
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Chapter 1. Introduction 
 
Cancer is a disease caused by abnormal cells growing in an uncontrollable way affecting all parts of 
human body, leading to multiple organ failures and ultimate death of the patients. Cancer cases are 
estimated to be over 14 million globally [Torre et al, 2015], posing a heavy burden on human society. 
Cancer is responsible for millions of deaths every year worldwide. As illustrated in Figure 1, the leading 
cause of cancer deaths are those involving cells of the lung, large intestine (colorectal), liver, breast, 
stomach (gastric), pancreas, oesophagus, prostate, uterus [Torre et al, 2015], most of which originate 
in epithelial cells and result in structures known as solid tumours. Research on these various epithelial-
derived cancers have facilitated a variety of preventative approaches and therapeutic treatments. With 
improvements in cancer care and a greater understanding of cancer biology, cancer death rates have 
been decreasing for many of these epithelial-derived cancers. In England and Wales, the 5-year survival 
rates for colorectal cancers have doubled since 1970, reaching nearly 60% in 2011. The 5-year survival 
rates for breast cancer, prostate cancer and melanoma have risen from 47.9-52.7%, 36.6-36.9%, 51.1-
52.3% in 1971-72 to 86.7%, 84.8-87.1%, 89-90.4% in 2010-11 [Quaresma et al, 2015]. Opposingly, 
improvements in these cancer management approaches have not had significant impact on improving 
















Figure 1. Global estimated cancer mortality by gender in 2012. 
The figure is adapted from Torre et al [Torre et al, 2015] with copyright permission from John Wiley and Sons. * 
Excluding non-melanoma skin cancers.  
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1.1 Background of pancreatic ductal adenocarcinoma (PDAC) 
 
Over 90% of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC). By 2020, the number of 
patients with PDAC is projected to exceed 420,000 worldwide with around 410,000 annual deaths 
[Neoptolemos et al, 2018]. PDAC is currently the fourth most common cause of death from cancer in 
Europe, estimating 128,000 deaths in 2018 [Ferlay et al, 2018]. The 5-year survival rate of patients 
diagnosed with PDAC has remained stable and is predicted to stay below 5 % for a long time [Siegel et 
al, 2015]. The median overall survival rate for patients with PDAC is currently 1–10 months worldwide 
[Hariharan et al, 2008]. The progression of ductal cells in the pancreas into aggressively proliferating 
PDAC and the dysregulation of cell signalling pathways associated with that conversion, especially 
those connecting yes-associated protein (YAP) signalling, will be reviewed. Studies to unravel the 
characteristics of this deadly disease and potential therapeutic strategies targeting YAP signalling are 
proposed in this chapter. 
 
1.1.1 Development of PDAC 
 
Due to a lack of reliable detection methods at early stage, about 80% of patients diagnosed with PDAC 
present locally advanced and metastatic disease [GM et al, 2018; Lau et al, 2017; Neoptolemos et al, 
2018; Salgado et al, 2018; Uccello et al, 2018]. Cellular and molecular changes in the pathogenesis of 
PDAC present a unique pancreatic cancer microenvironment, which are depicted in Figure 2 [Khan et 
al, 2017]. At the onset of pancreatic intraepithelial neoplasia (PanIN), pancreatic ductal cells become 
enlarged and the stroma begins to become modified in its composition of cells and collagen. As PanIN 
progresses, the size and the number of neoplastic cells increase while more stromal cells are recruited 
to the environment. Over time this environment loses its ability to suppress the growth of the 
hypertrophied epithelial cells and a transition to PDAC occurs. When PDAC develops, the pancreatic 
ductal cell transforms into a highly proliferative and invasive cell, gaining the ability to evade the 
immune-surveillance and tuning the stromal cells to be in favour of promoting tumour growth. 
Pancreatic cancer cells are the centre of a PDAC tumour. This not only means they are the origin of sins 
in the microenvironment but also the way they become surrounded by other components that position 
them at the central core in the tumour microenvironment (or multiple cores in the cancer tissue). 
Genetic and metabolic alterations occur in pancreatic cancer cells that enable them to evolve and 
survive in human body without limitations to their ability to divide. Pancreatic cancer cells are often 
positively stained with cell protein markers such as carcinoembryonic antigen (CEA), carbohydrate 
antigen (CA) 19-9, cancer antigen (CA) 125, SMAD4, cytokeratins, mucins and p53 [Ansari et al, 2016; 
Boj et al, 2015; Pang et al, 2015; Wormann et al, 2016]. Interestingly, only 10% of cells within pancreatic 
cancer tumour are pancreatic cancer cells [Neesse et al, 2011], indicating the immense detrimental 
impact of a few pancreatic cancer cells on human body. Compared to primary tumours in the pancreas 
site, more cancer cells are detected at metastatic site in the liver of patients with PDAC [Whatcott et 
al, 2015]; however, the exact percentage of cancer cell regions in the liver has not yet been confirmed 
in large cohort of patients with metastatic PDAC. 
In the PDAC microenvironment where cancer cells grow and evolve, pancreatic stellate cells (PSCs), a 
group of prominent stromal cells expression αSMA, are found to comprise as much as 80-90% of the 
pancreatic tumour, secreting large amount of extracellular matrix (ECM) such as collagen I, collagen IV, 
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fibronectin and laminins, as well as cytokines and chemokines to provide a supportive environment for 
pancreatic cancer progression [Erkan et al, 2008]. Moreover, the dense cell-cell and cell-matrix 
environments resulting from interactions between cancer cells and stellate cells create a barrier 
surrounding cancer cells to protect cancer cells from anti-cancer treatments and immune response 
[Diwakarla et al, 2017; Djurec et al, 2018]. Nonetheless, a contradictory role of PSCs and the fibrotic 
environment in pancreatic cancer microenvironment have been proposed, indicating that PSCs and 
fibrosis can serve to suppress tumour progression [Erkan, 2013; Ozdemir et al, 2014; Rhim et al, 2014]. 
This hypothesis is derived from the data that elimination of stromal components causes unexpected 
acceleration of pancreatic cancer growth [Ohuchida et al, 2004; Ozdemir et al, 2014; Rhim et al, 2014]. 
Early evidence could be traced back to a study where enhanced invasion of pancreatic cancer cells was 
observed after they were co-cultured with irradiated PSCs from a patient in vitro [Ohuchida et al, 2004], 
which raised the question about the undesired tumour-promoting effect that could potentially offset 
the beneficial outcomes of destroying the tumour stroma using radiotherapy. Recent evidences have 
indicated that a shorter survival due to an accelerated cancer progression in genetic modified mice 
with pancreatic cancer was observed after destroying the tumour stroma in two independent research 
groups [Ozdemir et al, 2014; Rhim et al, 2014]. Also, PDAC patients with low expression of stromal cell 
marker (αSMA) correlated with poorer overall survival compared to the ones with high expression of 
αSMA [Ozdemir et al, 2014] and high collagen deposition in clinical specimen was associated with 
longer survival [Erkan et al, 2008]. Hence, more prudent experimental designs to distinguish tumour-
promoting PSCs from tumour-suppressive PSCs and understand the role of fibrosis in the development 
of PDAC are required. 
Significantly, the immune cells that infiltrate PDAC tumours express immunosuppressive genotypes 
and phenotypes [Bailey et al, 2016; Seo et al, 2017]. Expression of genes related to regulatory T cells, 
overexpression of cytotoxic T lymphocyte-associated antigen (CTLA)-4, programmed cell death protein 
(PD)-1, and mutations of Toll-like receptors have been identified in PDAC tumours through genomic 
analysis [Bailey et al, 2016]. The number of T cells is markedly increased in tumours compared to those 
in the blood of patients with PDAC, with a great portion of cells expressing immune inhibitory markers 
[Seo et al, 2017]. Therefore, immune cells that might otherwise maintain a check on nascent cancerous 



























Figure 2. Histopathological and molecular changes in the pathogenesis of PDAC.  
The figure is adapted from Khan et al [Khan et al, 2017], which is distributed under the terms and conditions of 
the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). At the onset 
of pancreatic intraepithelial neoplasia (PanIN), pancreatic ductal cells become enlarged and the stroma begins to 
become modified in its composition of cells and extracellular matrix (ECM). As PanIN progresses, the size and the 
number of neoplastic cells increase while more stromal cells such as pancreatic stellate cells (PSCs) are recruited 
to the environment. When PDAC develops, the pancreatic ductal cell transforms into a highly proliferative and 
invasive cell, pancreatic cancer (PC) cell. Kirsten rat sarcoma oncogene homologue (KRAS) mutation, NOTCH and 
WNT/β-catenin signalling pathway dysregulation, epithelial growth factor receptor (EGFR), sonic hedgehog (SHH) 
protein overexpression, and upregulation of microRNA-21 (miR-21), miR-155, miR-182, miR-296-5p, miR-196b 
have all been associated with driving the oncogenic conversion associated with PanIN-1A to metastatic PDAC 
phenotype changes. During these transitions there are changes such as increased collagen, fibronectin, and 
hyaluronic acid present in the local environment and mutations in the p16/cyclin-dependent kinase (CDK)N2A 
gene, p53, SMAD4/DPC4, and BRCA1/2. Myeloid-derived suppressor cells (MDSCs) are also found in the PDAC 
environment to promote cancer immune tolerance. YAP (yes-associated protein) signalling has been linked to 







1.1.2 Dysregulation of cell signalling pathways in PDAC 
 
There are numerous abnormal alterations that can occur at the molecular level during the development 
of the PDAC. Kirsten rat sarcoma oncogene homologue (KRAS) mutation, NOTCH and WNT/β-catenin 
signalling pathway dysregulation, epithelial growth factor receptor (EGFR), sonic hedgehog (SHH) 
protein overexpression, and upregulation of microRNA-21 (miR-21), miR-155, miR-182, miR-296-5p, 
miR-196b have all been associated with driving the oncogenic conversion associated with PanIN-1A to 
metastatic PDAC phenotype changes [Khan et al, 2017]. During these transitions there are changes 
such as increased collagen, fibronectin, and hyaluronic acid present in the local environment and 
mutations in the p16/cyclin-dependent kinase (CDK)N2A gene, p53, SMAD4/DPC4, and BRCA1/2 
(Figure2) [Khan et al, 2017]. 
KRAS mutation, transforming growth factor- β (TGF-β)/SMAD4 pathway inactivation, NOTCH and 
WNT/β-catenin signalling pathway dysregulation and EGFR overexpression send continue growth-
promoting signals in cancer cells [Garrido-Laguna et al, 2015; Ruess et al, 2017]. Inactivation of 
CDKN2A/p16 causes cancer cells to lose the ability to suppress the cell cycle, resulting in enhanced 
proliferation in cancer cells [Ruess et al, 2017; Weinberg et al, 2015]. BRCA1/2 inactivation causes 
defective DNA damage repair responses in cancer cells, leading to an inability to correct gene 
malfunction [Garrido-Laguna et al, 2015; Greer et al, 2007]. Pancreatic cancer cells can produce 
excessive levels of SHH that activate pancreatic stellate cells, which in turn support the malignancy of 
cancer cells [Li et al, 2014].  
ECM constituents can have potent effects on cell signalling events within PDAC cells, which in turn 
regulate their proliferation capacity and susceptibility to chemotherapeutics. Collagens activate SMAD 
and the focal adhesion kinase pathway to disrupt E-cadherin/ β-catenin complexes, leading to EMT and 
tumour proliferation [Veenstra et al, 2018]. Fibronectin interacts with integrins to promote cell survival 
[Topalovski et al, 2016]. Fibronectin and laminins are reported to protect cancer against apoptotic 
death [Topalovski et al, 2016; Veenstra et al, 2018]. Abundant hyaluronic acid, a glycosaminoglycan, 
are present in the pancreatic cancer microenvironment and thus increase tumour interstitial fluid 
pressure to impair local drug delivery. Also, HA binds to the surface receptor EGRF and CD44, which 
are overexpressed in pancreatic cancer cells and contributes to cell proliferation and motility [Chen et 
al, 2018a; Kultti et al, 2012].  
In recent years, yes-associated protein (YAP) signalling has drawn attention due to its potential 
crosstalk between various cell signalling pathways [Rozengurt et al, 2018; Zhang et al, 2015]. YAP 






1.2 Laboratory/Biological Models for pancreatic cancer research 
 
Over the last 40 years, little progress has been made in improving PDAC outcomes. The desmoplastic 
and hypo-vascular microenvironment of this cancer limits access to therapeutic strategies. Stellate 
cells, comprising the majority of stroma and secreting large amount of extracellular matrix (ECM), have 
been suggested to provide a supportive environment for pancreatic cancer cells whilst certain subtypes 
of them can play a suppressive role in cancer growth. 2D culture models and animal models have been 
useful to study pancreatic cancer biology; however, they do not recapitulate the highly fibrotic 
properties in human pancreatic cancer microenvironment in late-stage of PDAC development. In order 
to identify strategies capable of modulating pancreatic cancer stroma without promoting cancer 
growth, it is imperative to establish an in vitro cancer model resembling the human PDAC 
microenvironment. The following sections will discuss the conventional and novel models in cancer 
research, focusing on pancreatic cancer. 
 
1.2.1 2D culture (mono-culture and co-culture) 
 
AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs 766T, MIA PaCa-2, PANC-1, SU.86.86, 
SUIT-2, SW 1990, and T3M4 are well-characterized human pancreatic cancer cell lines that have been 
used in a wide range of studies testing anti-cancer reagents in a 2D format [Deer et al, 2010; Iwamura 
et al, 1987; Missiaglia et al, 2004]. The majority of these research studies have examined abnormal 
cellular signalling events and explored the reduction or overexpression of certain proteins associated 
with uncontrolled proliferation [Deer et al, 2010; Missiaglia et al, 2004]. While 2D culture can be easily 
applied to high-throughput assay in a 96-well or 384-well plate, cancer cells are not grown in a 3D 
architecture as they are in patients with PDAC. Moreover, the cell-cell contact and cell-matrix contact 
that cancer cells are exposed to cannot be readily recreated in a 2D culture model, which might alter 
the gene expression and cell signalling compared to the cells inside patients. More importantly, in 
terms of mimicking how therapeutic strategies reach cancer cells, 2D culture fails to recapitulate 
multiple barriers in a tumour and thereby produce limited data on the effectiveness and efficiency of 
the penetration of treatments in a 3D environment with drug delivery obstacles. 
Alterations after cancer cells are grown in 3D culture compared to 2D culture have been excellently 
reviewed by Hoarau-Vechot et al and Yamada et al [Hoarau-Vechot et al, 2018; Yamada et al, 2007]. 
Cell proliferation and growth, cell polarity and tumour progression, migration and response to 
therapies are the main focus in those reviews. There are three key issues related to the improvement 
of pancreatic cancer treatment we would like to highlight using the literatures in pancreatic cancer 
research. 
Firstly, targeting cancer stem cells is crucial for long-term survival of patients because cancer stem cells 
are the leading cause of resistance to therapy and relapse in patients. Therefore, only models that 
recapitulate this phenomenon will facilitate the improvement in therapeutic strategies to eliminate 
cancer stem cells in the tumour microenvironment. 3D cultures are regarded to promote the stemness 
of cancer cell lines to a greater extent than 2D cultures [Hoarau-Vechot et al, 2018]. For instance, the 
ratio of cells in the whole cell populations expressing the stem cell marker CD44 was markedly 
increased from 40.8% in a 2D pancreatic cancer model to 72.4% in a 3D pancreatic cancer model [Yeon 
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et al, 2013]. Meanwhile, the ratio of cells with triple positive stem cell markers CD44, CD24 and 
epithelial specific antigen (ESA) in 3D pancreatic cancer models was twice as many as the one in 2D 
pancreatic cancer models [Yeon et al, 2013].  
Secondly, there are marked difference in metabolism-associated genes, apoptosis-related genes, 
chemoresistance-related genes, ECM genes, and miRNA profiles between 2D and 3D culture models 
[Yamada et al, 2007]. Lactate accumulation in the culture medium, expression of glucose transporter 1 
(GLUT1) and lactate dehydrogenase (LDHA) were higher in 3D than 2D [Longati et al, 2013]. Expression 
of miRNAs miR-21 and miR-335 that cause chemoresistance was elevated in 3D culture persistently 
compared to a decrease trend in 2D after cultured for 4 days [Longati et al, 2013]. Another miRNAs 
related to gemcitabine resistance in pancreatic cancer, miR-34 family and miR-221, were also 
upregulated in 3D culture compared with 2D culture [Yeon et al, 2013]. mRNA expression of relevant 
genes such as COL1A1 (collagen I), COL6A1 (collagen VI), FN1 (fibronectin I), and LUM (lumican) was 
increased in 3D compared to 2D [Longati et al, 2013]. Elevation of genes contributing to anti-apoptosis 
in cancel cells, such as Bcl-2, Bcl-x, c-IAP-1, and c-IAP-2, were detected in 3D pancreatic cancel models 
but not in 2D models [Tai et al, 2014].  
Thirdly, numerous studies have provided extensive evidences that higher concentration of anti-cancer 
agents are required to inhibit the proliferation and growth of cancer cells in 3D culture than 2D culture 
[Hoarau-Vechot et al, 2018]. For instance, the IC50 of gemcitabine and paclitaxel were significantly 
increased at 32-fold and 14-fold respectively for 3D pancreatic cancer models compared to 2D 
pancreatic cancer models [Tai et al, 2014]. Cell viability after treatment with a number of anti-cancer 
agents has been compared in 2D and 3D culture, as listed in Table 1 [Longati et al, 2013].  
Co-culture of pancreatic cancer cell lines with fibroblasts directly in 2D illustrated changes in signalling 
and proliferation in these pancreatic cancer cells [Fujita et al, 2009]. Pancreatic cancer cells were co-
cultured with pancreatic stellate cells (PSCs) directly and indirectly, exhibiting increased proliferative 
activity and activation of Notch signalling pathway in presence of PSCs [Fujita et al, 2009]. Of note, the 
PSCs are tumour stromal cells considered to be subjected to contact inhibitory effect in 2D culture; 
however, cancer cells can overcome contact inhibition in 2D culture [Hoarau-Vechot et al, 2018]. 
Whether growth rates of distinct cell types in the co-culture models in 2D are realistic to the ones in 













Table 1. Differential effects of anti-cancer agents on cell viability in 2D and 3D cultures. 
The table is adapted from Longati et al [Longati et al, 2013], which is distributed under the terms and conditions 

















1.2.2 Animal models of PDAC 
 
Animal models are frequently used to establish a 3D cancer model that can recreate certain aspects of 
the microenvironment in solid tumours observed in patients. Commonly used animal models for PDAC 
research can be divided into three categories: cell-line xenografts, patient-derived xenografts, and 
genetically engineered mouse models.  
Cell line xenograft models typically allow human pancreatic cancer cells to be propagated within 
immunocompromised (nude) mice. This model format provides an environment for cancer cells to 
grow in 3D organization, but the other cells within the tumours that are generated are of mouse, and 
not human, origin. For ease of xenograft generation and accessibility to growing tumours for analysis, 
human PDAC cells are injected in a subcutaneous site, commonly into the flank region of the mouse 
[Jiang et al, 2018]. In the case of PDAC, such a xenograft model does not represent the local 
environment of the pancreas where this cancer arises nor does it represent liver tissue that is the one 
of the primary sites of metastasis. Even after implanting various PDAC cell lines into the head of the 
pancreas in nude mice, the highly desmoplastic environment and metastatic sites are rarely seen 
[Logsdon et al, 2015], demonstrating that creating a xenograft PDAC model in nude mice is not readily 
possible. In order to induce a stroma that is characteristic of PDAC tumours, human pancreatic stellate 
cells can be injected together with cancer cell lines, resulting in a slight improvement in creating a more 
realistic tumour environment [Jiang et al, 2018]. However, species differences and a lack of tissue 
density in the subcutaneous space limit the ability of these models to create a realistic PDAC 
microenvironment, limiting this approach as a useful model to predict clinical benefit of therapeutic 
agents and methods.  
Patient-derived xenograft mouse models can also be established with fractions of cancer tissue in the 
subcutaneous space, using the same nude mice approach as cell line xenografts. Although the exact 
distance from the head of the pancreas is unknown, tumours retain similar gene patterns and stromal 
features as the original ones in patients after growth in nude mice as explants [Logsdon et al, 2015]. 
Introduction of human immune cells into these patient-derived xenograft models has also been 
attempted to restore, in part, the complex set of immunological events occurring within PDAC tumours 
[Logsdon et al, 2015]. However, the high cost for maintenance of such mouse models and the genetic 
differences in the cancer microenvironment still restrict the application of patient-derived xenograft 
mouse models as a tool to predict successful clinical translation of therapeutic agents and methods. 
Genetically engineered mouse models (GEMMs) are useful to precisely mimic gene alterations that 
occur in human PDAC cells, providing a tool to explore targeted therapies in vivo. GEMMs with KRAS 
mutation have been successfully generated in PDAC mice, which result in similar metastatic and 
histological patterns as patients with PDAC [Logsdon et al, 2015]. However, some gene changes, such 
as TP53, in GEMMs do not always match the situation in patients and the development of PDAC 
tumours is relatively faster in GEMMs than that observed in patients [Feigin et al, 2016; Gopinathan et 
al, 2015]. Again genetic discrepancies between species and high cost of such complex and labour-
intensive mouse models urge the need to establish other PDAC models. 
As noted above, there are substantial limitations for current mice models to adequately examine the 
effect of potential therapeutic agents and to predict outcomes in patients. While some of these models 
are lengthy and costly in their efforts to align with PDAC tumours, there remain still striking genetic 
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differences from human. Nevertheless, some of these models continue to play an important role in the 
evaluation of novel therapies in pre-clinical studies. 
 
1.2.3 3D culture (mono-culture and co-culture) 
 
There are numerous review articles summarizing how to establish 3D culture of cancer models 
[Friedrich et al, 2007; Hoarau-Vechot et al, 2018; Kapalczynska et al, 2018; LaBarbera et al, 2012]. The 
eight practical methods below are derived from those reviews, highlighting the past, the presence and 
the emerging trend of 3D culture establishments and potential use in high-throughput screening. 
1) 3D culture in spinner flasks/bioreactors 
The earliest report on 3D culture of cancer models was published in 1970 by Sutherland et al, who grew 
spheroids in matrix-free medium to mimic lung tumour and colorectal tumour in spinner flasks [Inch et 
al, 1970]. Since then, numerous studies have conducted in spinner flasks, roller tubes, rotating vessels 
(bioreactors) where cells are subjected to a swirling force, so as to prevent cells attaching to the surface 
of the culture vessels and promote cell-cell aggregates in suspension as shown in Figure 3 [Friedrich et 
al, 2007]. One of the major drawbacks that render this approach less suitable for high-throughput assay 
is the transferring steps where extra efforts are needed to transfer the spheroids from the flasks or 
bioreactors into the 96-well or 384-well plates, limiting the efficiency. In recent year, a novel bioreactor 







Figure 3. 3D culture in spinner flasks and bioreactors. 
The figure is adapted from Friedrich et al [Friedrich et al, 2007] with copyright permission from Taylor & Francis. 
Cells are subjected to a swirling force to prevent cells settle to the bottom and promote cell-cell aggregates in 
suspension in spinner flasks, roller tubes, rotating vessels (bioreactors). 
 
2) 3D culture with gel-like substances/scaffold: agarose, Matrigel®, collagen, silk, alginate, hyaluronic 
acid, methylcellulose 
In essence, the goal of 3D culture is to reduce odds of cell-surface attachment to zero because cells 
grown in vitro with a low density culture medium have the tendency to settle to the bottom surface of 
the culture vessels due to gravity. Another approach to counteract gravity was introduced by Yuhas JM 
et al in 1977 [Yuhas et al, 1977]. The method simply involved gel-like substances, agarose, to create 
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either a viscous environment or a layer between cells and the bottom surface of the culture vessels, 
preventing cells adhering to the surface. Nowadays, commonly used gel-like substances include 
naturally derived hydrogels such as Matrigel®, collagen, alginate, and fibrin, synthetic and some semi-
synthetic hydrogels with a combination of synthetic and natural polymers such as hyaluronic acid and 
methylcellulose [Caliari et al, 2016; Highley et al, 2016; Maritan et al, 2017]. Most of methods to build 
3D cancer models with cancer cells, fibroblasts and immune cells could be summarized as either 
embedding cells in gel-like substances or seeding cells on top of the solidified gel (Figure 4) [Hoarau-
Vechot et al, 2018]. Most of the gel-like substances are also naturally-occurring components in tumour 
microenvironment in patients, such as collagen, fibronectin, hyaluronic acid and laminins, contributing 
to tumorigenicity. Some of the gel-like substances such as agarose, alginate, silk and methylcellulose 
are not present in the tumour microenvironment but could increase the viscosity of the culture 
environment and serve as scaffolds for a 3D architecture [Gopinathan et al, 2018]. Naturally-occurring 
gel-like substances that present in human tumour environment, the biomaterials derived from non-
mammal species, and the synthetic hydrogels have advantages and limitations. For instance, naturally-
occurring gel-like substances including collagen, fibronectin, and laminins are the best materials to 
mimic the cell-matrix interactions that determine the genotypes and phenotypes of the cancer cells. 
However, they are usually extracted from animals, leading to batch-to-batch difference and relative 
high cost that hamper the standardization of the methods across different labs. The biomaterials 
derived from non-mammal species and the synthetic hydrogels are more consistent between batches 
than naturally-occurring gel-like substances, making them ideal for standardization. However, it is 
uncertain that whether they could pose changes to the genotypes and phenotypes of cancer cells that 






Figure 4. Building 3D culture with gel-like substances/hydrogels. 
The figure is adapted from Hoarau-Vechot et al [Hoarau-Vechot et al, 2018], which is distributed under the terms 
and conditions of the Creative Commons Attribution (CC BY) license 
(http://creativecommons.org/licenses/by/4.0/). Most of 3D culture methods to grow cancer cells, fibroblasts and 
immune cells could be summarized as either embedding cells in gel-like substances or seeding the cells on top of 
the solidified gel. 
 
3) 3D culture in a hanging drop format 
The pioneers of 3D culture using a hanging drop format are Harrison and Carrel, who reported culturing 
the 3D neutron cells in 1910-1911 [Carrel et al, 1911; Millet et al, 2012]. As shown in Figure 5A, the 
idea of a hanging drop format is to utilize surface tension to hang microliters of cell suspension (20-40 
µL) onto the lid of culture dishes or special device inside cell culture vessels so that aggregation of cells 
12 
 
occurs at the tip of a droplet to form 3D spheroids. Traditional hanging drop method involves 
transferring the spheroids on the lid to each well of 96-well plates, which is labour-intensive to the 
operator (Figure 5B). Commercially Hanging Drop plates markedly increase the efficiency but also the 
cost of establishment of the models for high-throughput assay. In our lab, we have cultured 3D 
pancreatic cancer spheroids in a hanging drop format using droplets on the lid of a dish (Figure 5B) and 
commercialized GravityPLUSTM HangingDrop Plates (Figure 5C), with the latter resulting in shorter 
experimental time. 
 





Figure 5. 3D culture in a hanging drop format. 
Aggregation of cells to form 3D spheroids occurs at the tip of a droplet after hanging microliters of cell suspension 
(20-40 µL) onto the lid of culture dishes or special device inside cell culture vessels. A. The figure is adapted from 
Friedrich et al [Friedrich et al, 2007] with permission from Taylor & Francis. B. Hanging drops in a culture dish. C. 
Diagram and figure of the GravityPLUSTM HangingDrop Plates from www.perkinelmer.co.uk. 
 
4) 3D culture in low-attachment plates with centrifugation 
Low-attachment 96-well plates with centrifugation are another commonly used approach to establish 
3D culture models. There are a number of ways to make the low-attachment plates. Gel-like substances 
such as agarose, collagen I and Matrigel® or poly(2-hydroxyethyl methacrylate) (polyHEMA) can be 
used to coat the growth surface of the microplates. Commercial low-attachment plates are also 
available. The centrifugation step facilitates cell aggregation to form spheroids with or without mixing 
with gel-like substances. This method has been widely used in various labs. For example, single 
spheroid in each well of 96-well plates using mixture of cancer cells with Matrigel® after centrifugation 
has been generated to analyse cell proliferation, invasion and test toxicity of agents [Ivascu et al, 2006; 
Li et al, 2011; Sperlich et al, 2018]. Agarose-coated microtiter plates were used to perform spheroid-
based drug screen on the basis of the NCI-DTP 60-cell line screen [Friedrich et al, 2009]. Most of the 
studies required 3-4 days for the cells to form an acceptable spheroid structure. Recently, pancreatic 
cancer spheroids were reported to be established 24 hours after centrifugation, which could speed up 






5) 3D culture in micropatterning 
As seen in Figure 6, without using 96-well low-attachment microplates or the gel-like matrix, large-
scale uniform 3D cancer spheroids, ranging from 150 μm in diameter [Hirschhaeuser et al, 2010] to 700 
μm [Yeon et al, 2013], can be formed in identical microwells printed by micropatterning. 
Micropatterning is a technology involving the poly(dimethylsiloxane) thin film printing to develop an 
alternative material surface for cells suspended in normal cell culture medium to adhere to each other 
without adhering to the surface. The material can be printed as a new microplate [Yeon et al, 2013] or 
as a membrane that can be inserted into 6-well plates [Hirschhaeuser et al, 2010]. Using the new 
microplates printed by micropatterning, doxorubicin and gemcitabine have been tested in 3D 
pancreatic cancer spheroids [Yeon et al, 2013]. The next step for the development of this technology 
is to determine whether it will be adapted to a large number of labs and commercialized into new 






Figure 6. 3D culture in micropatterning. 
The figure is adapted from Hirschhaeuser et al [Hirschhaeuser et al, 2010] with permission from Elsevier. 
Micropatterning is a technology involving poly(dimethylsiloxane) thin film printing to develop an alternative 
material surface for cells suspended in normal cell culture medium to adhere to each other without adhering to 
the surface.  
 
6) 3D culture using magnetic levitation  
Another growing trend to establish 3D culture is using magnetic levitation, which has been developed 
into products to market. This technology requires incubation of cancer cells with standardized gold and 
iron oxide nanoparticles and cell-adhesive peptide prior to assembling the spheroids [Souza et al, 
2010]. After cells are magnetized, aggregation of cells to form spheroids is aided by magnetic attraction 
as presented in Figure 7 [Leonard et al, 2016]. The materials have been validated to be biocompatible 
with cancer cells and fibroblasts; several types of cancer spheroids, e.g., glioblastoma, breast cancer, 
lung cancer, and colorectal cancer, are formed and used to perform anticancer drug testing after 
magnetic levitation [Bumpers et al, 2015; Haisler et al, 2013; Jaganathan et al, 2014; Leonard et al, 
2016; Souza et al, 2010; Turker et al, 2018]. 3D culture established by magnetic levitation could be used 
for high-throughput screening because of the availability of matching commercialized 96-well plates; 
however, the total cost of anti-cancer drug screening will be increased [Haisler et al, 2013]. Co-culture 
models with cancer cells and fibroblasts by magnetic levitation have illustrated the layers of cancer 
cells formed at the periphery of the co-culture spheroids, opposite to the situation where layers of 
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fibroblasts are formed outside the cancer cells core in human tumour microenvironment [Leonard et 






Figure 7. 3D culture using magnetic levitation. 
Schematic presentation is adapted from Leonard et al [Leonard et al, 2016] with permission from Springer Nature. 
After cells are magnetized, aggregation of cells to form spheroids is aided by magnetic attraction. 
 
7) 3D culture using bio-printing 
In recent years, efforts are undertaken to develop bio-printing, a technique based on machinery and 
computer programming, to build 3D culture models in an accurate, defined, consistent, fast and precise 
manner. Similar to embedding cells in gel-like material, cancer cells, fibroblasts, immune cells and ECM, 
the major components in the cancer microenvironment, are mixed with various approaches and 
spatially dispensed in a microscale within seconds, aided by state-of-art equipment [Zhang et al, 2016]. 
Another fascinating aspect of bio-printing is the capability to construct the vascularity in tumours. A 3D 
glioblastoma model with vascular niche [Knowlton et al, 2015], a 3D breast cancer co-culture model 
with cancer cells and macrophage [Knowlton et al, 2015], a 3D ovarian cancer co-culture model with 
cancer cells and fibroblasts [Xu et al, 2011] have been successfully established, opening brand new 
door for optimising 3D culture of human cancer models. Although there is limited data reporting 
building 3D culture models by bio-printing in 96-well plates to perform high-throughput anti-cancer 
agents testing, we are positive that it will be soon achievable. Nevertheless, as the issue accompany 
the development of almost every new technology, the cost of bio-printing has been relatively too high 








8) 3D culture using microfluidics 
Microfluidic methods contain a sophisticate chip device with micro-chambers or micro-channels where 
the cells are seeded by control pressure with injection or dielectrophoretic forces [Beer et al, 2017]. 
Dielectrophoresis is a phenomenon where forces in a non-uniform electric field can be exerted on 
particles including living cells [Beer et al, 2017]. This technology allows improved mixing with solutes 
and drugs in a 3D format and a more accurate way to mimic diffusion of drugs in 3D. Some research 
groups have developed self-made chips [Lee et al, 2018a; Patra et al, 2016]. The HepaChip®, the size of 
which is similar to the microscope slide (25 mm x 76mm x 1mm), is well-established and available on 
the market [Beer et al, 2017; Hagmeyer et al, 2014]. A self-made micro-channel chip has been used to 
establish 3D pancreatic cancer models separating pancreatic cancer cells with collagen I in one channel 
from stellate cells with collagen I in another channel, which lacked the direct cell-cell contact and 
interaction of the receptors on cancer cells with stellate cells [Lee et al, 2018a]. HepaChip® has been 
used to build a viable 3D pancreatic cancer mono-culture model with only pancreatic cancer cell lines 
and test the sensitivity of cisplatin in the models [Beer et al, 2017]. The microfluidic method has not 
been standardized across different labs so the future application in high-throughput screening needs 
further investigation, especially in the context of large-scale formation of hundreds of spheroids within 










Figure 8. 3D culture using microfluidics. 
A-C. The figure is adapted from Beer et al [Beer et al, 2017], illustrating the commercialized microfluidics, 
HepaChip®. D. The figure is adapted from Patra et al [Patra et al, 2016], illustrating the self-made microfluidics. 






In summary, growing pancreatic cancer cell lines in 3D cultures has been described in a number of 
studies. These approaches have used a variety of strategies that have included using centrifugation in 
low-attachment plates coated with polyHEMA [Phung et al, 2011], hydrogels [Tibbitt et al, 2009], or 
agarose-containing scaffold-free medium without ECM [Diep et al, 2012], hanging-drop plates 
containing scaffold-free medium without ECM [Tung et al, 2011], mixing cells with methylcellulose 
[Ware et al, 2016], and growing cells on top of animal-derived ECM containing collagen or Matrigel or 
both [Baker et al, 2016; Coleman et al, 2014b]. Co-cultures of pancreatic cancer cell lines with stellate 
cells by direct mixing has also been employed in similar 3D cultures [Coleman et al, 2014b]. 
Methylcellulose facilitates formation of 3D co-culture models with mixture of PANC-1, AsPc-1, BxPC-3, 
Capan-1 and MIA PaCa-2 cells with patient-derived pancreatic stellate cells [Ware et al, 2016]. In spite 
of the abundancy of HA in pancreatic cancer, only a few studies have included HA in a 3D model, mostly 
where there is an unnatural chemical cross-linked form of HA such as thiol-modified hyaluronic acid 
[Sherman et al, 2017]. An approach using unmodified HA would add value to a 3D pancreatic cancer 
models by optimising HA conditions in vitro.  
 
1.2.4 Patient-derived organoids 
 
A model using patient-derived cancer cells and stromal cells, termed organoids, has become common-
place in pancreatic cancer research as more and more papers published since 2014 have used this 
approach. Compared to animal models, organoids can potentially provide a more realistic model to 
recreate cellular composition and ECM components that are particularly relevant to the unique 
features of pancreatic cancer and the microenvironment of PDAC tumours observed in patients, with 
patient-derived tissue and rodent-derived ECM components being used by many research groups [Boj 
et al, 2015; Koikawa et al, 2018; Seino et al, 2018]. Immune cells can also incorporated into these 
models [Tsai et al, 2018]. Most studies still involved transplantation of organoids into mice to study the 
properties of cancer cells [Boj et al, 2015; Seino et al, 2018]. Moreover, patient-derived organoids have 
been utilized to test therapeutic anti-cancer agents.  For example, drug response of gemcitabine and 
JAK inhibitors such as AZD1480 has been assessed by optical metabolic imaging in human PDAC 
organoids [Walsh et al, 2016]. Therapeutic profiling of 5-fluorouracil, oxaliplatin, nab-paclitaxel and 
irinotecan has also been analysed on 66 organoids and revealed interpatient variability in drug 
response [Tiriac et al, 2018].  
Compared with animal models, patient-derived organoids can markedly reduce the cost of PDAC 
models and thus accelerate screening potential anti-cancer drugs using high-throughput assays, when 
evidence-based data showing that transplanting organoids in mice is unnecessary could be obtained. 
Thus, organoids provide a promising new tool to supplement traditional animal models. Heterogeneity 
between individual tumours, however, would need to be carefully stratified to identify effective 
treatments for distinct patient subgroups. Another issue is that animal-derived ECM factors provide 
additional variabilities between batches [Baker et al, 2016]. Reducing variations of these ECM factors 
by consistent, low-cost and standardized biomaterials would not only reduce the cost of these models 
but also make the PDAC models more realistic to human tumours. 
Since mouse models and commercial matrices used in 3D cultures and organoids can be expensive, it 
would be beneficial to explore other alternatives to reduce their cost, especially in the context of 
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screening large databases of potential novel therapeutics in conditions that represent the PDAC 
tumour environment [Baker et al, 2016]. In 3D culture models and organoids of PDAC, rat tail collagen 
I and Matrigel® (mouse sarcoma-derived products) are used to recreate an ECM environment 
containing collagen I, collagen IV, fibronectin, and laminins that are present in the pancreatic cancer 
tumour microenvironment [Laklai et al, 2016; Ohlund et al, 2009]. A decellularized ECM preparation 
obtained from skeletal muscle, termed Myogel, can be prepared in large quantities in an inexpensive 
manner from a wide variety of animal sources. Myogel contains collagen I, collagen IV, laminins, and 
fibronectin, making it a promising scaffold element for tissue engineering [Abberton et al, 2008; Wolf 
et al, 2012] and supports the growth of many cell types, such as C2C12 myoblasts, human perivascular 
stem cells, NIH 3T3 fibroblasts, NIH 3T3-L1 cells, HMEC endothelial cells, primary muscle progenitor 
cells, primary aortic smooth muscle cells, and corneal epithelial cells [Abberton et al, 2008; DeQuach 
et al, 2012; Francis et al, 2009; Stern et al, 2009; Wolf et al, 2012]. Importantly, the biomechanical 
properties of ECM from skeletal muscle can mimic the tissue tension properties present in some 
tumour microenvironments [Abberton et al, 2008; Francis et al, 2009; Gillies et al, 2011a; Gillies et al, 
2011b; Lin et al, 2014; Wolf et al, 2012]. 
Collagens in Myogel were reported to be between 27-72% of the total ECM extract [Abberton et al, 
2008; Stern et al, 2009], allowing it to be compressed and manipulated to create different levels of 
external pressures. In particular, the content of collagens was 486.7 ± 133 µg per mg of the porcine 
skeletal muscle extract [Abberton et al, 2008], higher than the one (0.029 µg per mg) reported in 
porcine pancreas [Mirmalek-Sani et al, 2013]. The investigation of cell proliferation and cell migration 
using Myogel [Cheema et al, 2013; Nyga et al, 2013] could provide novel insights into using Myogel as 
a potential alternative matrix to culture pancreatic cancer cells and pancreatic stellate cells to mimic 





1.3 Background of YAP signalling in cancer 
 
Yes-associated protein (YAP, UniProt P46937) is a transcriptional coactivator that can translocate 
between the cytoplasm and the nucleus. YAP protein domains consist of several sites that interact with 
other proteins. As seen in Figure 9, the N-terminal region of YAP, the transcription enhancer activator 
domain (TEAD) binding domain, can bind to TEADs once YAP enters the nucleus to enhance cell 
proliferation. This translocation is dependent upon phosphorylation at specific serine residues. 
Phosphorylation of serine at position 61 (S61), S109, and S127 inhibits the binding to TEAD whilst 
promotes binding to 14-3-3 in the cytoplasm to cause cell growth arrest [Abylkassov et al, 2016]. WW 
domains in YAP interact with serine-threonine kinases known as LATS1/2 and MST1/2 (discussed 
below), which are an integral part of Hippo pathway and can phosphorylate YAP under dense cell-cell 
contact conditions [Abylkassov et al, 2016; Harvey et al, 2013]. The Src homology domain 3 (SH3) 
binding domain can interact with p53-binding protein-2, a member of the apoptosis stimulating 
proteins of p53 family regulating apoptosis [Espanel et al, 2001; Sullivan et al, 2007]. Near the C-
terminal of YAP, there is a transactivation domain where S381, S384, tyrosine 391 (Y391), and Y407 can 
be phosphorylated. Phosphorylation at S397 is considered to induce YAP degradation by ubiquitin 
proteasome in the cytoplasm [Abylkassov et al, 2016]. The PDZ binding motif present in the YAP protein 
is also essential for transcription. 
The expression and localisation of YAP is the key to YAP signalling, which functions to sense signals 
from external and internal changes in cells. These changes affect cell fate with regard to proliferation 














Figure 9. YAP protein domains.  
The figure is from Abylkassov et al [Abylkassov et al, 2016], which is distributed under the terms and conditions 
of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). TEAD 
binding domain and transactivation domain can be phosphorylated, thus promoting binding to 14-3-3 and 
preventing YAP binding to TEAD. WW domains interact with serine-threonine kinases in Hippo pathways. The SH3 





As illustrated in Figure 10, YAP signalling exerts significant impact on tumour initiation, progression, 
metastasis, malignancy and drug resistance in a number of cancers. For instance, increased expression 
and nuclear accumulation of YAP in patients with lung cancer, breast cancer, colorectal cancer and liver 
cancer associate with cancer metastasis and poor prognosis [Zanconato et al, 2016b]. Reduced 
expression of YAP impairs cancer growth in mice transplanted with human cancer cell lines derived 
from lung cancer, colorectal cancer, liver cancer, prostate cancer, cervical cancer, melanoma, head and 
neck cancer, as well as osteosarcoma, suggesting that intervention of YAP signalling can control cancer 
progression [Zanconato et al, 2016b]. High level of YAP expression in the nucleus is correlated with 
treatment resistance in patients with colorectal cancer, esophageal cancer, and head and neck cancer 


















Figure 10. Role of YAP in different types of cancers. 
The figure is adapted from Zanconato et al [Zanconato et al, 2016b] with copyright permission from Elsevier. 
Increased expression and nuclear accumulation of YAP in patients with lung cancer, breast cancer, colorectal 
cancer and liver cancer associate with cancer metastasis and poor prognosis. Reduced expression of YAP impairs 
cancer growth in lung cancer, colorectal cancer, liver cancer, prostate cancer, cervical cancer, melanoma, head 
and neck cancer, and osteosarcoma. High level of YAP expression in the nucleus is correlated with treatment 





1.3.1 Upstream regulation of YAP signalling 
 
Complex signalling networks have been elucidated that involve mechanisms of YAP signalling in the 
context of cancer. As shown in Figure 11, cell junction/cell polarity, metabolic status, mechanical cues 
and G-protein-coupled receptors (GPCRs) are regarded to affect YAP subcellular localisation, and thus 
its function; their actions being capable of resulting phosphorylation or de-phosphorylation YAP to 
control the translocation of YAP between the cytoplasm and the nucleus. Phosphorylated YAP is 
sequestrated in the cytoplasm and is therefore unable to bind to TEADs in the nucleus to promote cell 
growth. Phosphorylation of YAP by the key kinases, Mammalian Sterile 20-like 1 and 2 kinases (MST1/2) 
and Large Tumour Suppressor 1 and 2 kinases (LATS1/2) in Hippo pathway, is regarded as an important 
mechanism to inhibit YAP nuclear entry [Yu et al, 2015]. However, researchers have proposed possible 
regulation of YAP by non-Hippo pathway in cancer because of two reasons: 1) mutations in LATS1/2 
are not common in all types of cancers while nuclear accumulation of YAP are often detected in cancer 
tissue [Zanconato et al, 2016b] and 2) tense mechanical cues such as a stiff matrix for cells to grow on 
or stressed metabolic status do not always cause changes in YAP phosphorylation by LATS1/2 because 
YAP is still found to be in the cytoplasm despite effective depletion of LATS1/2 [Aragona et al, 2013; 
Dupont et al, 2011; Mo et al, 2015; Wang et al, 2015]. Since cell junction/cell polarity, metabolic status, 
mechanical cues and GPCRs are all also upstream regulators of LAST1/2 and MST1/2, focusing on how 

















Figure 11. Upstream regulation of YAP signalling.  
The figure is adapted from Yu et al [Yu et al, 2015] with copyright permission from Elsevier. The binding of catenin 
proteins at AJs and Ocln at TJs to YAP, activation of AMPK, LATS1/2 and Gs-coupled receptors can promote 
phosphorylation of YAP and retain YAP in the cytoplasm. Tension in the cytoplasm, activation of mevalonate 




Cell junction/cell polarity involving adherens junction (AJ) and tight junction (TJ) structures plays a 
critical role in YAP signalling regulated by the Hippo pathway; events that can regulate cell growth 
[Gumbiner et al, 2014]. Recent studies have suggested localisation of YAP interactions may involve α-
catenin proteins at AJs and occludin (Ocln) at TJs [Cravo et al, 2015; Schlegelmilch et al, 2011]. These 
interactions at AJs and TJs may function as sensors for external cell-cell and cell-matrix interactions 
that signal to the cell as a way to maintain a stable, differentiated format despite adjacent cell jostling 
and transient changes to its environment. At times when AJs and TJs are dismantled, such as during 
the process of wound repair, YAP no longer has these stabilized cell-cell and cell-matrix signalling 
complexes within the cell to bind and is now more accessible to de-phosphorylation that will lead to 
its increased movement to the nucleus as part of the epithelial to mesenchymal transition (EMT) 
mechanism to stimulate proliferation. Under normal conditions, once these cell-cell and cell-matrix 
interactions are re-established as the drive for proliferation subsides, YAP returns to competent AJ and 
TJ structures to once again position itself in a non-proliferative organization within the cell as it 
undergoes a mesenchymal to epithelial (MET) transformation. In the context of solid tumours, the EMT 
that occurs as part of this repair process does not reverse, i.e. there is no ensuing MET event.  
Emerging evidence has suggested that the metabolic status in cells regulates YAP signalling by 
phosphorylating YAP and preventing nuclear translocation of YAP when cells are under energy stress. 
Indeed, reduced glucose levels in normal cells activates LATS1/2 in the Hippo pathway and the AMP-
activated protein kinase (AMPK) independently from the Hippo pathway to cause cytoplasmic 
retention of YAP by phosphorylation [Mo et al, 2015; Wang et al, 2015]. Active glucose uptake and 
glycolysis is one of the key features of cancer cells. By analysing clinical biopsies, tumours with a high 
glycolytic gene expression signature have been shown to have high YAP nuclear expression [Enzo et al, 
2015]. Blockage of glucose metabolism by small molecule glucose-mimics or 2-deoxy-glucose reverses 
YAP nuclear translocation in breast cancer cell lines [Enzo et al, 2015]. Moreover, activation of AMPK 
by anti-diabetic metformin induces YAP phosphorylation in vitro [Mo et al, 2015]. Another bit of 
interesting evidence is that statin molecules capable of inhibiting the mevalonate pathway that drives 
cholesterol biosynthesis can promote YAP cytoplasmic localization in cell lines derived from different 
solid cancer types [Sorrentino et al, 2014]. Such a finding correlates well with data showing that 
blunting the cholesterol synthetic pathway in gastric cancer cells can lead to induction of apoptosis 
[Goulitquer et al, 2018]. Notably, mutant p53, a prominent mutation in many epithelial-derived 
cancers, is found to be actively involved in the regulation of YAP by mevalonate pathway [Sorrentino 
et al, 2014]. In breast cancer cell lines grown in 2D, mutant p53 binds to YAP in the nucleus to enhance 
proliferation [Di Agostino et al, 2016] and depletion of mutant p53 reduces the production of enzymes 
critical to mevalonate pathway in cancer cells and the nuclear accumulation of YAP [Sorrentino et al, 
2014].  
Ligands that activate GPCRs have been widely studied to explore their effect on YAP signalling [Yu et 
al, 2015]. These results have suggested that stimulation of different subtypes of GPCRs can lead to 
either nuclear or cytoplasmic translocation of YAP. For instance, stimulation of G12/13-coupled receptors 
by lysophosphatidic acid and sphingosine 1-phosphophate activates the Rho GTPase pathway to de-
phosphorylate YAP and induce nuclear accumulation of YAP [Yu et al, 2012]. Also, activation of Gq-
coupled receptors increases inositol triphosphate and activation of Gi-coupled receptors that inhibit 
adenylyl cyclase, both of which promoting nuclear localisation of YAP [Yu et al, 2012]. However, 
activation of Gs-coupled receptors by glucagon or epinephrine activates protein kinase A, causing 
phosphorylation and sequestration of YAP in the cytoplasm [Yu et al, 2012]. Dobutamine, a ligand to 
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Gq-, Gi- and Gs-coupled receptors, has been shown to inhibit YAP nuclear translocation in some but not 
all pancreatic cancer cell lines [Cravo et al, 2015]. The dominant effects regulating the YAP signalling 
after activation of different subtypes of GPCRs need further investigation.   
Mechanical cues can modulate YAP signalling by re-organizing the F-actin/actomyosin that is associated 
with the cytoskeleton via the Hippo pathway and the Rho GTPase pathway. Using soft mechanical 
conditions as a cue where the Rho pathway is inhibited or F-actin is destroyed or the adhesive island 
area is reduced, YAP is still found to be in the cytoplasm despite the absence of LATS1/2 [Aragona et 
al, 2013; Dupont et al, 2011]. A stiff extracellular matrix (ECM) creates high tension, activates the 
integrin-focal adhesion-kinase-Src pathway and the Rho GTPase pathway, leading to the inhibition of 
YAP phosphorylation with or without the presence of LATS1/2 and subsequent nuclear YAP 
translocation [Aragona et al, 2013; Dupont et al, 2011]. Flattening the shape of a cell also increases 
stress fibre tension, F-actin contractility, and the opening of nuclear pores for YAP entry into the 
nucleus [Dobrokhotov et al, 2018]. Increased tension resulting from cell accumulation due to excessive 
proliferation rates is common in cancer and is associated with tumour progression [Butcher et al, 2009]. 
Interestingly, extracellular tension by high cell-cell contact frequency also acts on junction proteins 
such as catenins, resulting in the retention of YAP in the cytoplasm [Gumbiner et al, 2014]. Most of the 
studies on how mechanotransduction regulates YAP signalling, however, mainly focus on cells grown 
in 2D, which is unlike the native tumour architecture and microenvironment in patients where various 
cell types and factors are involved. The evolution of the cancer cell genotype and phenotype over time 
and the dynamic and complex nature of the tumour microenvironment would lead to various degrees 
of mechanical forces, possibly leading to a dynamic exchange of YAP nuclear and cytoplasmic 
accumulation over time.  
 
1.3.2 Dual downstream effect of YAP signalling 
 
Although YAP signalling is believed to induce cancer cell growth in solid tumours, it is considered to 
have tumour restraining function in haematological cancers [Cacemiro et al, 2017; Cottini et al, 2014]. 
For example, induction of YAP expression in leukaemia and myeloma cell lines reduced cell 
proliferation and promoted apoptosis [Cottini et al, 2014], as opposed to the suppression of cell growth 
resulting from the inhibition of YAP expression in solid tumours [Cravo et al, 2015; Diep et al, 2012]. In 
a transgenic mouse model with induced YAP expression in the haematopoietic system, YAP had no 
effect on the function of haematopoietic stem cells [Jansson et al, 2012]; however, up-regulation of 
YAP expression has been associated with tumorigenesis in many human solid tumours [Harvey et al, 
2013]. One potential mechanism underlying the tumour-inhibitory effect of YAP in haematological 
cancers involves the binding of YAP to p73 [Cottini et al, 2014]. As a result, some researchers have 
suggested introduction of YAP expression in haematological cancer cells as a possible strategy for 
managing haematological cancers, contrary to what one might consider for a strategy to treat solid 
tumours [Cottini et al, 2014; Luk et al, 2014]. To our knowledge, there is no comprehensive report on 
the expression of TEADs in haematological cancers; if TEADs are expressed in haematological cancers, 
it would be necessary to investigate the effect of the interactions between YAP and transcription 
factors such as TEADs and p73 on the cell fate in haematological cancer cells. Therefore, efforts are 
required to fully understand the YAP signalling in human haematological cancers, such as the selective 
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binding of YAP to TEADs or p73, so as to prevent the undesired tumour-promoting activity in the 
strategies involving the upregulation of YAP expression in patients with haematological cancers.  
Early studies identified the connective tissue growth factor (CTGF) gene as a target gene regulated by 
the binding of YAP to TEADs [Fan et al, 2013; Zhao et al, 2008]. Recently, YAP-upregulated gene 
signature in pancreatic cancer has been summarized as illustrated in Figure 12, including a gene 
encoding mitotic kinases (AURKA), a gene encoding cyclins (CCND1), a gene related to cell growth and 
division (NOTCH2) [Rozengurt et al, 2018]. Regulating the complex networks of gene expression by YAP 
can contribute to the tumour growth and tumour relapse in KrasG12D-driven pancreatic cancer mouse 











Figure 12. YAP-upregulated gene signature in pancreatic cancer. 
The figure is adapted from Rozengurt et al [Rozengurt et al, 2018], which is distributed under the terms and 
conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
The downstream effects of YAP signalling include activation of a gene encoding mitotic kinases (AURKA), a gene 
encoding cyclins (CCND1), a gene related to cell growth and division (NOTCH2) [Rozengurt et al, 2018].  
 
1.3.3 Pharmacological intervention of YAP signalling in treating epithelial cancer 
 
Intervention of YAP signalling to control solid cancer involves therapeutic approaches to regulate 
metabolic status, mechanical cues, GPCRs and YAP-TEADs binding. The current therapeutic methods 
are summarized in Figure 13 [Zanconato et al, 2016a]. Statins inhibit mevalonate pathway, Rho 
inhibitors reverse the stiff mechanical cue and block GPCR signalling, and verteporfin inhibits YAP-
TEADs binding, preventing the YAP functioning as a proliferative driving force in cancer cells [Zanconato 
et al, 2016a]. In recent years, the capabilities of natural products to inhibit tumour growth by facilitating 
degradation of YAP are promising [Chen et al, 2018b]. The expression and localisation of YAP could 
potentially be a biomarker to evaluate the therapeutic outcomes. If a novel reagent decreases YAP 





become a candidate in translational medicine. YAP is essential to survival in normal cells but there may 
be other mechanisms to compensate the loss of YAP function.  
 
Figure 13. Agents of potential 
therapeutic usage affecting YAP 
signalling.  
The figure is adapted from Zanconato et 
al [Zanconato et al, 2016a], indicating 
the strategies to inhibit nuclear 
accumulation of YAP and YAP-TEADs 
binding: Rho inhibitors reverse the stiff 
mechanical cue and block GPCR 
signalling [Zanconato et al, 2016a]. 
Statins inhibit mevalonate pathway 
[Zanconato et al, 2016a]. The natural 
products may facilitate degradation of 
YAP [Chen et al, 2018b]. Verteporfin 
inhibits YAP-TEADs binding [Zanconato 
et al, 2016a]. The article is distributed 
under the terms and conditions of the 
Creative Commons Attribution (CC BY) 
license (http://creativecommons.org/licenses/by/4.0/). 
 
1.3.4 Crosstalk between dysfunctional cell signalling pathways and YAP signalling 
 
As depicted in Figure 2, YAP signalling has been linked to dysregulated pathways involving EGFR, RAS, 
WNT/β-catenin, TGF- β/SMAD4, HH, and DNA damage response in various experimental models.  
Overexpression of YAP is able to increase mRNA and protein level of EGFR in ovarian cancer cell lines 
and human ovarian cancer xenografts [He et al, 2015]. Although activation of mutant HRAS increases 
YAP levels and nuclear localization of YAP in U87MG glia cell lines transfected with mutant HRAS [Reddy 
et al, 2013], suppressing mutant KRAS is not able to reduce YAP expression in a fraction of cancer cells 
in KRASG12D-driven GEMMs of pancreatic cancer, leading to relapse by amplification of YAP gene in 
cancer cells [Kapoor et al, 2014]. By reducing CTNNB1 (a gene encoding β-catenin) with RNA 
knockdown technique, decreased YAP mRNA levels is detected in colorectal cancer cells [Konsavage et 
al, 2012]. Meanwhile, the proliferation and survival of colorectal cancer cell lines transfected with β-
catenin reported genes and harbouring mutations in Wnt/β-catenin pathway are dependent on YAP 
and the formation of β-catenin-YAP complex [Rosenbluh et al, 2012]. In a live cancer GEMMs, nuclear 
translocation of YAP is induced by TGF-β in tumorigenic liver cells, leading to increased SMAD2/3 
activity which interacts with SMAD4 [Nishio et al, 2016]. Meanwhile, transfection of a mesothelioma 
cell line NCI-H290 with vectors carrying Smad2/3/4 and YAP is able to increase the transcription activity 
of CTGF, which is essential for cell proliferation and ECM production in mesothelioma [Fujii et al, 2012]. 
In osteosarcoma, high level of YAP is detected in tumour tissues from GEMMs with enhanced HH 
signalling and inhibiting HH signalling decreases YAP expression [Chan et al, 2014]. YAP signalling can 
also activate HH signalling when YAP translocate into the nucleus in a GEMM of skin cancer [Akladios 
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et al, 2017]. Amplification of YAP gene is found in mammary tumours from a breast cancer GEMM with 
deletion of BRCA1 by knocking out the BRCA1 gene [Overholtzer et al, 2006]. Our group has reported 
the YAP expression and localisation using AsPC-1 and HPAF-II cell lines cultured in 2D, where the tight 
junction protein Ocln induces YAP cytoplasmic localization to inhibit cell growth [Cravo et al, 2015]. 
Because PDAC cells are in an EMT state, loss of Ocln leads to the dissociation of a binding partner of 
YAP that can sequestered YAP in the cytoplasm, thus promoting nuclear translocation of YAP [Cravo et 
al, 2015].  
Recently, YAP expression has shown to be correlated with myeloid-derived suppressor cells (MDSCs) 
and tumour-associated macrophages (TAMs) in Kras:Trp53 mutant (KPC) mice and in patients with 
PDAC [Murakami et al, 2017]. Depletion of YAP in the pancreas of the mice resulted in less MDSCs and 
more major histocompatibility class II (MHCII) positive macrophages in the pancreas following 
pancreatitis, indicating that the YAP signalling plays a role in the immunosuppression in pancreatic 
cancer [Murakami et al, 2017]. The stiffness of matrix manipulated by collagen contraction affects the 
nuclear translocation of YAP in pancreatic cancer cell lines [Rice et al, 2017]. Fibronectin is considered 
to be more effective to induce nuclear accumulation of YAP in genetic modified non-tumorigenic 
epithelial cell line [Miroshnikova et al, 2017]. HA stimulates focal adhesion kinase (FAK), Ras GTPases, 
and modulates actin cytoskeleton as events that are associated with YAP signalling [Kultti et al, 2012]. 





1.3.5 Treatments for PDAC by targeting YAP signalling 
 
Surgery and chemoradiation are effective only in a small number of patients diagnosed with PDAC 
[Neoptolemos et al, 2018]. The treatment algorithm for patients with all stages of pancreatic cancer 
mostly consists of 5-fluorouracil and gemcitabine [Neoptolemos et al, 2018]. However, relapse and 
drug resistance are still common and the overall survival remains low. The pivotal reason for this low 
level of long-term survival rate is the desmoplastic and hypo-vascular microenvironment of pancreatic 
cancer, which limits access to the tumour by diagnostic methods and therapeutic strategies. 
Destroying the stroma in PDAC is one approach to overcome the obstacle(s) established by this 
acellular components for therapeutic strategies to reach and eradicate the PDAC cells. Although 
targeting hyaluronic acid using hyaluronidase combined with gemcitabine and nab-paclitaxel has 
elicited high response rate in phase I/II trials and has moved into phase III testing [Doherty et al, 2018], 
efforts to destroy the pancreatic stroma with therapeutic agents such as matrix metalloproteinases 
inhibitor Marimastat [Bramhall et al, 2001; Bramhall et al, 2002; Moore et al, 2003] and SHH pathway 
inhibitor Vismodegib [Kim et al, 2014] have failed to improve the survival rates in other clinical trials. 
Furthermore, efforts to induce stromal depletion by genetic modification in mouse models lead to 
acceleration of pancreatic cancer tumour growth [Ozdemir et al, 2014; Rhim et al, 2014] and patients 
with reduced numbers of PSCs suffered worse survival [Ozdemir et al, 2014], raising the possibility that 
at least some of the PSCs around pancreatic cancer cells may suppress cancer cell growth. Cautions in 
targeting tumour stroma in PDAC have been raised and more prudent experimental designs to 
eradicate tumour-promoting PSCs from tumour-suppressive PSCs in PDAC are required. It has been 
postulated that a subset of pancreatic cancer cells can regulate tissue tension to activate tumour-
promoting genes after the loss of pancreatic stellate cells [Laklai et al, 2016], linking to YAP signalling.  
As summarized in Table 1, outcomes of regulating YAP signalling in PDAC have been reported in vitro 
and in vivo. YAP expression has been shown to be responsible for chemo-resistance of gemcitabine in 
pancreatic cancer cells [Yuan et al, 2016], raising the possibility of combining gemcitabine with targeted 
therapy that can reduce YAP expression to augment therapeutic efficacy. Inhibition of YAP signalling 
using verteporfin and RAF signalling blockage reduces cell proliferation in 2D models [Zhao et al, 2017]. 
Effects of targeting YAP signalling have been assessed in mice models [Jiang et al, 2018]. Reduced YAP 
expression by YAP knockdown and verteporfin treatment in xenografts and GEMMs can inhibit tumour 
growth [Jiang et al, 2018; Wei et al, 2017; Zhao et al, 2017]. Depletion of YAP in the pancreas of mice 
has resulted in less MDSCs and more MHCII positive macrophages in the pancreas following 
pancreatitis, indicating the YAP signalling plays a role in the immunosuppression of pancreatic cancer 
[Murakami et al, 2017]. Combining YAP-depleting strategies or inhibiting YAP-TEADs interaction with 
verteporfin can sensitize the treatments against RAF kinases, one of the downstream pathway effectors 
of KRAS mutation, in pancreatic cancer cells and xenografts [Wei et al, 2017; Zhao et al, 2017]. 
Targeting GPCRs using dobutamine [Cravo et al, 2015], a widely used medicine in the clinic to assess 
cardiac function, can also considered as an approach to target YAP signalling if a pharmacological 
profile could be established for sustaining its actions on nuclear exclusion of YAP. Inhibiting the 
mevalonate pathway using statins and activating AMPK using metformin has shown to reduce YAP 
nuclear localization in vivo and in vitro [Mo et al, 2015] . Due to the extensive use of metformin in 
diabetic patient populations, epidemiological studies to examine favourable outcomes in PDAC might 
be warranted. Although around 74% of pancreatic cancer cells harbour a TP53 mutation [Waddell et 
al, 2015], it is currently unclear if targeting TP53 mutations that affect YAP function would be a feasible 
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therapeutic approach. Natural products have shown anti-tumour activity in epidemiological studies of 
PDAC [Boreddy et al, 2013]. Irinotecan and paclitaxel have been used in as parts of combinatory 
treatments for PDAC [Neoptolemos et al, 2018]. Tylophorinine and tylophorine are two interesting 
natural products that have drawn medicinal chemists’ attention on biosynthesis and extraction 
[Gantait et al, 2017; Govindachari et al, 1965]. A tylophorine analogue, DCB-3503, can inhibit 
pancreatic cancer cell growth by targeting the abnormal cell-cycle signalling in PANC-1 and HPAC 
pancreatic cancer cell lines, providing a promising new compound to be tested in PDAC [Shiah et al, 
2006]. The effects of tylophorinine on YAP signalling and PDAC growth remain to be determined. 
 
Table 2. Outcomes of regulating YAP signalling in PDAC. 
Genetic deletion and/or 
pharmacological 
inhibition of YAP PDAC Model Major outcomes Ref 





2D BxPC-3 and 
PANC-1 Inhibition of cell proliferation  
 [Diep et al, 
2012] 













Reactivation of T cells  
Promotion of apoptosis in neoplastic ducts  
Increased infiltration of MHCII+ 
macrophages 
Reduction of MDSCs and MDSC-polarizing 
cytokines 
Deletion of YAP with pan-
RAF inhibitor 
  
2D AsPC1 and 
PANC-1 
  
Suppression of PDAC cell proliferation and 
clonogenic ability 
 [Zhao et al, 
2017] 
  Sensitisation to the pan-RAF inhibitor 
Deletion of YAP and 
gemcitabine 2D PANC-1 Sensitisation to gemcitabine 





2D PANC-1 and 
SW1990 cells 
  
Inhibition of migration, cell proliferation and 
cell cycle progression  
 [Wei et al, 
2017] 




Suppression of tumour growth   
 [Wei et al, 
2017] Reduction of angiogenesis markers 
Verteporfin with pan-
RAF inhibitor 
2D AsPC1 and 
AsPC1 xenografts Sensitisation to the pan-RAF inhibitor 
 [Zhao et al, 
2017] 
Dobutamine 
2D HPAFII and 
AsPc1 Inhibition of cell proliferation  
 [Cravo et 
al, 2015] 
 
*: p48-Cre (Cre), Yapflox/flox;p48-Cre (YapKO), LSL-KrasG12V;LSL-p53R172H;p48-Cre (KPC) and LSL-KrasG12V;LSL-




1.4 Aims and objectives 
 
Little progress has been made in improving the overall survival of pancreatic cancer because the 
desmoplastic and hypo-vascular microenvironment of this cancer limits access to therapeutic 
strategies. Stellate cells, comprising the majority of stroma and secreting large amount of extracellular 
matrix (ECM), have been suggested to provide a supportive environment for pancreatic cancer whilst 
playing a suppressive role in cancer growth. 2D culture models and animal models have been useful to 
study pancreatic cancer biology; however, they fail to represent the highly fibrotic properties in human 
pancreatic cancer microenvironment in late-stage of PDAC development. In order to identify strategies 
capable of modulating pancreatic cancer stroma without promoting cancer growth, it is imperative to 
establish an in vitro 3D cancer model resembling the human cancer microenvironment. YAP has been 
shown to position itself as an integral part in the crosstalk between various cell signalling pathways to 
promote cancer growth in solid tumour [Rozengurt et al, 2018; Zhang et al, 2015]. Due to effects of the 
mechanical cues on YAP signalling, a realistic human PDAC model is required to recapitulate YAP 
signalling in the spatial manner.  
The aim of the project is to establish an in vitro 3D human cancer model with human pancreatic cancer 
cell lines, ECM-like materials, and human stellate cells to recreate the highly fibrotic human PDAC 
microenvironment in the liver and pancreas suitable for high-throughput assay and delineating YAP 
signalling in pancreatic cancer. 
The objectives are: 
1. To optimise the protocol for 3D co-cultures of human pancreatic cancer cell lines, ECM-like materials, 
and human stellate cells. 
2. To evaluate Myogel and unmodified hyaluronic acid as culture matrix elements for modelling 
pancreatic cancer. 
3. To study expression and subcellular localisation of endogenous YAP and the interactions of YAP, 
TEADs, and Ocln in 3D human pancreatic cancer models. 
4. To investigate the effects of natural products, Pseudopterosin A-D and Tylophorinine, on 3D human 




























Figure 14. Diagram of aims and objectives. 
In order to recreate human PDAC microenvironment to study YAP signalling and screen anti-cancer agents, an in 
vitro 3D human pancreatic cancer model with human pancreatic cancer cell lines, ECM-like materials, and human 
stellate cells will be established to mimic the human PDAC microenvironment in the liver and pancreas suitable 
for high-throughput assay.   
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Chapter 2.  Materials and Methods 
 
2.1 2D cell culture 
 
Human pancreatic cancer cell lines Capan-2 and PANC-1 were obtained from the American Type 
Culture Collection (Manassas, VA). Cells were maintained in DMEM cell culture medium with high-
glucose (4 g/L) (GibcoTM, Cat. # 41965-039) supplemented with 10% foetal bovine serum (FBS, GibcoTM, 
Cat. # 10500064), and 100 U/mL penicillin combined with 100 mg/mL streptomycin (P/S, Sigma-Aldrich 
Chemical Co., Cat. # P4333). 
Patient-derived hepatic and pancreatic stellate cells were generous gifts from Dr Erkan at KOҪ 
University hospital, Turkey. Ethical approval was obtained from Ethics Committee for Biomedical 
Sciences of KOҪ University. Stellate cells were maintained in DMEM/F12 cell culture medium 
containing DMEM with low-glucose (1 g/L) (GibcoTM, Cat. # 22320022) and Ham's F-12 Nutrient Mix 
(GibcoTM, Cat. # 21765029) at 1:1 (volume/volume) supplemented with 20% FBS and P/S as described 
[Jiang et al, 2009; Zhang et al, 2007] .  
All cells were routinely cultivated in a humidified incubator with 5% CO2 at 37 °C.  
 
2.2 3D cell culture 
 
2.2.1 Preparation of polyHEMA low-attachment plates 
 
PolyHEMA low-attachment plates were prepared as described previously [Phung et al, 2011]. A 120 
mg/mL stock solution of poly-HEMA (Sigma-Aldrich Chemical Co., Cat. # P3932) was prepared in 95% 
ethanol (VWR, Cat. # 20821.330) and incubated while stirring with a magnetic bar at room temperature 
(15-20°C) overnight. To make a working solution of poly-HEMA, 1 mL of poly-HEMA stock solution was 
pipetted into 23 mL of 95% ethanol to obtain a final concentration of 5 mg/mL. The fresh working 
solution was prepared every time new plates were made. 50-60 μL of poly-HEMA working solution was 
pipetted into each well of a 96-well U-bottomed plate (NuncTM, Cat. # 163320). The ethanol was 
evaporated at 37 °C for 72-96 hours under humid-free conditions. Before use, plates were sterilized in 
the hood with lids off using UV light for 40-60 minutes. Sterilised plates were sealed with Parafilm and 
stored at room temperature.  
 
2.2.2 Co-culture of cancer cells and stellate cells in scaffold-free conditions 
 
Stellate cells and cancer cells were grown to reach 60-90% confluence, trypsinized using 0.25% trypsin 
(GibcoTM, Cat. # 15090046, volume/volume) with 0.02% ethylenediaminetetraacetic acid (EDTA, Sigma, 
Cat. # E9884, weight/volume) diluted in phosphate buffered saline (PBS, Oxoid, Cat. # BR0014G) at 37 
°C, 1 minute for PANC-1 cells and 5 minutes for stellate cells and Capan-2 cells. Cells were isolated into 
single cell suspensions and were then mixed to achieve the final cell mixtures in each hanging drop 
composed of 0, 5,000, 10,000, 20,000 or 40,000 stellate cells with either 0 or 500 cancer cells, 
respectively. Cell suspensions were centrifuged and resulting pellets were suspended in DMEM/F12 
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with 10% FBS and P/S in final volumes of 20 μL or 40 μL in each drop at the stellate cells to cancer cells 
ratios of 0, 10:1, 20:1, 40:1 or 80:1. 20 μL of each cell mixture was pipetted manually as single droplets 
on the upside-down lid of the 100 mm cell culture dish (Falcon™, Cat. # 353003) and the lid with 20-40 
droplets was handled carefully to cover the dish containing 6 mL PBS or DMEM/F12 with P/S. In some 
experiments, 40 μL were pipetted into GravityPLUSTM HangingDrop plates (InSphero, Cat. # ISP-06-001). 
Suspended cell mixtures were cultivated in a humidified incubator with 5% CO2 at 37 °C.  
After 4 days in hanging drop culture, the spheroids that formed were transferred individually one-by 
one spheroid using large bore (cut) pipette tips to a polyHEMA plate well containing 100 μL fresh 
medium each well. In some experiments, ~200 µL of air was added through the inlet of the 
GravityPLUSTM Plate wells to push the spheroid to the polyHEMA plates. Spheroids were cultured in 
polyHEMA plates for 3 days without changing the medium. 
 
2.2.3 Preparation of Myogel 
 
Porcine skeletal muscle (PSM) was decellularized as previously described [Abberton et al, 2008]. The 
quadriceps and hamstring PSM was purchased from Waitrose without trace the strain of the pigs. 
Samples of PSM were weighed, aliquoted and stored in -20°C as ~30g per bag. PSM (~30g) was 
defrosted at room temperature and homogenised with 90 mL ice-cold 3.4 M sodium chloride (Sigma, 
Cat. # S9625), containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF, Sigma, Cat. # P7626), 2 mM 
EDTA, 0.1 M 6-aminocaproic acid (EACA, Sigma, Cat. # a2504), and 2 mM N-ethylmaleimide (Sigma, 
Cat. # e3876), using a Kenwood Hand Blender HB722A. After homogenisation, samples were 
centrifuged at 1780 x g for 5 minutes, and the supernatant was discarded. Pellets were then 
homogenised again with fresh 90 mL ice-cold 3.4 M sodium chloride buffer containing 0.5 mM PMSF, 
2 mM EDTA, 0.1 M EACA, and 2 mM N-ethylmaleimide and then centrifuged to collect the pellets. After 
the third homogenisation and centrifugation, the pellets were treated with 30 mL 2 M urea (Sigma, 
Cat. # u1250) in Tris Buffered Saline (TBS) with 0.05 M Tris base (Sigma, Cat. # T6066) with 0.15 M 
sodium chloride, overnight at 4 °C. The extraction in urea was centrifuged at 10,000 x g for 30 minutes 
and the supernatant was stored at 4 °C. Pellets were suspended in 30 mL 2 M urea/TBS and left 
overnight at 4 °C. The second urea extraction was centrifuged at 10,000 x g for 30 minutes and the 
supernatant was stored at 4 °C. The combined supernatants (~90 mL) were dialysed in SnakeSkinTM 
Dialysis Tubing 3.5K MWCO (Thermo ScientificTM, Cat. # 68035) or 10K MWCO (Thermo ScientificTM, 
Cat. # 68100) against 0.5% v/v chloroform (Sigma, Cat. # 288306) in 1.5 L TBS at 4 °C for approximately 
20 hours. After dialysis in 0.5% chloroform, the dialysate was changed to fresh 1.8 L TBS approximately 
every 12 hour for two days. After dialysis in TBS, the dialysate was changed to DMEM/F12 with P/S. 
After overnight dialysis, the resulting solution, Myogel, was stored at 4 °C and -20°C.  
The BCA Protein Assay (Thermo Scientific™ Pierce™, Cat. # 23227) was used to determine the total 
protein concentration of Myogel preparations. Bovine serum albumin (BSA) standards (125-2,000 
μg/mL) were prepared from BSA ampoule provided with the protein assay kits. The working detection 
reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B. 20 μL of a 
Myogel preparation (1:10 or 1:20 dilution in DMEM/F12) and standards, run as duplicates, were 
pipetted into a 96-well flat-bottom plate (Thermo Scientific™ Nunc™, Cat. # 167008) and then 200 μL 
working reagent was added to each well. Plates were incubated at 37°C for 30 minutes and measured 
for absorbance at 562nm using FLUOstar Omega spectrometer. The average of 562 nm absorbance 
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measurement for blank replicates (DMEM/F12) was subtracted from the 562 nm measurements of all 
BSA standard and unknown sample replicates. A standard curve for the BSA standards was prepared 
by plotting the average blank-corrected 562nm measurement vs. its concentration in μg/mL. This 
standard curve was used to determine the Myogel protein concentrations. 
 
2.2.4 Mono-culture of cancer cells or cancer spheroids in Myogel  
 
Initially, Myogel was mixed with 5 M NaOH (Fisher Chemical, Cat. # S/4920/53) to result in a pH of the 
preparation of 8 which was higher than the isoelectric points of collagen I, collagen IV, laminin, and 
fibronectin to reduce viscosity [Uquillas et al, 2012] and the chance of contamination. 30 μL of the 
resulting mixture was pipetted per well into polyHEMA plates. After the plates were incubated at 37 °C 
overnight, 70 μL of PANC-1 cells suspensions containing 2,000 cells in DMEM/F12 with 10% FBS and 
P/S was pipetted into each well and the plates were incubated for 10 days arbitrarily at 37 °C under 
standard cell culture conditions.  
In order to test the feasibility of using Myogel directly after dialysis without increasing the pH, Capan-
2 and PANC-1 grown in flasks as 2D was trypsinized. After centrifugation, cell pellets were suspended 
in FBS. 1 volume of FBS with cells were mixed with 9 volumes of Myogel and seeded at 100 μL per well 
into 96-well F-bottom μCLEAR® black plates (Greiner, Cat. # 655986) and cultured for 4 days. Myogel 
without cells was used as a control to test the contamination. 
Capan-2 and PANC-1 spheroids were formed from 500 cells per 40 μL DMEM/F12 with 10% FBS and 
P/S using hanging-drop method. On day 4 of incubation, spheroids were transferred into 96-well F-
bottom μCLEAR® black plates coated with 70 μL Myogel in 10% FBS per well, with one spheroid per 
well, and incubated at 37 °C for 4 days. 
  
2.2.5 Preparation of hyaluronic acid 
 
As previously reported in the product specification [Madihally et al, 1999], 200 mg hyaluronic acid (HA) 
sodium salt from Streptococcus equi (SIGMA, Cat. # 53747) was weighed and 20 mL PBS was added to 
make the 10 mg/mL HA stock solution. HA stock solution were autoclaved according to the reference 
[Madihally et al, 1999] stated on the manufacturer’s website and stored at 4°C until use. 
 
2.2.6 Mono-culture of cancer spheroids in hyaluronic acid 
  
On day 0, 500 cells per 40 µL DMEM/F12 with 10% FBS and P/S of Capan-2 and PANC-1 cell suspension 
was delivered into each well of GravityPLUSTM HangingDrop plates as 3D culture.  
On day 4, 10 mg/mL HA stocking solution was diluted using DMEM/F12 with P/S. 70 µL of 0, 1, 3, 5 
µg/µL HA in DMEM/F12 with P/S was pipetted into each well of the polyHEMA plate. FBS was adjusted 
to achieve the final concentration of 10% FBS in each well. ~200 µL of air was added to the 3D culture 
through the inlet of the GravityPLUSTM Plate wells to let one cancer spheroid drop into one well of low-
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attachment polyHEMA plates containing HA. Wells with the same volume of PBS (the solvent used to 
dissolve hyaluronic acid) as the ones in the highest concentration of hyaluronic acid (5 mg/mL) served 
as controls to observe spheroids grown in an environment with less nutrients than the ones grown in 
standard culture medium. 
 
2.2.7 Co-culture of cancer spheroids and stellate cells in hyaluronic acid 
 
On day 0, 500 cells per 40 µL DMEM/F12 with 10% FBS and P/S of Capan-2 and PANC-1 cell suspension 
was delivered into each well of GravityPLUSTM HangingDrop Plate as 3D culture.  
On day 4, 10 mg/mL HA stock solution was diluted using DMEM/F12 with P/S. 70 µL of 0 or 20,000 
stellate cells in DMEM/F12 with P/S and 0, 1, 3, 5 mg/mL HA was pipetted into each well of the 
polyHEMA plate. FBS was adjusted to achieve the final concentration of 10% FBS in each well. ~200 µL 
of air was added to the 3D culture through the inlet of the GravityPLUSTM Plate wells to let one cancer 
spheroid drop into one well of low-attachment polyHEMA plates containing HA with or without stellate 
cell suspension. Wells with HA and stellate cell suspension were used as control. The plates were 
incubated for 3-8 days. 
 
2.2.8 Co-culture of cancer spheroids and stellate cells in hyaluronic acid and collagen I 
 
On day 0, 500 cells per 40 µL DMEM/F12 with 10% FBS and P/S of Capan-2 and PANC-1 cell suspension 
was delivered into each well of GravityPLUSTM HangingDrop Plate as 3D culture.  
On day 4, 10 mg/mL HA stock solution was diluted using DMEM/F12 with P/S. 70 µL of 0 or 20,000 
stellate cells in DMEM/F12 with P/S, 5 mg/mL HA and 0.3 mg/mL rat tail collagen I (GibcoTM, Cat. # 
A1048301) was pipetted into each well of the polyHEMA plate. FBS was adjusted to achieve the final 
concentration of 10% FBS in each well. ~200 µL of air was added to the 3D culture through the inlet of 
the GravityPLUSTM HangingDrop Plate wells to let one cancer spheroid drop into one well of low-
attachment polyHEMA plates containing HA and collagen I. The plates were incubated for 3 days. 
 
2.2.9 Co-culture of cancer cells and stellate cells in collagen I 
 
Stellate cells and cancer cells were grown to reach 60-90% confluence. Cells were trypsinized and lifted 
using 0.25% trypsin with 0.02% EDTA at 37 °C, with the process being halted by the addition medium 
composed of DMEM/F12 + 10% FBS + P/S. Cell count in the collected cell preparations was determined 
using a glass haemocytometer. Mixtures of stellate cells and cancer cells were prepared at a 2:1 ratio 
to produce a final cell suspension of 1,000 stellate cells and 500 cancer cells per 50 µL (20,000 cells/mL 
stellate cells and 10,000 cells/mL cancer cells), in each well of a 96-well plate. Tubes with stellate cells 
and cancer cells mixture were centrifuged at 125 g for 5 minutes and the supernatant was aspirated to 
discard trypsin. Cell pellets were suspended in medium DMEM/F12 + 10% FBS + P/S with the volume 
matching the cell suspension of 20,000 cells/mL stellate cells and 10,000 cells/mL cancer cells. Collagen 
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I was added to reach the final concentration of 0.1 mg/mL and mixed well. 50 µL cell-collagen mixture 
was pipetted into each well of 96-well polyHEMA plates. 50 µL fresh medium DMEM/F12 + 10% FBS + 
P/S was added next day.  
 
2.2.10 Co-culture of cancer cells and stellate cells in collagen I and hyaluronic acid 
  
10 mg/mL HA in PBS was sterilized by autoclaving and stored at 4°C until use. 7 mg/mL HA was diluted 
using DMEM/F12 + P/S. Stellate cells and cancer cells were grown to reach 60-90% confluence. Cells 
were trypsinized and lifted using 0.25% trypsin with 0.02% EDTA at 37 °C, with the process being halted 
by the addition of medium composed of DMEM/F12 + 10% FBS + P/S. Cell count in the collected cell 
preparations was determined using a glass haemocytometer. Mixtures of stellate cells and cancer cells 
were prepared at a 2:1 ratio to produce a final cell suspension of 1,000 stellate cells and 500 cancer 
cells per 50 µL (20,000 cells/mL stellate cells and 10,000 cells/mL cancer cells), in each well of a 96-well 
plate. Tubes with stellate cells and cancer cells mixture were centrifuged at 125 g for 5 minutes and 
the supernatant was aspirated to discard trypsin. Cell pellets were suspended in medium DMEM/F12 
+ 10% FBS + P/S with half of the final total volume matching the cell suspension of 20,000 cells/mL 
stellate cells and 10,000 cells/mL cancer cells. The same volume as half of the final total volume of 7 
mg/mL HA in previous step was added to reach the final concentration of 3.5 mg/mL HA with gentle 
mixing. Collagen I was added to reach the final concentration of 0.3, 0.1, 0.05, 0.03 mg/mL with gentle 
mixing. 50 µL cell/collagen/HA mixture was pipetted into each well of 96-well polyHEMA plates. 50 µL 





2.3 Spheroid size measurement  
 
Phase-contrast images were acquired using Leica DMI4000 B (50x magnification) and 4-18 spheroids 
per group were captured on day 4, day 5, day 6 and day 7 after initiation of cell culture. Spheroid size 
was determined by CellProfiler software (version 3.0.0). The workflow for spheroid size measurement 
was as follows: 






























Coloured images were imported and converted to greyscale images by the module ‘ColorToGray’. Black 
colour in greyscale images resulting from the conversion were inverted to white colour by ‘ImageMath’ 
so that the black region where one spheroid located could become white in order to be recognized and 
measured by the image processing software. The white region indicating the whole spheroid was 
identified as the object by the module ‘IdentifyPrimaryObjects’, setting mostly 300–1700 pixels as the 
diameter to be identified so that the pipeline was versatile for measuring small spheroids (diameters 
of 350 pixels in average) containing stellate cells and large spheroids (diameters of 1400 pixels in 
average) containing PANC-1 cells. Objects outside the diameter range and touching the border of the 
image were discarded in order to reduce the false measurement of the background noise which led to 
long processing time and inaccurate identification of spheroids. Threshholding strategies were 
optimized to identify the objects, balancing the accuracy and efficiency. ‘Global’, ‘Otsu’ and ‘Three 
classes’ options were selected as the thresholding. The pixels in the middle intensity class were 
assigned to the background. The threshold smoothing scale was 1.3488 and the correction factor was 
1.0, with threshold range from 0.0 as lower bound and 1.0 as upper bound. ‘Intensity’ was selected as 
the method to distinguish clumped objects and draw dividing lines between clumped objects. The size 
of the smoothing filter for declumping and minimum allowed distance between local maxima were 
automatically calculated. 
The pipeline in counting large spheroids in HA and collagen I touching the borders of the images in the 
section 5.5.1 was modified because the areas where the spheroids were present exceed the limit of 
the field of view that the microscope could capture. In the module ‘IdentifyPrimaryObjects’, 300–3000 
pixels were set as the diameter to be identified. Objects outside the diameter range and touching the 
border of the image were retained. The pixels in the middle intensity class were assigned to the 
foreground due to a light appearance of the spheroids. 
The number of pixels in the region indicating the area of the spheroid in each image was extracted by 
the module ‘MeasureObjectSizeShape’ while the area of the spheroid was outlined by the module 
‘OverlayOutlines’. A new image was generated by the module ‘SaveImages’ for manual verification. All 
the images imported to the pipeline and exported as new images with overlay spheroids were 
inspected by one operator to ensure the correct area of spheroids on each image. Images showing false 
identification of areas of spheroids such as including excess background to the identified area of the 
actual spheroid were deleted from the final calculation. Areas of spheroids that were segmented into 
different objects were added together to count the final area.  
The measurements in pixel were exported by the module ‘ExportToSpreadsheet’. The mean of the 
values in the column ‘AreaShape_Area’ in each experiment group was calculated by Excel to be used 
as Area in the following formula. Normalisation of spheroid size was calculated by the following 
formula: 
100% x Area (Day X)  
Percentage of spheroid size = 
    Area (Day 4 or Day 5) 
 
The area in micrometre2 of spheroid size was calculated by the area in pixel multiply the ratio of the 





2.4 Cell viability in Myogel  
 
Cell viability of cancer cells in 2D and 3D with Myogel was examined using AlamarBlue® assay. 10 μL of 
freshly-made 5 μg/μL resazurin (Sigma, Cat. # R7017) in PBS was added to the wells (100 μL) with or 
without cells at the final concentration of 0.5 μg/μL after 2 and 4 days. After an 18-hour incubation at 
37°C in a humidified, 5% CO2 atmosphere, fluorescence intensities were measured using FLUOstar 
Omega spectrometer set at excitation of 540 nm and emission detection of 590 nm. Fluorescence of 
five-six wells containing cells or spheroids with or without Myogel were measured. Medium and 
Myogel only wells were measured as contamination control. 
 
2.5 MassSpec analysis of Myogel 
 
In order to validate the presence of collagen I, collagen IV, fibronectin and laminin in the Myogel as 
previously reported, tandem mass spectroscopy (MS/MS) was performed to identify those proteins. 
Before analysis by MS, in-solution digestion using trypsin or in-gel digestion was performed according 
to the protocol from the website: http://www.chem.ox.ac.uk/spectroscopy/mass-
spec/MS%20service/Proteomics%20protocols/Protocol%20In%20solution%20digestion_nov2016.pdf. 
180 μg Myogel (20 μL) was mixed with 100 μL 6 M urea in Tris buffer (0.4 M, pH 7.8) and vortexed for 
2 minutes. 40 μg of BSA (Sigma, Cat. # A7906) and 60 μg of collagen I were used as controls. 5 μL of the 
DTT (Fermentas, Cat. # R0862) reducing reagent was added and vortexed. The mixture was incubated 
for 60 minutes at room temperature or 37 °C. 20 μL of the iodoacetamide (Sigma, Cat. # I1149) 
alkylating reagent was added and vortexed. The mixture was incubated for 60 minutes at room 
temperature or 37 °C. 20 μL of the DTT reducing reagent was added and vortexed. The mixture was 
incubated for 60 min at room temperature or 37 °C. 775 μL MilliQ‐H20 was added and the solution was 
vortexed. 20 μL of 0.2 μg/μL trypsin (Sigma, Cat. # T1426) was added and the digestion was carried out 
overnight at room temperature or at 37 °C. 10 μL of acetic acid (Sigma, Cat. # 27225) was added and 
the solution was purified by phenomenexTM StrataTM C18-E column. After the proteins was dried 
completely in a speed‐vac, the pellets was resuspended in 50 μL 98% MilliQ‐H20 with 2% HPLC‐grade 
acetonitrile (VWR, Cat. # 83639.320) and 0.1% formic acid (Sigma, Cat. # 27001-M).   
For in-gel digestion, the protein mixtures in Myogel were separated in a single dimension by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 6% of acrylamide gel. Rat tail 
collagen I was used as a positive control for collagen I and BSA was used as a methodological control. 
The gel was stained with fresh Coomassie blue R-250 (Fisher BioreagentsTM, Cat. # BP101-25) at room 
temperature for 1 hour and destained in boiling water until the blue bands were visible and the 
background was transparent. The protein bands ranging from 100 kDa to 300 kDa in the lanes 
containing Myogel and collagen I while the single band near 70 kDa in the lane containing BSA were 
cut into smaller pieces (1-2 mm3). The gel pieces were placed in a 1.5 mL tube and sent to the 
Department of Biology to perform the in-gel digestion.  
MS instruments were operated by technical specialists, Shaun Reeksting and Mervyn Lewis, in Chemical 
Characterisation and Analysis Facility (CCAF). The Chip-based analysis was conducted using an HPLC-
Chip Cube system coupled to a 6520 quadrupole time-of-flight (QTOF) mass spectrometer (Agilent 
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Technologies, Santa Clara, CA) operated in ESI positive-ion mode. Liquid chromatography was 
performed using a Large-Capacity Chip (II) with a 160 nL enrichment column and analytical column of 
150 mm x 75 µM with Zorbax 300SB-C18 packing material at 5 µm (G4240-62010, Agilent, Santa Clara, 
CA, USA). The ChipCube source was operated at 300 °C with 5 L/min N2 drying gas, the capillary voltage 
set to 1900 V and fragmentor at 170 V. The TOF MS scan range was from 300 – 1700 mass-to-charge 
ratio (m/z) at an acquisition rate of 4 spectra per second. For MS/MS 5 multiply charged precursor ions 
per spectrum, having between 2 – 5 charges, were selected for MS/MS and thereafter excluded after 
collecting 2 spectra, then released after 0.1 minute. The MS/MS mode mass range was from 50 – 1700 
m/z at 3 spectra per second with the collision energy set relative to the ion mass with the formula 
3.6m/z / 100 - 4.8. The source was interfaced with an Agilent 1260/1200 series HPLC system consisting 
of a 1260 Cap pump, 1200 Nano pump, 1200 Micro WPS and 1290 Infinity Thermostat (Agilent, Santa 
Clara, CA, USA). Between 0.2 and 1 µL sample was loaded on the enrichment column using the capillary 
pump flow with H2O + 0.1% formic acid (FA) at a flow rate of 4 µL/min. The sample was eluted onto the 
analytical column using the nano pump at a flow rate of 0.3 µL/min. Solvent A and B consisted of H2O 
+ 0.1% formic acid (FA) and ACN:H2O 90:10 with 0.1% FA. Gradient step were as follows: 0-28 minutes 
from 3% B to 50%B, 28-30 min to from 50% B to 100% B, 30-31 minutes 100%B, 31-32 minutes from 
100% to 3% B. Internal lock mass calibration was active during the run using one calibrant reference 
mass at 1221.9906 m/z. Data processing and file exporting was performed using the Masshunter 
Workstation software version B.50.00 (Agilent, Santa Clara, CA, USA). Automated MS/MS database 
searching was performed using Mascot v2.4.1 (Matrix Science, MA, USA) with the SwissProt database 
using the following search parameters: allowed 2 max trypsin cleavages, fixed carbamidomethyl and 
variable oxidation of methionine modifications with a peptide mass tolerance of 20 ppm and a 
fragment mass tolerance of 0.1 Da. 
 
2.6 Immunoblotting  
 
Twenty spheroids were collected in 1.5 mL Eppendorf tube on ice and the cell culture medium was 
discarded as much as possible. 100 μL of Radio-Immune Precipitation Assay (RIPA, Thermo ScientificTM, 
Cat. # 89900) lysis buffer containing Halt Protease Inhibitor Cocktail (Thermo ScientificTM, Cat. # 78430) 
and Phosphatase Inhibitors Cocktail IV (Fisher BioreagentsTM, Cat. # 12851650) was added to each tube, 
homogenised with Axygen™ Tissue Grinder for 1.5 And 2.0 mL tubes (Axygen™, Cat. # Axygen PES-15-
B-SI) and vortexed about 10 second and the tubes were left on ice for 10 minutes. The homogenisation 
and vortex was repeated twice. The total time for cell lysis was 1 hour. After the cell lysis on ice, the 
tubes were centrifuged at 4 °C, 16,000 g for 10 minutes. The supernatants were stored in - 80°C until 
further analysis.  
10x SDS-PAGE stock running buffer was made by dissolving 30.3 g Tris base, 144 g glycine (Fisher 
BioreagentsTM, Cat. # BP381-1), and 10 g sodium dodecyl sulfate (SDS, Fisher, Cat. # S/5200/53) in 1 L 
Milli-Q water. 100 mL of the stock running buffer was diluted to 1 L using Milli-Q water to make 1x SDS-
PAGE running buffer. Running buffer was stored at room temperature.  
10x stock transfer buffer was made by dissolving 30.3 g Tris base, and 144 g glycine in 1 L Milli-Q water. 
100 mL of the stock transfer buffer was diluted to 800 mL using Milli-Q water and 200 mL methanol 
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(VWR, Cat. # 20864.320) was added to make 1x transfer buffer, which was put in 4 °C at least 1 hour 
before transfer steps. The 1x transfer buffer was freshly made every time. 
10x stock TBS was made by dissolving 24.2 g Tris base, and 80 g sodium chloride in 800 mL Milli-Q 
water. After the pH was adjusted to 7.5 using HCl (VWR, Cat. # 20254.401), Milli-Q water was added to 
make the final volume of 1 L stock TBS. 100 mL of the stock TBS was diluted to 1 L using Milli-Q water 
to make 1x TBS. 1 mL TWEEN® 20 (Sigma, Cat. # P1379) was added to 1 L TBS to make 1x TBS-T. 
The blocking buffer contained 5% (w/v) BSA in 1x TBS or 1x TBS-T. 
Preparation of the SDS-PAGE gel was as follows: 8% resolving gel solution was made of 53% Milli-Q 
water, 20% Acrylamide/Bis-acrylamide (40% solution, Mix ratio 29:1, Sigma, Cat. # A7802), 25% Tris/HCl 
(1.5 M, pH 8.8), 1% SDS (10% solution), 1% ammonium persulfate (APS, 10% solution, w/v, Fisher, Cat. 
# A/P470/46), and 0.1% tetramethylethylenediamine (TEMED, Fisher Chemical, Cat. # T/P190/04). The 
solution was pipetted into the cassettes and overlaid with butanol (Fisher, Cat. # B/4800/08). After 30 
minutes, the butanol was washed off with tap water and the excess water was wiped with tissue. 4% 
stacking gel solution was made of 58% Milli-Q water, 15% Acrylamide/Bis-acrylamide (40% solution), 
25% Tris/HCl (0.5 M, pH 6.8), 1% SDS (10% solution), 1% APS (10% solution), and 0.1% TEMED. The 
solution was pipetted into the cassettes to overlay the resolving gel and the sample lane combs were 
inserted. After 30 minutes, gels were ready and stored at 4°C for no more than 1 week.  
Reduced samples were prepared with loading buffers by mixing 52 μL protein sample (cell lysate or 
Myogel preparation) with 20 μL NuPAGE® LDS sample buffer (4x, Invitrogen™, Cat. # NP0007) and 8 μL 
NuPAGE® Reducing Agent (10x, Invitrogen™, Cat. # NP0009). Samples with loading buffers were heated 
for denaturing electrophoresis at 95 °C for 3-5 minutes and then stored in -80 °C until further analysis. 
10 μL of cell lysates with loading buffers or 20 μL of Myogel with loading buffers were loaded at each 
well and 1-3 μL PageRuler™ Prestained 10-180 kDa Protein Ladder (Thermo Scientific™, Cat. # 26616) 
or Spectra™ Multicolor High Range Protein Ladder (Thermo Scientific™, Cat. # 26625) were used. Rat 
tail collagen I, Matrigel® Basement Membrane Matrix (Matrigel, Corning, Cat. # 734-0269P) and 
fibronectin bovine plasma (Sigma, Cat. # F1141) were used as controls in characterisation of Myogel. 
Two gels were run at 100 V for about 2 hour until the 40 kDa band in the protein ladders was at 20% 
above the bottom of the gel.  
Prior to the transfer step, two Immobilon® FL PVDF transfer membranes (EMD Millipore, Cat. # 
IPFL00010) were cut and soaked in 100% methanol for 15 seconds and then placed in the transfer 
buffer. The blotting pads were soaked in transfer buffer and air bubbles were removed by squeezing 
the blotting pads while they were submerged in buffer.  
At the end of the running step, the gels were removed from the cassettes and the stacking gels were 
trimmed away. The remaining gels were placed in transfer buffer until use. Filter papers were soaked 
briefly in transfer buffer immediately before use. One blotting pad was placed into the cathode (-) core 
of the blot module (InvitrogenTM, Cat. # EI9051) and one filter paper was placed onto the blotting pad, 
followed by strict order of one gel, one membrane, one filter paper, one blotting pad and then one 
filter paper. The other gel was placed on top of the last filter paper with the membrane on top of the 
gel and then one filter paper followed by the blotting pad. The blot module containing the 
gel/membrane sandwich was secured in the lower buffer chamber. The blot module and the outer 
buffer chamber were filled with cold transfer buffer. The transfer conditions were 30 V constantly for 
1.5 hours.  
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After the transfer step, the membranes were briefly placed in TBS and then blocked with 5% (w/v) BSA 
in TBS or TBS-T at room temperature for 1 hour. Each membrane was then probed with one antibody 
against one target protein and one housekeeper protein antibody from different species at 4°C 
overnight. The dilution of antibodies were summarized in Table 2. The membranes were washed thrice 
for 5 minutes each time in TBS-T. Fluorescent secondary antibodies in blocking buffer were added to 
the membranes and the membranes were incubated in dark boxes prevented from light at room 
temperature for 1-1.5 hours. The membranes were washed thrice for 3-5 minutes each time in TBS-T 
and scanned by Odyssey® CLx Infrared Imaging System LI-COR Bioscences.  
 
Table 3. List of antibodies in immunoblotting. 
Antibody Species Clonality Manufacturer Cat. # Dilution 
HDAC1(10E2) Monoclonal Mouse IgG1 
Santa Cruz 
biotechnology sc-81598  1:5,000 
αSMA  Goat polyclonal Abcam ab21027  1:1,000 
αSMA  Rabbit polyclonal  Abcam ab5694  1:1,000 
GAPDH Antibody (FL-
335)  Rabbit polyclonal  
Santa Cruz 
biotechnology sc-25778  1:10,000 
p53 (DO-1) Monoclonal Mouse IgG2a 
Santa Cruz 
biotechnology sc-126  1:1,000 
YAP(63.7) Monoclonal Mouse IgG2a 
Santa Cruz 
biotechnology sc-101199  1:1,000 
COL1A1(3G3) Mouse monoclonal IgG3 
Santa Cruz 
biotechnology sc-293182  1:100 
Laminin β-2 (C4) Monoclonal Mouse IgG1 
Santa Cruz 
biotechnology sc-59980  1:500 
Fibronectin (EP5) Monoclonal Mouse IgG1 
Santa Cruz 
biotechnology sc-8422   1:500 
COL4A6 (G-2) Monoclonal Mouse IgG1 
Santa Cruz 
biotechnology sc-398655  1:500 
IRDye 680RD Donkey 
anti-Mouse IgG Donkey LI-COR 926-68072  1:10,000 
IRDye 800CW Donkey 
anti-Goat IgG Donkey LI-COR 926-32214  1:10,000 
IRDye 680RD Donkey 
anti-Rabbit IgG Donkey LI-COR 926-68073  1:10,000 
IRDye 800CW Donkey 







2.7 Treatments of anti-cancer agents on the co-culture models in collagen I 
 
3D co-culture was done as in the section 2.2.8. 50 mM gemcitabine hydrochloride (Santa Cruz 
Biotechnology, Cat. # sc-204763), 10 mM Pseudopterosin A-D (PsA-D) from Prof. Dr. Russell Kerr, 
Veterinary College, University of Prince Edward Island and 10 mM Tylophorinine from Prof. Dr. Proksch, 
Institute of Pharmacological Biology and Biotechnology, Heinrich-Heine University Düsseldorf, all of 
which were dissolved in Dimethyl Sulfoxide (DMSO, Sigma, Cat.# D2650), were added to the spheroids 
on day 4 to reach the final concentration of 100 µM gemcitabine, 70 µM PsA-D and 0.1 µM 
Tylophorinine respectively. The concentration of 100 µM gemcitabine was chosen according to the 
IC50 previously reported in 3D mono-culture of MIAPaCa-2 and PANC-1 cells [Wen et al, 2013]. The 
concentrations of 70 µM PsA-D and 0.1 µM Tylophorinine were chosen based on the IC50 results 
provided by our collaborators, Janina Betz, Julia Sperlich, and Nicole Teusch. 0.7% DMSO was used as 
the solvent control and 10% fresh medium was used as untreated control. After the addition of agents, 




The following protocol was kindly provided by Silvia Muñoz Descalzo from Department of Biology 
[Nichols et al, 2009] and was modified slightly. 3-6 spheroids were fixed in 4% paraformaldehyde (PFA, 
Sigma, Cat. # P6148) in PBS using Eppendorf tubes for 0.5-1 hour at room temperature. After fixing, 
the spheroids were rinsed 4 times in 3 mg/mL polyvinylpyrrolidone (PVP, Sigma, Cat. # P0930) in PBS 
(PBS/PVP) and then stored in 4 °C for no more than 1 week until immunofluorescence studies.  
Before antibodies staining, the spheroids were permeabilised in 0.25% Triton™ X-100 (Sigma, Cat. # 
X100) in PBS/PVP for 0.5-1 hour. After permeabilisation, the spheroids were placed in blocking solution 
(0.1% BSA and 0.01% Tween 20 in PBS) for 0.5 hour. The spheroids were incubated in primary antibody 
solution (1:100 in blocking solution) for 19-24 hours with gentle shaking in the 4 °C. Antibodies were 
summarized in Table 3. Before incubation with secondary antibodies, the spheroids were rinsed thrice 
for 15 minutes each time in blocking solution with vigorous shaking at room temperature. The 
spheroids were incubated in secondary antibody solution (1:200 in blocking solution) and 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI, Sigma, Cat. # D9542) with gentle shaking in the 4 °C, 
protected from light. After an overnight incubation, the spheroids were rinsed 4 times for 15 minutes 
in blocking solution with vigorous shaking at room temperature, protected from light.  
Extra cautions were taken for processing PANC-1 mono-culture spheroids due to their loose nature. 
Quick centrifugation was performed to collect fragments of PANC-1 mono-culture spheroids before 
aspiration of solution. 
After the ending of the final shaking, the blocking solution was aspirated as much as possible and the 
spheroids were incubated with at least 500 µL of increasing ethanol concentration mixed with MiliQ 
water for 30 minute at room temperature in the following sequence: 1) 30% ethanol; 2) 50% ethanol; 
3) 70% ethanol; 4) 90% ethanol; 5) 96% ethanol; 6) 100% ethanol; 7) 100% ethanol. At the end of the 
ethanol incubation, the ethanol was aspirated as much as possible and the spheroids were incubated 
in benzyl alcohol (Alfa Aesar, Cat. # L03258) and benzyl benzoate (Alfa Aesar, Cat. # L03292) at 1:2 (v/v, 
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BABB) for at least 1 hour at room temperature. At the end of the BABB incubation, spheroids were 
transferred to the wells of an ibidi µ-Plate 96 well black (ibidi, Cat. # 89626) with as little BABB as 
possible to prevent the movement of spheroids in BABB so that the spheroids stayed stationary in the 
wells. The plates could be stored at 4 °C until analysis. 
 
Table 4. List of antibodies used in immunofluorescence. 
 
Antibody Species Clonality Manufacturer Cat. #  Dilution 










biotechnology sc-101199  1:100 
YAP(H-125) Rabbit polyclonal  
Santa Cruz 
biotechnology sc-15407  1:100 
Occludin (H-279) Rabbit polyclonal  
Santa Cruz 
biotechnology sc-5562  1:100 
Pan-TEAD(D3F7L) Rabbit monoclonal  
Cell Signaling 
Technology #13295  1:100 
αSMA  Goat polyclonal Abcam ab21027  1:100 
αSMA  Rabbit polyclonal  Abcam ab5694  1:100 
FAP Rabbit polyclonal  Abcam ab53066  1:100 
Ki67(H-300) Rabbit polyclonal  
Santa Cruz 
biotechnology SC-15402  1:100 
Donkey anti-Goat IgG 
secondary antibody, Alexa 
Fluo 488 Donkey polyclonal 
Invitrogen/ThermoFis
her A-11055  1:200 
Donkey anti-Rabbit IgG 
secondary antibody, Alexa 
Fluo 546 Donkey polyclonal 
Invitrogen/ThermoFis
her A10040  1:200 
Chicken anti-Mouse IgG 
secondary antibody, Alexa 
Fluor 647 Donkey polyclonal 
Invitrogen/ThermoFis
her A-21463   1:200 
Rabbit IgG Isotype Control (3 
mg/mL) Rabbit Invitrogen 10500C  1:1000 
Goat IgG (5 mg/mL) Goat Invitrogen  02-6202  1:500 
Mouse IgG (0.4 mg/mL) Mouse 
Santa Cruz 





2.9 Confocal laser scanning microscopy (CLSM) 
  
Images were acquired on a Zeiss 880 confocal laser scanning microscope with Airyscan (Carl Zeiss) using 
a Plan-Apochromat 5x/0.16 M27 (12.1 mm working distance), a Plan-Apochromat 10×/0.45 NA 
objective lens (2 mm working distance), a Plan-Apochromat 20×/0.8 NA objective lens (0.55 mm 
working distance) or a Plan-Apochromat (oil) 40×/1.3 NA objective lens (0.21 mm working distance) 
below 20 °C. Fluorophores were excited simultaneously using at least two different laser wavelengths 
as specified below, 488/561/633 main beam splitter and -405 main beam splitter_InVis with the non-
descanned detector to acquire the differential interference contrast (DIC) images.  
The lasers and filter settings were as follows: 405nm (Argon) excitation and 410–497 nm filters for DAPI 
as DAPI channel; 488 nm (Argon) excitation and 500–553 nm filters for Alexa Fluor 488 as Alexa488 
channel; 561 nm (Argon) and 562–624 nm filters for Alexa Fluor 546 as Alexa546 channel; 633 nm 
(HeNe) and 624-735 nm filters for Alexa Fluor 647 as Alexa647 channel. 
Unless specified otherwise, most of the images in chapter 3 were recorded using two tracks with DAPI 
channel and Alexa546 channel in one track while Alexa488 channel and Alexa647 channel in the other. 
Images in chapters 4 and 5 were recorded in multitracking mode separating each channel into one 
track individually. 
Spectral unmixing was done in Zen 2.5 (blue edition) or Zen 2.3 (blue edition) using Automatic 
Component Extraction (ACE) or spheroid controls. ACE was done in the software by detecting the 
individual spectrum of three or four dyes in the images automatically to unmix the image. Alternatively, 
individual spectrum of different dyes was obtained by staining the spheroids with only one dye as 
spheroid controls and using the same acquisition settings as the spheroids stained with three dyes. The 
spectrum of each dye was saved and used as a reference spectrum to unmix the images acquired with 
three dyes in the software. 
When acquiring the single image (one optical section) near the core of spheroids in chapter 3 and 4 
stained with the following combination: DAPI, rabbit anti-YAP antibodies, mouse anti-p53 antibodies, 
or the following combination: DAPI, goat anti-p53 antibodies, and rabbit anti-YAP antibodies, DAPI, 
Alexa Fluor 488, Alexa Fluor 546 and Alexa Fluor 647 were excited simultaneously using 405 nm at 2% 
laser power, 488 nm at 2% laser power 561 nm at 2% laser power and 633 nm at 10% laser power. 
Either 10x or 20x objective lens was selected to capture the whole spheroid area/region in one 1x1 
image tile. When using a 40x objective lens, tile scanning was performed using 2x2 image tiles. 512x512 
pixels image size in unidirectional and line sequential mode with 2 frame averaging and 8-bit depth 
were used. > 30% laser power setting was also used in non-cleared samples. 
When acquiring a single image (one optical section) near the core of spheroids cultured in hyaluronic 
acid stained with DAPI and goat anti-p53 antibodies, DAPI and Alexa Fluor 488 were excited 
simultaneously using 405 nm at 2% laser power (master gain 570) and 488 nm at 5% laser power 
(master gain 605). Either 10x or 20x objective lens was selected to capture the whole spheroid 
area/region in one 1x1 image tile. 1024x1024 pixels image size or 512x512 pixels image size in 




When acquiring a single image (one optical section) near the core of spheroids cultured in HA and 
collagen I stained with DAPI and goat anti-p53 antibodies, DAPI and Alexa Fluor 488 were excited 
simultaneously using 405 nm at 2% laser power and 488 nm at 5% laser power. Master gains were 
adjusted to minimise pixel saturation. A 10x objective lens was selected to capture the one optical 
section in one 1x1 image tile. 1024x1024 pixels image size or 512x512 pixels image size in unidirectional 
and line sequential mode with 2 frame averaging and 8-bit depth were used. 
When imaging an entire spheroid in collagen I with or without HA on day 4 stained with DAPI and goat 
anti-p53 antibodies, DAPI and Alexa Fluor 488 were excited simultaneously using 405 nm at the 2% 
laser power and 488 nm at the 2% or 5% laser power. When imaging the entire spheroids on Day 4 
stained with DAPI and mouse anti-p53 antibodies, DAPI and Alexa Fluor 647 were excited 
simultaneously using 405 nm at 2% laser power and 633 nm at 2% or 3% laser power. Master gains 
were adjusted to minimise pixel saturation. 5x, 10x or 20x objective lens was used in order to capture 
the whole spheroid in one 1x1 image tile. Z-stack acquisition was performed at the optimal slice interval 
determined by the Zen 2.3 SP1 FP1 (black edition). 1024x1024 pixels image size or 512x512 pixels image 
size in unidirectional and line sequential mode with 2 frame averaging and 8-bit depth were used. 
When acquiring a single image (one optical section) of spheroids (collected on day 4 after initial culture) 
that were stained with DAPI, goat anti-p53 antibodies, rabbit anti-pan-TEAD antibodies or rabbit anti-
Ocln antibodies, and mouse anti-YAP antibodies in Chapter 5, fluorescent dyes were simultaneously 
excited using 405 nm, 488 nm, 561 nm and 633nm lasers. The laser powers at 10% maximum and 
master gains were adjusted to minimise pixel saturation. A 20x objective lens, 1024x1024 pixels image 
size in unidirectional and line sequential mode with 2 frame averaging and 8-bit depth were used. 
When imaging an entire spheroid (collected on day 4 after initial culture) stained with DAPI, rabbit anti-
αSMA antibodies and mouse anti-p53 antibodies in Chapter 5, DAPI, Alexa Fluor 561 and Alexa Fluor 
647 were excited simultaneously using 405 nm at 2% laser power, 561 nm at 2% laser power laser and 
633nm laser at 5% laser power. Master gains were adjusted to minimise pixel saturation. Z-stack 
acquisition was performed at 2.683 μm slice interval using a 10x objective lens and 1024x1024 pixels 
image size in unidirectional and line sequential mode with 2 frame averaging and 8-bit depth. 
When imaging entire spheroids treated with or without anti-cancer agents, DAPI, Alexa Fluor 488 and 
Alexa Fluor 561 were excited simultaneously using 405 nm (master gain 500) at 2% laser power, 488 
nm (master gain 700 if using a 20x objective lens or 650 if using a 10x objective lens) at 2% laser power 
and 561 nm lasers (master gain 700 if using a 20x objective lens or 650 if using a 10x objective lens) at 
1% laser power were used. Z-stack acquisition was performed in a defined X/Y/Z (2.768/2.768/2.683 
μm) volume and 512x512 pixels image size with 1.54 µs pixel dwelling time if using a 10x objective lens 
or X/Y/Z (0.692/0.692/0.748 μm) volume and 1024x1024 pixels image size with 0.77 µs pixel dwelling 
time if using a 20x objective lens. All the Z-stack imaging was done in unidirectional and line sequential 
mode with 1 frame averaging and 8-bit depth. 
When acquiring a single image (one optical section) near the core of spheroids treated with or without 
anti-cancer agents in Airyscan mode, all 4 fluorophores were excited simultaneously using 405 nm at 
0.2% laser power, 488 nm at 1% laser power, 561 nm at 1% laser power, and 633 nm at 2 % laser power. 
A 10x objective lens, 4096x4096 pixels image size and 750 master gain in unidirectional and line 
sequential mode with 1 frame averaging and 8-bit depth were used. Airyscan processing was done in 
Zen 2.5 (blue edition). 
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2.10 Multiphoton microscopy (MP) 
 
Multiphoton (MP) imaging was acquired using Zeiss 880 with Spectra Physics multiphoton lasers. 20x 
objective lens, 2048x2048 pixels image size in unidirectional and line sequential mode with 8 frame 
averaging and 8-bit depth were used.  
MP wavelength optimisation was performed by Anne Gesell in Microscopy and Analysis Suit (MAS). MP 
excitation wavelengths ranging from 690 – 980 nm was performed on spheroids stained with 3 dyes 
and CLSM images at the same position were used as reference. The SP filter of 485 nm for DAPI 
coloured blue was considered as DAPI channel; the BP filter of 500-550 nm for Alexa Fluor 488 coloured 
green as Alexa488 channel; the BP filter of 570-610 nm for Alexa Fluor 546 coloured red as Alexa546 
channel. After optimising the excitation wavelength, DAPI was excited with 690nm and the SP filter of 
485 nm was used to collect the photons; Alexa Fluor 488 was excited with 950nm and the BP filter of 
500-550 nm was used to collect the photons; Alexa Fluor 546 was excited with 850nm and the BP filter 





2.11 Image analysis for immunofluorescence 
 
Workflow for p53 expression measurement by CellProfiler in fluorescent images was as follows: 






























The images acquired in the p53 channel were exported individually and coloured green. Green images 
were imported and converted to greyscale images by the module ‘ColorToGray’ in order to measure 
the intensities. The regions indicating the positive p53 staining of nuclei were identified as objects by 
the module ‘IdentifyPrimaryObjects’, setting 5–200 pixels as the typical diameter of objects for the 
image acquired by MP while 5-80 for CLSM. Objects outside the diameter range and touching the 
border of the image were discarded. Threshholding strategies were optimized to identify the objects, 
balancing the accuracy and efficiency. ‘Adaptive’, ‘Otsu’ and ‘Three classes’ options were selected as 
the thresholding. The pixels in the middle intensity class were assigned to the background. The 
threshold smoothing scale was 1.3488 and the correction factor was 1.0, with threshold range from 0.5 
as lower bound and 1.0 as upper bound. The size of adaptive window was 50. ‘Shape’ was selected as 
the method to distinguish clumped objects and draw dividing lines between clumped objects. The size 
of the smoothing filter was 20. After a few testing on the number of minimum allowed distance to use 
as a parameter to separate objects (local maxima), local maxima that were over 20 minimum allowed 
distance can result in under-segmentation, leading to merging too many objects together and false 
identification of individual p53 positive nucleus. Therefore, local maxima that were closer than 20 
minimum allowed distance was suppressed in order to separate individual p53 positive object. 
The regions indicating the areas of the p53 positive nuclei in each image were extracted by the module 
‘MeasureObjectSizeShape’. The intensities of the areas of the p53 positive nuclei were extracted by 
the module ‘MeasureObjectIntensity’. The areas of the p53 positive nuclei were outlined by the module 
‘OverlayOutlines’. A new image was generated by the module ‘SaveImages’ for manually verification 
of the correctness of region measured to eliminate the incorrect identification of the p53 positive nuclei 
due to background noise. Objects identified as p53 positive were numbered on top of p53 positive 
objects in the image by ‘DisplayDataOnImage’ to aid matching the nuclei in the image acquired by CLSM 
and by MP. The resulting p53 intensities and the corresponding area were exported by the module 
‘ExportToSpreadsheet’. The value of p53 intensities in the column ‘Intensity_IntegratedIntensity’ 
divided by the area used to extract p53 intensities in the column ‘AreaShape_Area’ was used to 
compare the p53 relative expression between cells in the core region and near the edge of the spheroid 














Workflow for YAP expression measurement by CellProfiler in fluorescent images was as follows: 




























Figure 17. Workflow for YAP expression measurement by CellProfiler. 
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The images acquired in DAPI channel coloured blue and YAP channel coloured red were exported 
individually. Coloured images were imported and converted to greyscale images by the module 
‘ColorToGray’ in order to measure the intensities. The regions indicating the DAPI staining of nuclei 
were identified as primary objects by the module ‘IdentifyPrimaryObjects’, setting 3–20 pixels as the 
typical diameter of objects for the image. Objects outside the diameter range and touching the border 
of the image were discarded. Threshholding strategies were optimized to identify the objects, 
balancing the accuracy and efficiency. ‘Adaptive’, ‘Otsu’ and ‘Three classes’ options were selected as 
the thresholding. The pixels in the middle intensity class were assigned to the background. The 
threshold smoothing scale was 1.3488 and the correction factor was 1.0, with threshold range from 0.2 
as lower bound and 1.0 as upper bound. ‘Intensity’ was selected as the method to distinguish clumped 
objects and draw dividing lines between clumped objects. The size of adaptive window, the size of the 
smoothing filter, local maxima and minimum allowed distance were modified in different images in 
order to optimise the outcomes of separating individual objects identified as nuclei. 
The regions indicating the YAP staining were identified as secondary objects by the module 
‘IdentifySecondaryObjects’, using DAPI staining nuclei identified by the module 
‘IdentifyPrimaryObjects’ as referenced input objects. ‘Distance – B’ was selected to identify the 
secondary objects. ‘Global’, ‘Otsu’ and ‘Three classes’ options were selected as the thresholding. The 
pixels in the middle intensity class were assigned to the background. The threshold smoothing scale 
was 0.0 and the correction factor was 1.0, with threshold range from 0.0 as lower bound and 1.0 as 
upper bound. The pixels to expand the primary object were adjusted in different images in order to 
optimise the outcomes of identifying the edge of each individual cell according to the cytoplasmic 
localisation of YAP. Secondary objects touching the border of the image were discarded. 
The regions indicating the areas of YAP expression in nuclei were selected in the module ‘MaskObjects’ 
where the objects identified by YAP staining were masked by the objects identified by DAPI staining. 
The intensity of YAP expression in the nucleus of each individual cell and in the whole cell of each 
individual cell were extracted by the module ‘MeasureObjectIntensity’ separately. The areas of YAP 
expression in nuclei and the YAP expression in the whole cells were outlined by the module 
‘OverlayOutlines’. A new image was generated by the module ‘SaveImages’ for manually verification 
of the correctness of region measured to eliminate the incorrect identification of the YAP expression 
due to background noise. The resulting YAP intensities were exported by the module 
‘ExportToSpreadsheet’ as a file with YAP expression in the nucleus of each individual cell generated by 
the module ‘MaskObjects’ and a file with YAP expression in the whole cell of each individual cell 
generated by the module ‘IdentifySecondaryObjects’. The value in the column 
‘Intensity_IntegratedIntensity’ was used to compare the YAP intensities between cells in the core 
region and near the edge of the spheroid or between YAP localisation in the nucleus and the cytoplasm 
in one optical slide. The YAP intensity in the cytoplasm of each individual cell was calculated by 







2.12 Statistical analysis 
 
Data were presented as mean value ± standard deviation (SD) except in Figure 23-25 where the value 
in each group was presented. Graphs were generated in Microsoft Excel 2016. Normality of data was 
analysed by Shapiro-Wilk test in IBM® SPSS® Statistics version 25.  
Non-parametric Kruskal-Wallis H test in IBM® SPSS® Statistics version 25 was used to compare the 
percentages of spheroid size and p53 expression. Error bars indicated SD of two-three independent 
experiments in spheroid size measurement or 9-17 cells in analysis of p53 expression in one 
independent experiment. Error bars and Graph were made by Microsoft Excel 2016. P-values were 
calculated by IBM® SPSS® Statistics version 25. P<0.05 (*) was considered as significant difference. 
Whisker box graphs generated in Microsoft Excel 2016 were made from all the values of total YAP 
intensity in the whole cell of each individual cell or the intensity ratios of nuclear YAP intensity to total 
YAP intensity in the whole cell or cytoplasmic YAP intensity to total YAP intensity in the whole cell from 
around 3-150 cells near the core of the spheroid and the edge of the spheroid. Mean markers were 
shown. Median was exclusive from quartile calculation. Dots indicated the values in cells automatically 
generated by Microsoft Excel 2016. Non-parametric Mann Whitney U test in IBM® SPSS® Statistics 
version 25 was used to compare intensities and ratios. P-values were calculated by IBM® SPSS® 
Statistics version 25. P<0.05 (*) was considered as significant difference. 
Two-tailed t-Test in Microsoft Excel 2016 was used to compare the fluorescence intensities in cell 
viability assay. Error bars indicated standard deviation of five or six wells in one independent 
experiment. P-value was calculated by Microsoft Excel 2016 using two-tailed two-sample equal 
variance t-Test if the sample sizes between two groups were the same or unequal variance t-Test if the 
sample sizes between two groups were not the same. P<0.05 (*) was considered as significant 
difference. 





Chapter 3.  YAP signalling in the 3D scaffold-free co-culture models with 
high ratios of stellate cells to cancer cells 
  















Figure 18. Diagram of YAP signalling in the 3D scaffold-free co-culture models with high ratios of stellate cells 
to cancer cells. 
 
In Brief 
Direct mixture of cancer cells and stellate cells co-cultured in a scaffold-free environment created a 
model where cancer cells became wrapped around a sphere of stellate cells. Thus, this format failed to 
create a model that emulated the organization observed in pancreatic tumours where clusters of 
cancer cells are surrounded by and intermingle with multiple layers of stellate cells. In the current 
models, higher level of endogenous YAP was found in the cytoplasm than in the nucleus in the majority 
of cancer cells, indicating a small amount of YAP localised in the nucleus might be sufficient to drive 
PDAC growth.  
Highlights 
Validation of immunofluorescence-based microscopic assessment of intact 3D co-culture spheroids 
with stellate cells and cancer cells using an optical clearing method with ethanol, benzyl alcohol and 










YAP signalling has been studied in pancreatic cancer cell lines transfected with YAP expression lentivirus 
[Yuan et al, 2016] or retroviral phosphorylation-deficient YAP [Yang et al, 2015] , cell-line xenografts 
and genetically engineered mouse models (GEMMs) [Murakami et al, 2017; Wei et al, 2017; Yang et al, 
2015; Zhao et al, 2017]. Genetic knock-out or knock-down of YAP has been shown to suppress 
pancreatic cancer growth while genetic inhibition of YAP phosphorylation, a method to facilitate YAP 
entering the nucleus, promotes cancer cell growth. Nuclear YAP expression is higher than its 
cytoplasmic expression in 2D culture of pancreatic cancer cells [Cravo et al, 2015; Diep et al, 2012]. 
Immunohistochemistry and immunofluorescence studies of pancreatic ductal adenocarcinoma (PDAC) 
tissues, however, can show that this bias of cellular localization may not occur consistently in these 
tumours [Diep et al, 2012; Morvaridi et al, 2015; Yang et al, 2015]. Whether a small amount of YAP in 
the nucleus or a higher ratio of YAP localised in the nucleus than the one in the cytoplasm is essential 
to induce proliferation in PDAC needs further investigation. To date, there are limited data on 
endogenous YAP expression in 3D co-culture models with pancreatic cancer cells and stellate cells 
derived from PDAC patients. 
One hallmark of PDAC tumours is their highly fibrotic nature with the large number of stellate cells 
present in the tumour, secreting extracellular matrix (ECM) components and growth factors that can 
interact with and influence the cancer cells. PDAC co-culture models composed of stellate cells and 
cancer cells can thus provide a more realistic representation of these tumours. Previously in in vitro 
studies, stellate cells are grown in one compartment of Transwell® plates, separating from cancer cells 
in the other compartment [Fujita et al, 2009]. This method lacks 3D architecture and cell-cell contact 
as cancer cells experienced in patients. Alternatively, stellate cells are seeded on top of animal-derived 
matrix in 24-well plates and then the cancer cells are plated on the matrix layer with stellate cells 
[Coleman et al, 2014b]. This protocol does not provide a complete barrier surrounding the cancer cells 
and is less ideal for high-throughput assays testing hundreds of anti-cancer agents. To our 
understanding, the use of 3D co-culture models as a robust tool to screen potential therapeutic agents 
is not yet optimal. It is our opinion that the lack of a simplified protocol to prepare consistently a 3D 
co-culture model has limited acceptance of this approach as a screening tool.  
In the PDAC microenvironment, a number of cancer-associated fibroblasts (CAFs) are originated from 
stellate cells, some of which are quiescent and play a role in repairing pancreatic injury [Erkan et al, 
2012]. Normal stellate cells are present in a variety of tissues in human body, including liver and 
pancreas [Erkan et al, 2012]. During PDAC development, stellate cells are activated by neoplastic cells 
to become CAFs, secreting large amount of ECM and promoting tumorigenicity [Bolm et al, 2017; Erkan 
et al, 2012; Hwang et al, 2008]. The terms CAFs and stellate cells are often interchangeable in PDAC 
research. However, hepatic stellate cells and pancreatic stellate cells have distinct features, separating 
them from the subtypes of fibroblasts such as skin fibroblasts. The transcriptional phenotypes of skin 
fibroblasts, hepatic stellate cells and pancreatic stellate cells were compared [Buchholz et al, 2005]. In 
the same study, the morphological and functional features of HSCs and PSCs were also compared by 
micro-array technology and expression profiling analyses [Buchholz et al, 2005]. The results indicated 
skin fibroblasts were drastically different from hepatic stellate cells and pancreatic stellate cells in 
extracellular and cell surface genes, signalling molecules and transcription factors [Buchholz et al, 
2005]. HSCs and PSCs, however, have shown to share high degree of similarities, indicating the 
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properties of HSCs could potentially be found in PSCs [Buchholz et al, 2005]. Of note, mesenchymal 
stem cells and myofibroblasts are regarded as the source of CAFs in PDAC [von Ahrens et al, 2017]. In 
the present study, patient-derived stellate cells are considered as CAFs. However, further studies are 
needed to identify the tumour-promoting stellate cells or mesenchymal stem cells or myofibroblasts 
as CAFs from the tumour-suppressing stellate cells in the patient-derived stellate cells we used. 
AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs 766T, MIA PaCa-2, PANC-1, SU.86.86, 
SUIT-2, SW 1990, and T3M4 are well-characterized human PDAC cell lines that can proliferate almost 
indefinitely outside the patients and grow into substantial number of cells to accommodate high-
throughput assays [Deer et al, 2010; Iwamura et al, 1987; Missiaglia et al, 2004]. Capan-2 and PANC-1 
cell lines possess distinct features representing the heterogeneity of PDAC. For instance, Capan-2 cells 
are well differentiated while PANC-1 cells are poor differentiated [Deer et al, 2010]. TP53 mutation is 
detected in PANC-1 cells while Capan-2 cells have wild-type p53 [Deer et al, 2010]. They serve as a tool 
to assess the sensitivity of anti-cancer agents in subgroups of PDAC patients. 
Establishing and optimising the 3D co-culture models using human PDAC cell lines with patient-derived 
stellate cells can overcome the scarcities of primary PDAC cells while maintain the same species’ 
characteristics between the in vitro PDAC models and the patients with PDAC. Because stellate cells 
comprise the majority of the PDAC tissue and acquire the proliferative ability by interacting with PDAC 
cells [Erkan et al, 2012; Ohlund et al, 2017], patient-derived stellate cells could be produced in large 
amount for high-throughput assays with relatively low variation in the laboratory.  
Thus, our goal is to improve the co-culture models by simplifying the current protocols, reducing 
animal-derived matrix and increasing the ratios of stellate cells to cancer cells in a scaffold-free 
condition. A series of studies have been performed to develop an easy-to-use 3D co-culture model that 
could be consistent, efficient and economical. One of the criteria was to make sure that a single 
spheroid with multilayers of stellate cells surrounding the cancer cells could be formed in each well of 
96-well plates. Another criterion was to evaluate if 10-20% cell composition in the 3D co-culture models 
were cancer cells so that the models could mimic the pancreatic cancer environment in the patients 
diagnosed with late-stage PDAC. Meanwhile, expression and localisation of endogenous YAP was also 




3.2 Validation of cell distribution and protein expression in the 3D scaffold-free 
co-culture models 
 
3.2.1 Increasing ratio of stellate cells to cancer cells results in reduced spheroid expansion  
 
Due to a lack of reliable detection methods at early stage, about 80% of patients diagnosed with PDAC 
present locally advanced and metastatic disease, with frequent liver metastasis  [GM et al, 2018; Lau 
et al, 2017; Neoptolemos et al, 2018; Salgado et al, 2018; Uccello et al, 2018]. Hepatic stellate cells 
(HSCs) derived from metastatic PDAC in liver share similar features with activated pancreatic stellate 
cells such as profibrogenesis, contractility, and ECM producing abilities [Erkan et al, 2012]. The common 
ratio of stellate cells to cancer cells reported for modelling 3D co-culture PDAC models is 2:1 [Coleman 
et al, 2014b; Fujiwara et al, 2016; Lee et al, 2018a; Ware et al, 2016], which is lower than the ones 
detected in the clinical specimens [Neesse et al, 2011]. Due to higher supply of HSCs than PSCs from 
our collaborator, we first attempted to establish a model recapitulating liver metastatic sites in PDAC 
by exploring the changes in the spheroid size to determine the optimal ratio of stellate cells to cancer 
cells from 10:1 to 80:1, in order to achieve the a PDAC model with 10% cancer cells [Neesse et al, 2011]. 
Cell suspensions of HSCs and established pancreatic cancer cell lines were mixed in a hanging drop 
format to form 3D spheroids. After 4 days of culture in these hanging drops, spheroids were transferred 
to poly-HEMA low-attachment 96-well plates that resulted in the production of one spheroid per well. 
Phase-contrast imaging was used to follow spheroid growth over time with images being acquired daily 
from day 4 to day 7. 3D mono-culture of cancer cells were used as a negative control to study the 
effects of HSCs on cancer cells. 
As seen in Figure 19-21, there was a reduction in sphere expansion from day 4 to day 7, as the ratio of 
HSCs to cancer cells was increased. Comparing spheroid sizes measured on day 4 with the ones on day 
7, the expansion in spheroids prepared with an 80:1 ratio of HSCs to Capan-2 cells (40K HSCs with 500 
Capan-2 cells) was 14% whereas the expansion in spheroids was 73% in spheroids prepared with a 10:1 
ratio of HSCs to cancer cells (5K HSCs with 500 cancer cells). Meanwhile, 3D spheroids prepared with 
an 80:1 of HSCs to PANC-1 cells did not change significantly over this time frame whereas there was an 
expansion of 58% and 80% in the group of 10:1 HSCs to PANC-1 cells in two independent experiment. 
The variability observed for the 10:1 ratio suggests this ratio to be less acceptable based upon our 
identification of consistency as desired aspect of a viable 3D co-culture format. 
Because the data presenting percentages of spheroid size normalized to the ones on day 4 in each 
individual experiment did not follow normal distribution and not have the same shape of distribution, 
mean ranks of percentages of spheroid size normalized to the ones on day 4 between groups on four 
different time points were compared using non-parametric Kruskal-Wallis H test. As seen in Figure 19-
21, statistically significant differences in percentages were detected between different days in mono-
culture of Capan-2 and PANC-1 whereas not found in mono-culture of HSCs and co-culture of cancer 
cells with HSCs. The spheroid size of 3D mono-culture of HSCs with the initial number of 5,000 (5K) 
remained basically unchanged from day 4 to day 7 while nearly 25-30% decrease were seen in mono-
cultures of 20,000 (20K) and 40,000 (40K) HSCs on Day 7 compared to Day 4 (Figure 19). Compared 
with the ones on day 4 (Figure 20-21), the spheroid size of the 3D mono-culture of Capan-2 and PANC-
1 with the initial number of 500 cells in hanging drops increased significantly from day 4 to day 7 after 
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dropping into 96-well plates, with a mean rank of 3.0 for Day 4, 7.5 for Day 5, 12.0 for Day 6 and 17.0 
for Day 7, Kruskal-Wallis H = 17.196, p = 0.001 in Capan-2 groups; 3.0 for Day 4,  7.5 for Day 5, 13.0 for 
Day 6 and 16.0 for Day 7, Kruskal-Wallis H = 15.911, p = 0.001 in PANC-1 groups.  Although insufficient 
statistically power was present in the groups of 3D co-culture spheroids, it is possible that the sample 
sizes in terms of independent experiments were not large enough to get sufficient information out of 
the datasets.  
When cancer cells and stellate cells encountered in this environment, it was likely that higher number 
of stellate cells surrounded a few cancer cells, depriving more nutrient, oxygen and space for cancer 
cells to grow than lower number of stellate cells. However, cancer cells might have had developed 
mechanisms, for instance, becoming dormant, to survive this harsh environment. Based on the 
observation that the size of cancer mono-spheres increased overtime whereas the size of mono-
spheres with stellate cells remained the same or reduced, the increase in size was likely to be due to 
the proliferation of cancer cells at the edge of the spheroids. Whether there were cancerous cores full 








































Figure 19. 3D mono-culture of hepatic stellate cells in a hanging drop format.  
5,000 (5K), 20,000 (20K) and 40,000 (40K) hepatic stellate cells (HSCs) were grown in a hanging drop format to 
form 3D mono-cultures. After 4 days, spheroids were transferred to the poly-HEMA low-attachment 96-well 
plates, resulting in one spheroid per well. A. Phase-contrast live-cell images were acquired by Leica DMI4000 B 
(50x magnification) daily from day 4 to day 7 after spheroid transfer into 96-well plates. Results of 3D HSCs were 
from two independent experiments except in the instance where only one independent experiment was done in 
the groups of 3D culture with 40K HSCs. The images of mono-culture spheroids with 40K HSCs on Day 5 were 
missing when image analysis was performed. Scale bar, 500 μm. B. Percentages of spheroid sizes on Day 5, Day 6 
and Day 7 normalized to the ones on day 4. 4-16 spheroids in each group from two independent experiments 
were used for calculation (n=2). The areas were measured using CellProfiler. The mean area in pixels of spheroids 
on day 5, day 6 and day 7 were divided by the mean area in pixels of spheroids on day 4 and then multiplied by 
100. Graph was created by Excel, averaging the percentages in each group from two independent experiments 
except in the group of 40K HSCs. Error bars represented standard deviations from two independent experiments. 
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Figure 20. 3D mono-culture of Capan-2 and 3D co-culture of Capan-2 with hepatic stellate cells in a hanging 
drop format.  
0, 5,000 (5K), 20,000 (20K) and 40,000 (40K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 cells 
respectively in a hanging drop format to form 3D culture models at 0, 10:1, 40:1 and 80:1 ratios of stellate cells 
to cancer cells. After 4 days, spheroids were transferred to the poly-HEMA low-attachment 96-well plates, 
resulting in one spheroid per well. A. Phase-contrast images were acquired by Leica DMI4000 B (50x 
magnification) daily from day 4 to day 7 after spheroid transfer into 96-well plates. Results of Capan-2 mono-
culture were from five independent experiments. Results of co-culture spheroids were from 2-3 independent 
experiments except in the instance where only one independent experiment was done in the groups of 40K HSCs 
with Capan-2. Scale bar, 500 μm. B. Percentages of spheroid sizes on Day 5, Day 6 and Day 7 normalized to day 
4. 4-16 spheroids in each group from 2-5 independent experiments were used for calculation (n=2-5). The areas 
were measured using CellProfiler. The mean area in pixels of spheroids on day 5, day 6 and day 7 were divided 
by the mean area in pixels of spheroids on day 4 and then multiplied by 100. Graph was created by Excel, 
averaging the percentages from 2-5 independent experiments in each group. Error bars represented standard 
deviations from 2-5 independent experiments. P-value was calculated using non-parametric Kruskal-Wallis H test. 
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Figure 21. 3D mono-culture of PANC-1 and 3D co-culture of PANC-1 with hepatic stellate cells.  
0, 5,000 (5K), 20,000 (20K) and 40,000 (40K) hepatic stellate cells (HSCs) were mixed with 500 PANC-1 cells 
respectively in a hanging drop format to form 3D culture models at 0, 10:1, 40:1 and 80:1 ratios of stellate cells 
to cancer cells. After 4 days, spheroids were transferred to the poly-HEMA low-attachment 96-well plates, 
resulting in one spheroid per well. A. Phase-contrast images were acquired by Leica DMI4000 B (50x 
magnification) daily from day 4 to day 7 after spheroid transfer into 96-well plates. Results of PANC-1 mono-
culture were from five independent experiments. Results of co-culture spheroids were from 2-3 independent 
experiments except in the instance where only one independent experiment was done in the groups of 40K HSCs 
with PANC-1. Scale bar, 500 μm. B. Percentages of spheroid sizes on Day 5, Day 6 and Day 7 normalized to day 4. 
4-16 spheroids in each group from 2-5 independent experiments were used for calculation (n=2-5). The areas 
were measured using CellProfiler. The mean area in pixels of spheroids on day 5, day 6 and day 7 were divided 
by the mean area in pixels of spheroids on day 4 and then multiplied by 100. Graph was created by Excel, 
averaging the percentages from 2-5 independent experiments in each group. Error bars represented standard 
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3.2.2 Increasing ratio of stellate cells to cancer cells is associated with reduced localization of 
cancer cells outside hepatic stellate cells cores  
 
Mutations within the TP53 that affect expression and actions of p53 are associated with PDAC 
malignancy [Cicenas et al, 2017]. Although low level of p53 was detected in rat hepatic stellate cells 
(HSCs) [Jeong et al, 2005; Longxi et al, 2011; Zhao et al, 2016a], p53 expression was stronger in cancer 
cells than adjacent non-cancerous cells in tumour biopsies from patients with PDAC [Dong et al, 2000; 
Jeong et al, 2005; Zhao et al, 2016a]. Therefore, we chose p53 as the cancer cell marker to detect the 
cancer cells and cell distribution in the current 3D co-culture spheroids with human cancer cells and 
human hepatic stellate cells. 
At first, we validated the total cellular p53 expression in mono-culture spheroids and co-culture 
spheroids using immunoblotting. Also, we tested whether hepatic stellate cells promote or inhibit 
cancer cell growth by comparing the total p53 protein changes. HSCs and cancer cells were co-cultured 
in hanging drops for 4 days to form 3D spheroids, transferred and grown in 96-well plates for another 
3 days. 20 spheroids were collected for protein analysis by immunoblotting on day 4 and day 7. Because 
the spheroids collected in each group, the volume used to lyse the same number of spheroids and load 
the protein samples into the gel for immunoblotting was the same across mono-culture and co-culture 
spheroids, the total protein could be expected to be proportional to the total number of cells sampling.  
As can be seen in Figure 22, p53 was not found in mono-culture spheroids of HSCs whereas there was 
a clear band at 55 kDa when the spheroids included Capan-2 and PANC-1 cells, suggesting that HSCs 
cultured in this condition did not express p53 and the p53 protein from cancer cells contributed to the 
p53 levels in the 3D co-culture models. The bands at 55 kDa appeared weaker when the spheroids were 
formed from higher ratio of HSCs to cancer cells (40:1) than the ones from lower ratio (10:1).  
Because all the cells in the 3D mono-culture spheroids, 1 to 10 of total cells in the 3D co-culture 
spheroids, and 1 to 40 of the total cells in the 3D co-culture spheroids should be cancer cells, we 
postulated that fewer cells expressing p53 should be expected to drop proportionally in the co-culture 
models. The absolute p53 intensities of bands at 55 kDa in Figure 23, however, demonstrated that 
there was a nonlinear decline in p53 intensities as the number of cancer cells co-cultured with HSCs 
decreased. Meanwhile, the intensities of GAPDH fluctuated, sometimes constant or increased, among 
groups of mono-culture of cancer cells, co-culture of cancer cells with 5K HSCs and co-culture of cancer 
cells with 20K HSCs in Figure 24. The saturation of primary antibodies and secondary antibodies was 
considered to be negligible because both membranes containing groups with Capan-2 cells and PANC-
1 cells respectively were incubated with the same solutions with the antibodies in one run of 
immunoblotting. It appeared that the decrease in p53 intensities was not proportional to the dropping 
of number of cancer cells in the co-culture models, indicating different growth rates in 3D mono-culture 
and 3D co-culture of cancer cells. After being normalized to levels of the housekeeping protein GAPDH, 
reduction of p53 expression was found in most co-culture spheroids composed of HSCs with cancer 
cells on day 4 and day 7 comparing to mono-culture spheroids of cancer cells in Figure 25. An exception 
was observed in one individual experiment where a higher level of p53 expression was found when 
spheroids of PANC-1 co-cultured with 5K HSCs on day 4 than the one of mono-culture spheroids of 
PANC-1 cells on day 4. The inconsistent data suggest the requirement of more independent 
experiments using immunoblotting to test the correlation of p53 expression with the number of HSCs 
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in the current models. Whether the decrease in p53 level was due to the dilution of cancer cells in the 


















Figure 22. Immunoblotting analysis of p53 expression in 3D mono-culture and 3D co-culture. 
0, 5,000 (5K) and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-1 cells 
respectively in a hanging drop format to form the co-culture models at 0, 10:1 and 20:1 ratios of stellate cells to 
cancer cells. 3D mono-culture of HSCs were grown in parallel. After 4 days, spheroids were transferred to the 
polyHEMA low-attachment 96-well plates, resulting in one spheroid per well. Immunoblotting analysis of p53 
were performed on the indicated time points. Twenty spheroids in each group were lysed in 100 µL RIPA buffer 
to extract the total protein on day 4 and day 7. 6 µL of the cell lysate was loaded into the wells of SDS-PAGE gel. 
Two-colour near-infrared detection was performed to detect p53 (green) and GAPDH (red) simultaneously. Two 
datasets from two independent experiments in 3D mono-culture of cancer cells and 3D co-culture of cancer cells 
with HSCs were presented.  One dataset from two independent experiments in 3D mono-culture of HSCs were 
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Figure 23. Quantification of absolute p53 expression in 3D mono-culture and 3D co-culture.  
0, 5,000 (5K) and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-1 cells 
respectively in a hanging drop format to form the co-culture models at 0, 10:1 and 20:1 ratios of stellate cells to 
cancer cells. After 4 days, spheroids were transferred to the polyHEMA low-attachment 96-well plates, resulting 
in one spheroid per well. Immunoblotting analysis of p53 expression were performed on the indicated time 
points. Twenty spheroids in each group were lysed in 100 µL RIPA buffer to extract the total protein on day 4 and 
day 7. 6 µL of the cell lysate was loaded into the wells of SDS-PAGE gel. The groups with Capan-2 cells were run 
on the same gel. Meanwhile, the groups with PANC-1 cells were run on the other gel. The two gels were 
transferred in the same blot module and the same chamber. The membranes were incubated with the same 
batch of dilutions of antibodies in blocking buffer. Two-colour near-infrared detection was performed to detect 
p53 and GAPDH simultaneously. The intensities of p53 were analysed by Licor ImageStudio and graphed using 
Excel. Data from two independent experiments in 3D mono-culture of cancer cells and 3D co-culture of cancer 
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Figure 24. Quantification of absolute GAPDH expression in 3D mono-culture and 3D co-culture.  
0, 5,000 (5K) and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-1 cells 
respectively in a hanging drop format to form the co-culture models at 0, 10:1 and 20:1 ratios of stellate cells to 
cancer cells. After 4 days, spheroids were transferred to the polyHEMA low-attachment 96-well plates, resulting 
in one spheroid per well. Immunoblotting analysis of p53 expression were performed on the indicated time 
points. Twenty spheroids in each group were lysed in 100 µL RIPA buffer to extract the total protein on day 4 and 
day 7. 6 µL of the cell lysate was loaded into the wells of SDS-PAGE gel. The groups with Capan-2 cells were run 
on the same gel. Meanwhile, the groups with PANC-1 cells were run on the other gel. The two gels were 
transferred in the same blot module and the same chamber. The membranes were incubated with the same 
batch of dilutions of antibodies in blocking buffer. Two-colour near-infrared detection was performed to detect 
p53 and GAPDH simultaneously. The intensities of GAPDH were analysed by Licor ImageStudio and graphed using 
Excel. Data from two independent experiments in 3D mono-culture of cancer cells and 3D co-culture of cancer 
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Figure 25. Normalisation of p53 expression to GAPDH in 3D mono-culture and 3D co-culture.  
0, 5,000 (5K) and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-1 cells 
respectively in a hanging drop format to form the co-culture models at 0, 10:1 and 20:1 ratios of stellate cells to 
cancer cells. After 4 days, spheroids were transferred to the polyHEMA low-attachment 96-well plates, resulting 
in one spheroid per well. Immunoblotting analysis of p53 expression were performed on the indicated time 
points. Twenty spheroids in each group were lysed in 100 µL RIPA buffer to extract the total protein on day 4 and 
day 7. 6 µL of the cell lysate was loaded into the wells of SDS-PAGE gel. The groups with Capan-2 cells were run 
on the same gel. Meanwhile, the groups with PANC-1 cells were run on the other gel. The two gels were 
transferred in the same blot module and the same chamber. The membranes were incubated with the same 
batch of dilutions of antibodies in blocking buffer. Two-colour near-infrared detection was performed to detect 
p53 and GAPDH simultaneously. The intensities of p53 and GAPDH were analysed by Licor ImageStudio. 
Normalization of p53 intensities to GAPDH intensities were calculated and graphed using Excel. Data from two 
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The total amount of p53 analysed by immunoblotting was not able to provide us with the details of 
cancer cell distribution in the 3D co-culture models, such as whether cancer cells were located at the 
core of the spheroids. In order to investigate the distribution of cancer cells and stellate cells in these 
co-cultures, whole spheroids were fixed in PFA, stained for p53 and confocal laser scanning microscopy 
(CLSM) using Zeiss LSM880 was performed using one optical sectioning through the largest area of a 
spheroid, representing the detection near the core of the spheroid. As can be seen in Figure 26-28, 
HSCs showed little nuclear staining for p53 with the non-specific signal from p53 channel coming from 
the outside of the nuclei. Meanwhile, cancer cells showed strong nuclear p53 staining (Figure 27 and 
28). Interestingly, the p53 expression was stronger near the edge of the spheroids than in the spheroid 
core. Examples where p53 staining was negative in a number of cancer cells at the edge of the 
spheroids with easy access to antibodies were observed, as shown in red arrows in Figure 27 and 28. It 
was possible that these negative staining outcomes were due to inappropriate storage of samples at 
the moment when the samples were not protected by low temperature, resulting in the deterioration 
of fluorophores. There was little possibility that the cancer cells at the edge of the spheroids co-
cultured with 20K HSCs did not express p53 because p53 expression in those spheroids was detected 
using immunoblotting as shown in Figure 22. Another line of evidence that p53 was expressed in the 
co-culture models with high ratio of stellate cells to cancer cells was illustrated in Figure 29, where 
Capan-2 and PANC-1 cells near the edge of the spheroids co-cultured with 40K HSCs were p53 positive 
using higher laser power than the ones in Figure 26-28. Judging from the enlarged nuclei observed in 
cancer cells demonstrated by DAPI staining (red arrows), a second criterion of the nuclear size and 
morphology could be employed to discriminate cancer cells from HSCs. In general, the regions of cancer 
cells identified by this criteria were also reduced as the number of HSCs increased in the current 3D co-





























Figure 26. Immunofluorescence analysis of p53 expression in intact 3D mono-culture of hepatic stellate cells.  
5,000 (5K), 10,000 (10K), and 20,000 (20K) hepatic stellate cells (HSCs) were grown in a hanging drop format to 
form 3D mono-culture spheroids. After 4 days, spheroids were transferred to the polyHEMA low-attachment 96-
well plates, resulting in one spheroid per well. After 3 days, whole spheroids were fixed in PFA and stained with 
DAPI and anti-p53 antibodies using immunofluorescence. Confocal laser scanning microscopy using Zeiss LSM880 
was performed on intact spheroids near the edge and the core of the spheroids. Image analysis was performed 
in Zen 2.3 (blue edition). Representative images from two spheroids in one independent experiment were shown 




























Figure 27. Immunofluorescence analysis of p53 expression in intact 3D mono-culture of Capan-2 cells and 3D 
co-culture of Capan-2 cells with hepatic stellate cells.  
0, 5,000 (5K), 10,000 (10K), and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 
respectively in a hanging drop format to form the 3D models at 0, 10:1, 20:1 and 40:1 ratios of stellate cells to 
cancer cells. After 4 days, spheroids were transferred to the polyHEMA low-attachment 96-well plates, resulting 
in one spheroid per well. After 3 days, whole spheroids were fixed in PFA and stained with DAPI and anti-p53 
antibodies using immunofluorescence. Confocal laser scanning microscopy using Zeiss LSM880 was performed 
on intact spheroids near the edge and the core of the spheroids. Image analysis was performed in Zen 2.3 (blue 
edition). Representative images from two spheroids in one independent experiment were shown (n=1). Red 
arrows: p53 negative Capan-2 cells. Scale bar, 100 μm. 
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Figure 28. Immunofluorescence analysis of p53 expression in intact 3D mono-culture of PANC-1 cells and 3D 
co-culture of PANC-1 cells with hepatic stellate cells.  
0, 5,000 (5K), and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 PANC-1 cells respectively in a 
hanging drop format to form the 3D models at 0, 10:1, and 40:1 ratios of stellate cells to cancer cells. After 4 days, 
spheroids were transferred to the polyHEMA low-attachment 96-well plates, resulting in one spheroid per well. 
After 3 days, whole spheroids were fixed in PFA and stained with DAPI and anti-p53 antibodies using 
immunofluorescence. Confocal laser scanning microscopy using Zeiss LSM880 was performed on intact spheroids 
near the edge and the core of the spheroids. Image analysis was performed in Zen 2.3 (blue edition). 
Representative images from two spheroids in one independent experiment were shown (n=1). Red arrows: p53 
negative PANC-1 cells. Scale bar, 100 μm. 
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Figure 29. Immunofluorescence analysis of p53 expression in intact 3D co-culture of cancer cells with hepatic 
stellate cells using high laser power. 
40,000 (40K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-1 cells respectively in a hanging 
drop format to form the co-culture models at a 80:1 ratio of stellate cells to cancer cells. After 4 days, some 
spheroids were transferred to the polyHEMA low-attachment 96-well plates while the rest were fixed in PFA. 
After 3 days when the total growth time was 7 days, spheroids in the plates were fixed in PFA and 
immunofluorescence was performed on the whole spheroids collected on day 4 and day 7. Fluorescent images 
were acquired by confocal laser scanning microscopy (CLSM) using Zeiss LSM880. Image analysis was performed 
in Zen 2.3 (blue edition). Staining with DAPI (blue) and for p53 (green) was shown. Laser power for CLSM was 
over 30%. Representative images were from two spheroids in one independent experiment. Scale bar, 100 μm.  
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The immunofluorescence microscopy was optimized by an optical clearing protocol of samples and the 
use of multi-photon (MP) imaging was attempted to test the performance in detecting thick specimen. 
An effort was also made to examine potential antibody staining differences due to the antibody 
penetration between the core and edge of spheroids by acquiring images using CLSM and MP 
procedures to allow for improved p53 visualization at the spheroid core. As seen in Figure 30, clearing 
with ethanol and mixture of benzyl alcohol and benzyl benzoate at 1:2 (v/v, BABB) allowed improved 
consistency for nuclear staining with DAPI and p53 immuno-staining at the spheroid core. With the 
help from Anne Gesell in Microscopy and Analysis Suit (MAS), wavelengths were optimised with 
scanning from 690 – 980 nm between 10 to 40 nm wavebands for 3-coloured MP imaging using DAPI, 
anti-p53 antibodies and anti-YAP antibodies as representatives to incubate a co-culture spheroids with 
PANC-1 cells and 5K HSCs. The image acquired at 950 nm with the BP filter of 500-550 nm exhibited 
the best signal from the staining for p53 with least interference from the staining of DAPI and for YAP 
(Figure 31). As a result, when the secondary antibodies linked to Alexa Fluor 488 were used in 
combination with primary anti-p53 antibodies, 950 nm and the BP filter of 500-550 nm was selected as 
the optimal excitation and emission wavelengths.  
After optical clearing, CLSM and MP imaging were performed and p53 intensities were calculated by 
matching same cell outcomes identified by the CellProfiler software as shown in Figure 32. Nine cells 
in the spheroid core region were considered representatives of cancer cells positively stained with p53. 
Seventeen cells were selected in the region of the spheroid edge as representatives of cancer cells 
positively stained with p53. Because the data presenting p53 intensities divided by areas did not follow 
normal distribution and not have the same shape of distribution, mean ranks were compared using 
non-parametric Kruskal-Wallis H test. By comparing all the values of the p53 intensity divided by the 
area used to extract the intensity in each individual cell, there was no significant difference between 
the p53 expression levels in the cells near the core of the spheroids compared to those at the edge of 
the spheroids by Kruskal-Wallis H test with mean rank of 29.65 for the cells in the core by CLSM 
scanning, 25.13 for the cells near the edge by CLSM scanning, 23.12 for the cells in the core by MP 
scanning and 22.13 for the cells near the edge by MP scanning (p = 0.519). Henceforth, MP scanning 
will not be conducted in the following sections whereas optical clearing with CLSM will be used due to 
the improvement in the visualization of 3D spheroids. 
Taken together, two to four cells could be demonstrated to be p53 positive inside the stellate cells 
core, indicating the presence of cancer cells among stellate cells. However, no cancer cell clusters with 
more than ten cells or ductal structures were formed in the co-culture spheroids even when the ratio 
of stellate cells to cancer cells reached 80:1. We decided to discontinue the work presented in this 
section to explore other approaches in the next sections because of two major reasons: 1) the data 
presented in this section failed to indicate any potential for the stellate cells to wrap around the cancer 
cells in scaffold-free conditions to form multiple layers of stellate cells around cancer cells core; 2) the 
number of stellate cells required in the models may be too high, possibly resulting in consuming 



























Figure 30. Effects of optical clearing on large intact spheroids. 
40,000 (40K) hepatic stellate cells (HSCs) were mixed with 500 PANC-1 cells respectively in a hanging drop format 
to form the co-culture models at a 80:1 ratio of stellate cells to cancer cells. After 4 days, spheroids were fixed in 
PFA and immunofluorescence was performed on the whole intact spheroids. Spheroids were stained with anti-
p53 antibodies (green) and DAPI (blue). Spheroids with or without optical clearing using mixture of benzyl alcohol 
and benzyl benzoate at 1:2 (v/v, BABB) were scanned near the core by confocal laser scanning microscopy using 
Zeiss LSM880. Image analysis was performed in Zen 2.3 (blue edition). Histogram indicated consistent brightness 
and contrast were used to export the images. Representative images were from six spheroids of 40K HSCs with 
Capan-2 cells in one independent experiment. Scale bar, 200 μm.   
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Figure 31. Multi-photon scanning from 690 – 980 nm of a co-culture spheroid. 
5,000 (5K) hepatic stellate cells were mixed with 500 PANC1 cells respectively in a hanging drop format. After 4 days, 
whole spheroids were fixed in PFA and stained with DAPI, anti-p53 antibodies with secondary antibody conjugated 
to Alexa Fluo 488 (green) and anti-YAP antibodies with secondary antibody conjugated to Alexa Fluo 546 (red), using 
immunofluorescence. Optical clearing with BABB was performed. Multi-photon microscopy using Zeiss LSM880 with 
Spectra Physics multiphoton lasers was performed near the core of an intact spheroid, with 10-40 nanometre 
wavebands from 690 – 980 nm on one optical slide. Image analysis was performed in Zen 2.3 (blue edition). 
Representative images from one spheroids in one independent experiment were shown (n=1). Scale bar, 100 μm. 
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Figure 32. Semi-quantification of p53 expression in a co-culture spheroid.  
Co-culture spheroids of 500 PANC-1 cells and 5,000 (5K) HSCs were grown in a hanging drop format for 4 days 
and stained with anti-p53 antibodies only. Optical clearing with BABB was performed. Confocal laser scanning 
microscopy (CLSM) and multi-photon microscopy (MP) were performed on the same focal plane position of the 
spheroid. Intensities and areas of every single cell in the two images presented were generated by CellProfiler. 
Whisker box graph was made from one optical section of a spheroid with all the values of intensity divided by 
respective area from nine cells near the core of the spheroid (CLSMcore and MPcore) and seventeen cells near 
the edge of the spheroid (CLSMedge and MPedge). Mean markers were shown. Median was exclusive from 
quartile calculation. Mean ranks were compared using non-parametric Kruskal-Wallis H test. 
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3.2.3 αSMA is not only a marker for hepatic stellate cells but is also found in pancreatic cancer 
cells 
 
Alpha smooth muscle actin (αSMA) has been widely accepted as a marker for activated stellate cells 
[Erkan et al, 2008; Jiang et al, 2018; Ozdemir et al, 2014; Wei et al, 2017]. In order to detect the stellate 
cells in the 3D co-culture models and validate the presence and activation status of the hepatic stellate 
cells (HSCs), we investigated αSMA expression patterns alongside cancer cell distributions using the 
p53 marker. Also, we intended to test whether cancer cells could promote the proliferation of HSCs by 
using total αSMA protein levels. 
Two different antibodies were used to detect αSMA: one is a rabbit polyclonal antiserum made from 
immunogens overlapping with amino acids 1-100 of the N-terminus of αSMA (rabbit anti-αSMA) and 
the other is a goat antiserum raised against a synthetic peptide (EEEDSTALVC) that emulates amino 
acids 3 to 12 of αSMA (goat anti-αSMA). 
As seen in Figure 33 and 34, a clear band at 42 kDa could be detected using rabbit anti-αSMA in all 
spheroids including mono-spheroids with cancer cells only. The pattern was the same using goat anti-
αSMA antiserum except that there was no band near 42 kDa in Capan-2 mono-culture spheroids. The 
goat anti-αSMA antiserum, however, was able to stain Capan-2 cells and PANC-1 cells using 
immunofluorescence microscopy with a non-specific goat IgG being used as a negative control. 
Therefore, αSMA was expressed in both HSCs and cancer cells grown in the current co-culture models. 
As αSMA could also be detected in mono-spheroids with cancer cells only, no conclusion could be 




























Figure 33. Immunoblotting analysis of αSMA in 3D mono-culture and 3D co-culture. 
0, 5,000 (5K), 10,000 (10K), and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-
1 cells respectively to form the co-culture models at 0, 10:1, 20:1 and 40:1 ratios of stellate cells to cancer cells 
in a hanging drop format. After 4 days, spheroids were transferred to the poly-HEMA low-attachment 96-well 
plates, resulting in one spheroid per well. The spheroids were grown for another 3 days. Immunoblotting analysis 
of αSMA using two different antibodies on the indicated time points was performed. Two-colour near-infrared 
detection by immunoblotting was used to detect αSMA using goat anti-αSMA antibodies (green) and GAPDH (red) 
in A) or αSMA using rabbit anti-αSMA (red) and HDAC1 (green) in B). Representatives were from two independent 
experiments (n=2).  
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                    HSCs         5K     10K     20K    0      5K    10K   20K    0     5K    10K     20K       
Capan-2          -         -         -        +      +       +       +       -        -        -         -       
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Figure 34. Immunofluorescence analysis of αSMA 
expression near the core of the spheroids.  
40K HSCs, 500 Capan-2 cells and 500 PANC-1 cells were 
grown respectively in a hanging drop format to form 3D 
mono-culture spheroids. After 4 days, the whole 
spheroids were fixed in PFA and stained with goat anti-
αSMA antibodies or goat IgG, followed by incubation of 
donkey anti-goat secondary antibodies conjugated to 
Alexa-Fluor 488. Fluorescent images were acquired by 
confocal laser scanning microscopy using Zeiss LSM880 
with the same power at 488 nm and the signals from 
Alexa Fluor 488 were coloured white. Image analysis 
were performed using Zen 2.3 (blue edition). 
Consistent whiteness in Histogram among the images 
was used. The patterns were observed in at least three 
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3.2.4 YAP mainly localizes in the cytoplasm near the edge of 3D spheroids while cancer cells at 
the edge occasionally presented with nuclear localisation of YAP 
 
Nuclear accumulation of YAP is considered to be one of the driving forces that can promote cancer cell 
growth. However, signalling through cell-cell contact inhibits YAP nuclear translocation, leading to its 
cytoplasmic retention. Intense cell-cell contact interactions can be established in the co-culture models 
presented here. Based on the data showing the spheroid expansion in the 3D mono-culture and co-
culture, we also investigated YAP localization during this process.  
Total YAP expression in whole spheroids was examined by immunoblotting using the antibodies raised 
against YAP of human origin. 65 kDa is generally accepted as the molecular weight of YAP [Basu et al, 
2003; Sudol, 1994; Tomlinson et al, 2010], which is different from the molecular weights listed in 
Uniprot website. According to the Uniprot website (http://www.uniprot.org/uniprot/P46937), there 
are 9 isoforms of YAP produced by alternative splicing, with the molecular weights of 36 kDa, 48 kDa, 
49 kDa, 50 kDa, 50.47 kDa, 53 kDa, 54.46 kDa, and 55 kDa. As illustrated in Figure 35, multiple bands 
could be detected ranging from 40 kDa to 100 kDa with distinct bands pattern. There were two weak 
bands at 55 kDa and 65 kDa detected in 3D mono-culture of HSCs, 3D mono-culture of Capan-2 cells 
and 3D co-culture of HSCs with Capan-2 cells. By comparison, the 55 kDa and 65 kDa bands in 3D mono-
culture of PANC-1 cells and 3D co-culture of HSCs with PANC-1 cells were stronger than the ones in 
HSCs and Capan-2 cells. The bands at 48 kDa in Capan-2 groups were stronger than the ones in PANC-
1 groups. The exact molecular weights of bands between 48 to 55 kDa need further verification. The 
band observed between 70 kDa and 100 kDa was postulated to be the phosphorylated YAP, as 75 kDa 
was reported to be the phosphorylated YAP in breast cancer cells [Lee et al, 2018b], liver cancer cells 
[Jeric et al, 2016], and kidney cells [Matsudaira et al, 2017]. This assumption should be verified by using 
commercially available antibodies against phosphorylated YAP, which needs further investigation. The 
bands indicating YAP expression seen in the co-culture models were postulated to come mainly from 
cancer cells because the bands seen in mono-culture of HSCs were much weaker than the ones in 
mono-culture of cancer cells. Therefore, the co-culture of cancer cells with HSCs was able to reduce 
YAP expression in cancer cells, indicating the possibility of HSCs to reduce the proliferative ability of 
cancer cells. However, considering the possible differences in total cell numbers between mono-
culture and co-culture, the lack of nutrients due to the consumption by HSCs in the co-culture models 















Figure 35. Endogenous YAP expression detected by immunoblotting in 3D spheroids.  
0, 5,000 (5K), 10,000 (10K), and 20,000 (20K) hepatic stellate cells (HSCs) were mixed with 500 Capan-2 or PANC-
1 cells respectively to form the 3D co-culture models at 0, 10:1, 20:1, and 40:1 ratios of stellate cells to cancer 
cells using the hanging drop method. 3D mono-culture of HSCs were grown in parallel. After 4 days, spheroids 
were transferred to the poly-HEMA low-attachment 96-well plates, resulting in one spheroid per well. After 3 
days when the total growth time was 7 days, YAP expression were analysed by immunoblotting. Two-colour near-
infrared detection was performed to detect YAP and GAPDH simultaneously. The band patterns of YAP expression 
in 3D mono-culture of 20K HSCs, Capan-2 cells or PANC-1 cells and 3D co-culture of 20K HSCs with Capan-2 or 
PANC-1 cells respectively were observed in three independent experiments. The band patterns of YAP expression 
in 3D mono-culture of 5K HSCs and 10K HSCs were observed in one independent experiments. The band patterns 
of YAP expression in 3D co-culture of Capan-2 cells with 5K or 10K HSCs respectively were observed in one 
independent experiments. The band patterns of YAP expression in 3D co-culture of PANC-1 cell with 5K or 10K 
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Total YAP expression is insufficient to study YAP localisation in each individual cell, especially as two 
cell types were involved in the current co-culture models. Hence, confocal laser scanning 
immunofluorescence microscopy was conducted to analyse YAP localisation in single cell in the models. 
Initial images acquired to examine intracellular YAP distribution suggested extensive nuclear 
localization as demonstrated in Figure 36. However, later it was found that there was spectral 
overlapping with DAPI staining because staining spheroids with DAPI only also elicited fluorescent 
signals in YAP channel (Figure 36), which turned out to be false nuclear expression of YAP. This was 
verified by examining spheroids labelled for YAP but without DAPI staining, showing that YAP was found 
to mainly localize in the cytoplasm of the majority of cancer cells in 3D mono-cultures of Capan-2 and 
PANC-1 cells as well as co-culture spheroids prepared from PANC-1 cells mixed with 5K HSCs, all being 
cultured using the hanging drop protocol for 4 days (Figure 37-39). As seen in Figure 40, spectral 
unmixing can separate DAPI overlapping with YAP, resulting in a YAP cytoplasmic localisation similar to 
the spheroids stained with single anti-YAP antibodies.  
Additional efforts were made to describe accurately the subcellular distribution of YAP in the cancer 
cells of these 3D spheroid systems. The images were acquired using two tracks with DAPI channel and 
Alexa546 channel which was used to detect YAP expression while Alexa488 channel and Alexa647 
channel in the other track as dual tracking in Figure 36-40. Multitracking mode separating each channel 
into one track individually was utilized, so as for the emitted photons from DAPI, Alexa Fluo 488, Alexa 
Fluo 546, Alexa Fluo 647 to be collected in individual track. Combined channels mode as in Figure 36-
40 and multitracking mode as in Figure 41 were used to capture the same optical section of the 
spheroid stained with DAPI, anti-YAP antibodies and 2nd antibodies conjugated to Alexa Fluo 546. As 
seen in Figure 41, YAP nuclear expression was dramatically reduced (green arrows) using multitracking 
mode, indicating multitracking was able to minimize the negative effect of spectral overlapping on YAP 
expression. We next assessed the effect of unmixing on the images acquired using multitracking with 
ACE unmixing. Meanwhile, single dye spectrum acquired using the same CLSM setting for manual 
unmixing was generated by staining the spheroids with single DAPI, anti-YAP antibodies, anti-p53 
antibodies, respectively. As illustrated in Figure 42 and 43, ACE unmixing and manual unmixing did not 
improve multitracking imaging but led to signal loss (red arrows). Moreover, the unmixing steps had 
added unnecessary steps that would slow down the image analysis. These outcomes did not favour the 
continuation of ACE or manual unmixing. There was little artefacts and background staining involved 
in the current imaging methods as confirmed by negative controls in Figure 44-46. Taken together, 
multitracking scanning by CLSM will be the optimal method for future fluorescence imaging in the 
current study.  
As seen in the Figure 37-39 and 42 (green arrow heads), there were a few cancers cells with nuclear 






























Figure 36. Effects of spectral overlapping on YAP subcellular localisation. 
3D mono-culture of 500 Capan-2 and PANC-1 cells respectively were grown in a hanging drop format. After 4 
days, whole spheroids were fixed in PFA and stained with DAPI alone or both DAPI and anti-YAP antibodies, 
followed by incubation of secondary antibodies conjugated to Alexa Fluor 546. Fluorescent images were acquired 
by confocal laser scanning microscopy using Zeiss LSM880 with excitation at 405 nm and 561 nm simultaneously. 
DAPI channel (blue) collecting photons resulted from the emission from DAPI was combined with YAP channel 
(yellow) collecting photons resulted from the emission from Alexa Fluor 546 in one track. The pattern was 
observed in three independent experiments.  
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Figure 37. Subcellular 
localisation of YAP in 3D mono-
culture of Capan-2 cells 
detected by 
immunofluorescence with anti-
YAP antibodies only.  
3D mono-culture of 500 Capan-2 
cells were grown in a hanging 
drop format for 4 days, fixed in 
PFA and then stained with anti-
YAP antibodies, followed by 
incubation of secondary 
antibodies conjugated to Alexa 
Fluor 546. Images with one optical section or Z-stack images were acquired with excitation at 405 nm and 561 
nm simultaneously. DAPI channel (blue) collecting photons resulted from the emission from DAPI was combined 
with YAP channel (yellow) collecting photons resulted from the emission from Alexa Fluor 546 in one track, 
consistent with the setting in Figure 36. 3D rendering was done by Zen 2.3 (blue edition) using Z-stack images of 
spheroids stained with DAPI and YAP, exporting only images in YAP channel. Representative images from two 













































Figure 38. Subcellular localisation of 
YAP in 3D mono-culture of PANC-1 
cells detected by 
immunofluorescence with anti-YAP 
antibodies only.  
3D mono-culture of 500 PANC-1 cells 
were grown in a hanging drop format 
for 4 days, fixed in PFA and then 
stained with anti-YAP antibodies, 
followed by incubation of secondary 
antibodies conjugated to Alexa Fluor 
546. Images with one optical section 
or Z-stack images were acquired with excitation at 405 nm and 561 nm simultaneously. DAPI channel (blue) 
collecting photons resulted from the emission from DAPI was combined with YAP channel (yellow) collecting 
photons resulted from the emission from Alexa Fluor 546 in one track, consistent with the setting in Figure 36. 
3D rendering was done by Zen 2.3 (blue edition) using Z-stack images of spheroids stained with DAPI and YAP, 
exporting only images in YAP channel. Representative images from two spheroids in two independent 















































Figure 39. Subcellular localisation of YAP in 3D co-culture of PANC-1 cells with hepatic stellate cells detected 
by immunofluorescence with anti-YAP antibodies only. 
3D co-culture of 500 PANC-1 cells with 5,000 hepatic stellate cells (HSCs) were grown in a hanging drop format 
for 4 days, fixed in PFA and then stained with anti-YAP antibodies, followed by incubation of secondary antibodies 
conjugated to Alexa Fluor 546. Images with one optical section were acquired with excitation at 405 nm and 561 
nm simultaneously. DAPI channel (blue) collecting photons resulted from the emission from DAPI was combined 
with YAP channel (yellow) collecting photons resulted from the emission from Alexa Fluor 546 in one track, 
consistent with the setting in Figure 36. Only the image in YAP channel was exported. Representative images 





























Figure 40. Effects of linear unmixing on detecting DAPI, expression of p53 and subcellular localisation of YAP in 
the nucleus and cytoplasm with multi-coloured imaging.  
3D mono-cultures of 500 Capan-2 cells or 5,000 HSCs were grown in a hanging drop format for 4 days, fixed in 
PFA and then stained with DAPI (blue), anti-p53 antibodies (green) and anti-YAP antibodies (red). Optical clearing 
by ethanol and BABB was performed. Images with one optical section were acquired with excitation at 405 nm 
and 561 nm simultaneously. DAPI channel (blue) collecting photons resulted from the emission from DAPI was 
combined with YAP channel (yellow) collecting photons resulted from the emission from Alexa Fluor 546 in one 
track. Linear unmixing was done in Zen 2.3 (blue edition) using Automatic Component Extraction (ACE).   












































































Figure 41. Effects of multitracking on detecting DAPI and subcellular localisation of YAP in the nucleus and 
cytoplasm with multi-coloured imaging. 
3D co-cultures of 500 Capan-2 cells mixed with 40,000 hepatic stellate cells (HSCs) were grown in a hanging drop 
format for 4 days, fixed in PFA and then stained with DAPI (blue), anti-p53 antibodies (channel not shown) and 
anti-YAP antibodies (yellow). Optical clearing by ethanol and BABB was performed. Images with one optical 
section were acquired with excitation at 405 nm and 561 nm simultaneously. DAPI channel (blue) collecting 
photons resulted from the emission from DAPI was combined with YAP channel (yellow) collecting photons 
resulted from the emission from Alexa Fluor 546 in one track, as shown in the left panel. Multitracking mode was 
used in the right panel, separating DAPI channel from YAP channel. Green arrows indicated the disappearance of 
































         
 
 
Figure 42. Effects of ACE unmixing and manual 
unmixing with multi-coloured imaging on 
detecting DAPI, p53 and subcellular localisation 
of YAP in the nucleus and cytoplasm of 3D co-
culture with PANC-1 cells and 5K hepatic stellate 
cells. 
Co-culture of 500 PANC-1 cells mixed with 5K 
hepatic stellate cells (HSCs) were grown in a 
hanging drop format for 4 days and then stained 
with DAPI (blue), and for p53 (green) and YAP 
(yellow). Optical clearing by ethanol and BABB 
was performed. Fluorescent images were 
acquired by confocal laser scanning microscopy 
using Zeiss LSM880. ACE unmixing was done in 
Zen 2.5 (blue edition). Single dye spectrum was 
generated by staining the spheroids with single 
dye and acquired using the same CLSM setting for 
manual unmixing, which was done in Zen 2.5 
(blue edition). Red arrows indicated undesired 
signal loss after ACE unmixing. Green arrow 
heads: nuclear localisation of YAP. Scale bar, 50 









   
 
   
  




































































































Figure 43. Effects of ACE unmixing 
with multi-coloured imaging on 
detecting DAPI and subcellular 
localisation of YAP in the nucleus 
and cytoplasm of 3D co-culture 
with cancer cells and 40K hepatic 
stellate cells. 
Co-culture of 500 Capan-2 cells or 
PANC-1 cells mixed with 40K 
hepatic stellate cells (HSCs) were 
grown in a hanging drop format for 
4 days and then stained with DAPI 
(blue), p53 (not shown) and YAP 
(yellow). Optical clearing by 
ethanol and BABB was performed. 
Fluorescent images were acquired 
by confocal laser scanning 
microscopy using Zeiss LSM880. 
ACE unmixing was done in Zen 2.5 
(blue edition). Scale bar, 100 μm  
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PANC-1 + 40K HSCs  
ACE Unmixed Image  
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Figure 44. Representative images of 3D spheroids without fluorophores. 
3D mono-culture of Capan-2 cells or 5,000 (5K) hepatic stellate cells (HSCs) respectively and 3D co-culture of 500 
Capan-2 cells mixed with 5K HSCs were grown in a hanging drop format. After 4 days, whole spheroids were fixed 
in PFA and optical clearing by ethanol and BABB was performed. Confocal laser scanning microscopy with 
multitracking was performed on spheroids without any staining of fluorophores. Excitation wavelengths were 
405nm, 488nm, 561nm and 633nm with the same laser powers and gains as the ones used in Figure 42-43. Images 













































Figure 45. Representative images of 3D spheroids stained with 2nd antibodies conjugated to fluorophores. 
3D mono-culture of Capan-2 cells or 5,000 (5K) hepatic stellate cells (HSCs) respectively and 3D co-culture of 500 
Capan-2 cells mixed with 5K HSCs or 20K HSCs respectively were grown in a hanging drop format. After 4 days, 
spheroids were fixed in PFA and incubated with 2nd antibodies conjugated to Alexa Fluo 488, Alexa Fluo 546 and 
Alexa Fluo 647 respectively. Optical clearing by BABB and confocal laser scanning microscopy with multitracking 
were performed. Excitation wavelengths were 405 nm, 488 nm, 561 nm and 633 nm with the same laser powers 
and gains as the ones used in Figure 42-43. Images exported were coloured black and white. CH: channel. DIC: 
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Figure 46. Representative images of 3D spheroids stained with DAPI, IgGs and 2nd antibodies conjugated to 
fluorophores. 
3D mono-culture of Capan-2 cells and 3D co-culture of 500 Capan-2 cells mixed with 5,000 (5K) hepatic stellate 
cells (HSCs) or 20K HSCs respectively were grown in a hanging drop format. After 4 days, whole spheroids were 
fixed in PFA and incubated with DAPI, IgGs, 2nd antibodies conjugated to Alexa Fluo 488, Alexa Fluo 546 and Alexa 
Fluo 647 respectively except that DAPI was missing by accidence in 3D co-culture of 500 Capan-2 cells mixed with 
20K HSCs. Optical clearing by BABB and confocal laser scanning microscopy with multitracking were performed. 
Excitation wavelengths were 405 nm, 488 nm, 561 nm and 633 nm with the same laser powers and gains as the 























From these method improvements, it appeared that YAP was mainly localized in the cytoplasm for the 
3D mono-culture and co-culture spheroids grown using the hanging drop protocol for 4 days. Semi-
quantification of YAP intensities by CellProfiler in Figure 47. YAP intensities in the nucleus, cytoplasm 
and the whole cells were measured in at least 25 cells near the edge of the spheroid and the core of 
the spheroid in the mono-culture of Capan-2 cells and HSCs using one optical slide. The YAP expression 
in the whole cell between the cells located near the core of the spheroid and the ones located near the 
edge of the spheroid was compared using total YAP intensity. Meanwhile, the intensity ratios of YAP 
intensity measured in the nucleus (nuclear YAP intensity) to total YAP intensity in the whole cell were 
compared to the intensity ratios of YAP intensity measured in the cytoplasm (cytoplasmic YAP intensity) 
to total YAP intensity in the whole cell, in order to compare the relative amount of YAP localisation in 
the nucleus between the cytoplasm. 
Because the data representing YAP intensities and ratios did not follow normal distribution and not 
have the same shape of distribution, mean ranks of the datasets were compared using a non-
parametric Mann-Whitney U test in Figure 47. Comparing the total YAP intensities in the whole cells 
near the edge and the cores, the cells near the edge exhibited significantly higher YAP expression (mean 
rank of 25.55 for Capan-2 cells near the core and 62.91 for Capan-2 cells near the edge while mean 
rank of 16.07 for HSCs in the core and 44.74 for HSCs near the edge, p < 0.001). The ratio of cytoplasmic 
YAP intensities was significantly higher than the ratio of nuclear YAP intensities in the Capan-2 cells 
near the edge of the spheroids (mean rank of 47.60 for ratio of cytoplasmic YAP intensity and 23.40 for 
nuclear intensities of YAP, p < 0.001), HSCs near the core of the spheroids (mean rank of 42.50 for ratio 
of cytoplasmic YAP intensity and 14.50 for nuclear intensities of YAP, p < 0.001), and HSCs near the 
edge of the spheroids (mean rank of 52.86 for ratio of cytoplasmic YAP intensity and 18.14 for nuclear 
intensities of YAP, p < 0.001). However, there was no significant difference between the ratio of 
cytoplasmic YAP intensities and the ratio of nuclear YAP intensities in the Capan-2 cells located near 
the core of the spheroid (p = 0.443). There was obvious cytoplasmic localisation of YAP and nuclear 
exclusion of YAP in the Figure 37 and 40, showing 3D mono-culture of Capan2 cells. Therefore, the 
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Figure 47 Semi-quantification 
of YAP subcellular expression 
in 3D mono-culture of Capan-
2 cells and hepatic stellate 
cells in scaffold-free 
conditions. 
 
3D Mono-cultures of 500 
Capan-2 cells or 5,000 hepatic 
stellate cells (HSCs) were 
grown in a hanging drop 
method for 4 days and then 
stained with DAPI (blue), and 
YAP (red). Optical clearing by 
ethanol and BABB was 
performed. CLSM with dual 
tracking was performed near 
the core of the Capan2 and 
HSCs spheroids. Linear 
unmixing was done in Zen 2.3 
(blue edition) using Automatic 
Component Extraction (ACE). 
Intensities of YAP in single cell 
on one optical section from 
one spheroid in one 
independent experiment were 
generated by CellProfiler (A). 
Whisker box graph was made 
from all the values of total YAP 
intensity in the whole cell (B) 
or the intensity ratios of 
nuclear YAP intensity to total 
YAP intensity in the whole cell 
or cytoplasmic YAP intensity to 
total YAP intensity in the 
whole cell (C) from at least 
twenty cells near the core of 
the spheroid and the edge of 
the spheroid, using Excel. 
Mean markers were shown. 
Median was exclusive from 
quartile calculation. Dots 
indicated the values in cells 
automatically generated by 
Excel. Non-parametric Mann-
Whitney U test was used to 
calculate the p values. Nu: 
nucleus, Cy: cytoplasm, W: 
whole cell. 
p < 0.001 
 p < 0.001 
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3.3 Step-wise process of coating pre-formed 3D cancer cell spheroids with 
stellate cells 
 
We next attempted to establish a 3D co-culture model by first forming cancer cell spheroids and then 
placing these into a stellate cells suspension in standard cell culture medium. 500 Capan-2 or PANC-1 
cells per 40 µL, the same number as what was used in section 3.2, were seeded into the inlet of the 
GravityPLUSTM HangingDrop Plate. After 4 days, each droplet containing a single cancer spheroid was 
pushed into a stellate cells suspension containing hepatic stellate cells (HSCs) introduced into the wells 
of polyHEMA low-attachment plates. The number of HSCs placed into these wells were calculated to 
achieve 10:1, 20:1 and 40:1 ratios of stellate cells to cancer cells. Our previous data suggested that the 
average cancer cell number in Capan-2 and PANC-1 3D spheroids formed by the hanging drop protocol 
was approximately 2,000 cells on day 4. Therefore, the cell numbers of HSCs in suspension ranged from 
20,000 to 100,000 cells per well were used.  
As illustrated in Figure 48, HSCs in the low-attachment plates formed a single spheroid by themselves 
without centrifugation, presenting a dark area in the well. As shown in Figure 49 and 50, compared to 
the dark area indicating the HSCs, the cancer mono-culture spheroids presented as a lighter area in the 
well. On the first day (Day 4) when the cancer spheroid was dropped in the stellate cells suspension, 
no more than one third of spheroids dropped into the HSCs spheroid region (images in the solid outline) 
whereas the rest of the spheroids only touched the edge of HSCs spheroid (images in the dotted 
outline). We expected the HSCs could migrate towards the cancer spheroids. However, more wells 
were observed with the light area touching the dark area in the wells on day 5 and day 6, indicating the 
majority of cancer cell spheroids situated at the edge of the HSCs spheroids. The different brightness 
and contrast between the cancer cell spheroids and the HSCs spheroids were sufficient to distinguish 
the cancers area from the HSCs area, thereby eliminating the need for immunofluorescence analysis of 
p53 expression. In sum, this approach of using pre-formed 3D mono-cultures of pancreatic cancer cells 
and then co-mixing these with HSCs suspension failed for produce a co-culture organization that 
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Figure 48. Spheroid formation of hepatic stellate cells suspension in scaffold-free condition.  
20,000 (20K), 40,000 (40K), 100,000 (100K) cells per well of hepatic stellate cells (HSCs) suspensions were seeded 
in the poly-HEMA low-attachment 96-well plates with standard cell culture medium. The experiment was done 
in parallel with dropping cancer spheroids to HSCs suspensions. Day 4 indicated the day when cancer spheroids 
pre-formed in hanging drops were dropped to the HSCs suspension. Images were acquired by Leica DMI4000 B 

















































Figure 49. Dropping 3D Capan-2 mono-spheroids into hepatic stellate cells suspension in scaffold-free 
condition.  
3D Capan-2 spheroids were first grown in a hanging-drop format for 4 days and then put into the wells of 
polyHEMA low-attachment 96-well plate where 20,000 (20K), 40,000 (40K), 100,000 (100K) cells per well of 
hepatic stellate cells (HSCs) suspensions were seeded respectively in standard cell culture medium at 10:1, 20:1 
and 40:1 ratios of stellate cells to cancer cells according the cancer cell count on day 4. Images were acquired by 
Leica DMI4000 B (50x magnification). Images in the solid outline represented the spheroids dropped into the 
HSCs spheroid region on day 4 whereas the images in the dotted outline represented the edge of some cancer 
spheroids only touched the edge of HSCs spheroids on day 4. Representative images shown were from six wells 














































Figure 50. Dropping 3D PANC-1 mono-spheroids into hepatic stellate cells suspension in scaffold-free condition.  
3D PANC-1 spheroids were first grown in a hanging-drop format for 4 days and then put into the wells of 
polyHEMA low-attachment 96-well plate where 20,000 (20K), 40,000 (40K), 100,000 (100K) cells per well of 
hepatic stellate cells (HSCs) suspensions were seeded respectively in standard cell culture medium at 10:1, 20:1 
and 40:1 ratios of stellate cells to cancer cells according the cancer cell count on day 4. Images were acquired by 
Leica DMI4000 B (50x magnification). Images in the solid outline represented the spheroids dropped into the 
HSCs spheroid region on day 4 whereas the images in the dotted outline represented the edge of some cancer 
spheroids only touched the edge of HSCs spheroids on day 4. Representative images shown were from six wells 





In this chapter, increasing ratio of stellate cells to cancer cells led to reduced spheroid expansion and 
fewer cancer cells near the edge of the spheroids. However, localization of cancer cells occurred 
outside stellate cells cores, which was opposite to the cell distribution in PDAC. One possible reason 
why cancer cells wrapped around the stellate cells was that the stellate cells derived from PDAC 
patients in the current models tend to attach to stellate cells themselves in the scaffold-free condition.  
Efforts were made in this chapter to optimise the microscopic scanning of the 3D spheroids with the 
size around 500 μm with the methods causing as little damage to the 3D structure as possible and 
minimizing the steps involved in the traditional histology methods to increase efficiency. Multiphoton 
scanning has been considered to improve the light penetration and reduce the light scattering in thick 
tissue compared to CLSM [Tauer, 2002]. However, by comparing p53 expression by CLSM scanning and 
MP scanning after optical clearing with ethanol and BABB, there was no significant difference between 
the p53 expression levels in the cells near the core and the edge of the spheroids. Besides, the lasers 
excitation mode in Zeiss LSM 880 currently used for MP scanning is not as fast as CLSM scanning. 
Henceforth, optical clearing with ethanol and BABB using CLSM will be utilized as the standard imaging 
technique to acquire the images in the next sections. 
Our data indicate the p53 was not detected in patient-derived hepatic stellate cells grown in 3D mono-
culture and 3D co-culture. This is inconsistent with the findings in hepatic stellate cells isolated from 
rat [Huang et al, 2018; Longxi et al, 2011; Nishizawa et al, 2016]. Immunoblotting demonstrated a 
baseline level of p53 expression in 2D primary isolated rat HSCs while the staining of p53 in vivo was 
weak [Nishizawa et al, 2016]. Primary rat HSCs grown in 2D for 3 days exhibited p53 expression 
detected by immunoblotting [Huang et al, 2018]. As far as we know, there has been no report on p53 
expression in patient-derived HSCs in pancreatic cancer. Whether the growth conditions change p53 
expression and 2D culture promotes p53 expression in HSCs remain to be determined.   
Our data suggest that the decrease in p53 intensities was not proportional to the reduced number of 
cancer cells in the 3D co-culture models analysed by immunoblotting, indicating that different growth 
rates may be present in 3D mono-culture of cancer cells and 3D co-culture of cancer cells and HSCs. 
Different growth rates have been observed between stromal cells and cancer cells not only in 2D 
culture but also in 3D culture [Hoarau-Vechot et al, 2018]. After robust data could be obtained to verify 
the reliable markers for cancer cells in the co-culture models, stringent experiments need to be 
designed to determine the initial ratio of HSCs to cancer cells so that a 3D co-culture model matching 
the growth conditions in patients with PDAC could be achieved. 
Of note, contradictory data on p53 expression was found in this section in the images used to quantify 
p53 expression (Figure 32) where strong p53 staining was detected in the core of the spheroid and the 
images showing p53 expression in Figure 27-29 where weak p53 staining was detected in the core of 
the spheroid. One of the reasons could be the position of the scanning in the spheroids. It could be an 
isolated incident that the scanning happened to be a position where high p53 expression in the cancer 
cells between the core and the edge of the spheroids. Also, the judgements of the operators on 
positioning the core of the spheroids are critical. In general, more data in this chapter support that p53 
expression was reduced in the cells grown further away from the edge of the 3D spheroids. 
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The data on the association of increasing ratio of stellate cells to cancer cells with reduced p53 
expression seemed to support the inhibitory role of stellate cells on cancer cell proliferation [Ozdemir 
et al, 2014; Rhim et al, 2014]. However, the observations and assessments were undertaken in the 
environment of small volume that led to severe nutrient depletion and metabolites accumulation. 
Meanwhile, it was possible that ECM levels in the environment where stellate cells and cancer cells 
were only together for 4 days had not reached the same level as the ones in patients with PDAC. Further 
models with realistic cells and ECM composition are needed to elucidate the cancer-supportive or 
cancer-suppressive roles of stellate cells in different context and stage in PDAC.  
Although our data is consistent with the commonly acknowledged fact that αSMA is a marker for 
activated stellate cells [Erkan et al, 2008; Jiang et al, 2018; Ozdemir et al, 2014; Wei et al, 2017], the 
two pancreatic cancer cell lines, Capan-2 and PANC-1 cells, also exhibited strong expression of αSMA. 
This unexpected finding might suggest that the anti-αSMA antibodies used in the current project would 
not be able to distinguish between some subsets of HSCs and pancreatic cancer cells. Since EMT is 
common in PDAC, αSMA expression in Capan-2 and PANC-1 cells can be considered as the biomarker 
of EMT cells [Hill et al, 2017].  
In this section, YAP mainly localizes in the cytoplasm near the edge of 3D spheroids while cancer cells 
at the edge occasionally presented with nuclear localisation of YAP. The data validate that cell-cell 
contact promote YAP cytoplasmic localization [Gumbiner et al, 2014], which is one of the reasons that 
more cancer cells with nuclear exclusion of YAP could be seen. The YAP expression in the wholes cells 
near the edge of the spheroids was higher than the ones near the core of the spheroids, indicating cells 
near the edge of the spheroids subjected to less cell-cell contact inhibition and more nutrients 
accessibility than the ones near the core. This is one of the possibilities that Capan-2 spheroids 
expanded significantly. However, even though HSCs spheroids exhibited the same YAP expression 
pattern as the Capan2 spheroids, their sizes remained the same over time, indicating that YAP 
expression may not promote cell growth in certain cell types. Interestingly, in spite of higher ratio of 
cytoplasmic YAP intensities near the edge of the spheroids, Capan2 spheroids did not enter a growth 
arrest state as suggested by the findings in 2D culture [Cravo et al, 2015], indicating that pancreatic 
cancer cells grown in 3D culture might require a lower level of nuclear localisation of YAP as a driving 
force for proliferation.    
There are a few limitations in the current chapter. For instance, the work presented fail to recreate a 
model that is the formation of a single sphere/tumouroid consisted of stellate cells surrounding the 
cancer cells in each well to lay the foundation to perform high throughput drug screening. More optical 
sections are needed to quantify the protein expression to determine whether the antibodies are able 
to evenly bind to the antigens from the edge to the core of the spheroids. The current study lacked the 
measurement of ECM in the current models. It is necessary to characterize the collagens, fibronectin, 
laminins and hyaluronic acid (HA) in PDAC models using specific antibodies or HA detection kits to 





Chapter 4.  Effect of an artificial ECM on YAP signalling in a 3D mono-
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Figure 51. Diagram of effects of an artificial ECM on YAP signalling in a 3D mono-culture model of pancreatic 
cancer cells  
 
Highlights 
Myogel was prepared as a source of ECM elements. Collagen I, collagen IV, fibronectin and laminin 
could be detected in Myogel. Myogel was biocompatible with certain subtypes of PDAC cells. 
Unmodified hyaluronic acid was biocompatible with Capan-2 and PANC-1 cells and could promote 
nuclear accumulation of YAP.  
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4.1 YAP signalling in the 3D model with pancreatic cancer cells and Myogel 
                    
4.1.1 Background  
 
Since mouse models and commercial matrices used in 3D culture and organoids are expensive, it would 
be beneficial to explore other alternatives to reduce the cost of current pancreatic cancer models, 
especially in the context of screening large databases of potential novel therapeutics in conditions that 
represent the pancreatic cancer tumour microenvironment [Baker et al, 2016]. In 3D culture and 
organoids, rat collagen I and Matrigel (mouse sarcoma-derived products) are used to recreate an 
extracellular matrix (ECM) environment containing collagen I, collagen IV, fibronectin, and laminin that 
are present in the pancreatic cancer tumour microenvironment [Laklai et al, 2016; Ohlund et al, 2009]. 
A decellularized ECM preparation obtained from skeletal muscle, termed Myogel, can be prepared 
from a wide variety of animal sources in large quantities as an inexpensive source of ECM constituents. 
Myogel contains collagen I, collagen IV, laminin, and fibronectin, making it a promising scaffold element 
for tissue engineering [Abberton et al, 2008; Wolf et al, 2012] supports the growth of many cell types, 
including C2C12 myoblasts, human perivascular stem cells, NIH 3T3 fibroblasts, NIH 3T3-L1 cells, HMEC 
endothelial cells, primary muscle progenitor cells, primary aortic smooth muscle cells, and corneal 
epithelial cells [Abberton et al, 2008; DeQuach et al, 2012; Francis et al, 2009; Stern et al, 2009; Wolf 
et al, 2012].  
Collagens in Myogel were reported to be between 27-72% of the total ECM extract [Abberton et al, 
2008; Stern et al, 2009], allowing it to be compressed and manipulated to create different levels of 
external pressures. The collagen content was 486.7 ± 133 µg per mg of the porcine skeletal muscle 
(PSM) extract [Abberton et al, 2008], higher than the one (0.029 µg per mg) in porcine pancreas 
[Mirmalek-Sani et al, 2013]. The investigation of cell proliferation and cell migration using Myogel 
[Cheema et al, 2013; Nyga et al, 2013] could provide novel insights into using Myogel as a potential 
alternative matrix to culture pancreatic cancer cells and pancreatic stellate cells to mimic the PDAC 
tumour microenvironment. Further, Myogel from PSM could potentially provide a relatively 
inexpensive source for ECM elements that could act as an alternative matrix to mimic the pancreatic 






4.1.2 Myogel characterization  
 
Myogel was prepared as indicated in Materials and Methods. The total protein concentration of 
Myogel in the preparations that were examined ranged from 5 mg/mL to 9 mg/mL. De-cellularization 
was confirmed by DAPI staining as illustrated in Figure 52 A. The nuclei of muscle cells and the PANC-1 
cells were able to be stained with DAPI while the intact nuclei and the tissue structure were not seen 
in the Myogel compared with the porcine skeletal muscle tissue.  
MS/MS was performed to characterize the components within Myogel. Collagen I from rat tail was 
used as a control to test the ability of MS method to detect collagen I. The results indicated that Myogel 
components included myosins 1, 2, 4, and 7 as well as actins, glyceraldehyde-3-phosphate 
dehydrogenase, and Troponin T. In addition, an array of proteins from other species such as human, 
cow, chicken, mouse, rat, rabbit, and horse were also present, possibly due to the similarity of their 
mass. Unexpectedly, collagen I, collagen IV, fibronectin and Laminins were not identified in the Myogel 
using MS/MS.  
Immunoblotting was also used to detect ECM components in Myogel using specific antibodies. Rat tail 
collagen I, Matrigel® containing collagen IV and Laminins, and fibronectin from bovine serum were 
used as positive controls. As illustrated in Figure 52 B, weak bands of collagen I, collagen IV, fibronectin 
and Laminin β-2 could be detected in these Myogel preparations using respective antibodies, indicating 
its potential to mimic the complexities of ECM in pancreatic cancer microenvironment. However, as 
the amount of detected ECM components was very low, further extraction and purification methods 
are needed to increase the concentration of collagen I, collagen IV, fibronectin and laminins in Myogel 































Figure 52. Myogel Characterization.  
A. DAPI staining of porcine muscle, PANC-1 cells grown with Myogel for 10 days. Porcine muscle and the PANC-1 
cells with Myogel were fixed in PFA, embedded in wax and sectioned in 5 μm per slide by microtome. After 
deparaffinization, DAPI (white) was incubated with the slides and images were acquired using Leica DMI4000 B 
(100x magnification). Scale bar, 100 μm. B. Immunoblotting of Myogel with antibodies against collagen I (COL1), 
collagen IV (COL4), fibronectin and Laminin β-2 (LAMININ2). Rat tail collagen I, Matrigel® and fibronectin from 
bovine serum were used as positive controls. Capan-2 cells were used as negative control.  
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4.1.3 Biocompatibility of Capan-2 and PANC-1 cells and spheroids with Myogel 
 
We next mixed the Myogel preparation with Capan-2 or PANC-1 cell suspensions. Meanwhile, Capan-
2 and PANC-1 spheroids prepared using the hanging drop protocol were transferred into 96-well plates, 
one spheroid per well coated with Myogel. Sphere growth and cell viability at 2 and 4 days after the 
cells and spheroids were put into Myogel were analysed. The cell suspension in Myogel was used to 
test the viability and proliferation of single cancer cell in Myogel so as to validate the ability of Myogel 
to support pancreatic cell growth and spheroids formation. The pre-formed spheroids in Myogel were 
used to test the potential of Myogel as a matrix for modelling cell invasion in ECM. 
As shown in Figure 53 A, compared to the single layer of cells grown as 2D in standard cell culture 
medium, the Capan-2 cells suspension in Myogel formed multiple spheres and spheroid expansion 
could be seen on day 4. The spheroid expansion pattern in Capan-2 and PANC-1 was similar between 
the pre-formed spheroids dropped to the standard culture medium and the spheroids dropped to 
Myogel. Comparing the sizes of the spheroids on two different days and in two different growth 
conditions, there was no significant difference between spheroids grown in medium on day 2 and day 
4 (p > 0.05). The sizes of Capan-2 spheroids increased significantly when cultured with Myogel for 4 
days compared to 2 days (p = 0.01). However, the sizes of PANC-1 spheroids remained the same when 
cultured with Myogel for 4 days compared to 2 days (p = 0.26). Interestingly, there was no significant 
difference between Capan-2 spheroids grown in medium and in Myogel (p = 0.72) whilst significant 
increase could be seen in PANC-1 spheroids in Myogel compared to the ones in medium (p = 0.04). 
As shown in Figure 54, the fluorescence intensity detected by incubation with resazurin, as a 
measurement of cell viability, was higher in spheroids grown in Myogel on Day 4 than those examined 
at Day 2 (p < 0.05) in Capan-2 groups. Moreover, there was no significant difference between the cell 
viability of 3D Capan-2 spheroids in Myogel and those incubated in standard cell culture medium (p = 
0.202).  
PANC-1 cell suspensions in Myogel, however, failed to form multiple spheres similar to those seen in 
Capan-2 group (Figure 53). As can be seen in Figure 54, the cell viability of PANC-1 cells suspension 
dropped significantly on Day 4 compared to Day 2 (p < 0.05). Also, there was significantly decrease in 
cell viability in PANC-1 spheroids grown 4 days in Myogel compared to the ones grown in medium (p < 
0.05). Of note, cell viability was markedly increased on Day 4 in PANC-1 cell spheroids in Myogel 
compared with the ones on Day 2 in one independent experiment (p < 0.05) while remained statistically 
unchanged in another (p = 0.86, Exp2), indicating the variability among individual experiments. The 
batch difference, the unknown factors and proteins due to insufficient purification of Myogel 
preparation might cause the inconsistency in the biocompatibility of Myogel with PANC-1 cells and 
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Figure 53. 2D and 3D culture in Myogel.  
A. Representative phase-contrast imaging of 2D and 3D culture of Capan-2 and PANC-1 cells grown with or 
without Myogel in 96-well plates. Images were acquired using Leica DMI4000 B (50x and 100x magnification). 
Scale bars, 500 μm; 100 μm (insert). N=2. B. Graph of areas in μm2 of Capan-2 and PANC-1 spheroids on Day 2 
and Day 4. The areas were measured using CellProfiler. Error bars and graph were generated in Excel. Error bars 
represented standard deviations from 5-9 spheroids in each group from one independent experiment (n=1). P-
value was calculated by two-tailed two-sample equal variance t-Test if the sample size between two groups were 
the same or unequal variance t-Test if the sample size between two groups were not the same using Excel. *: p < 


























































Figure 54. Cell viability of Capan-2 and PANC-1 cells and spheroids with Myogel by AlamarBlue® assay.  
2D and 3D culture of Capan-2 cells and PANC-1 cells were grown with or without Myogel in 96-well plates. 
Fluorescence intensities in five-six wells detected by incubation with resazurin in cell suspensions and spheroids 
with or without Myogel in one independent experiment were calculated except three wells were managed to be 
detected in Exp2. Error bars indicated standard deviation of five or six wells in one independent experiment except 
three wells in Exp2. P-value was calculated by two-tailed two-sample equal variance t-Test if the sample size 
between two groups were the same or unequal variance t-Test if the sample size between two groups were not the 




4.1.4 YAP signalling in Capan-2 spheroids and PANC-1 spheroids grown in Myogel  
 
YAP expression and localization was investigated in 3D mono-culture of Capan-2 and PANC-1 grown in 
Myogel. As illustrated in Figure 55, there was no striking difference in YAP expression between Capan-
2 spheroids and PANC-1 spheroids grown in standard cell culture medium and Myogel for 2 days.  





















Figure 55. Subcellular localization of YAP in 3D mono-culture of Capan-2 spheroids and PANC-1 spheroids with 
or without Myogel.  
500 Capan-2 cells and PANC-1 cells were seeded in a hanging drop format for 4 days and then spheroids were 
dropped to standard cell culture medium with or without Myogel. After 2 days, immunofluorescence microscopy 
with single anti-YAP antibodies was performed. Fluorescent images were acquired by confocal laser scanning 








Hyaluronic acid (HA) is accumulated in 80-87% of PDAC and contributes to the high interstitial fluid 
pressure that hinders drug delivery to these tumours [Kultti et al, 2012; Sato et al, 2016b]. Pancreatic 
cancer cells and the tumour-stromal interactions induce the production of HA in the PDAC 
microenvironment [Mahlbacher et al, 1992; Sato et al, 2016a]. HA metabolism results in small HA 
fragments to large molecular weight polymers (2,000–25,000 disaccharide unit) in the cancer 
microenvironment, which can bind to cell surface receptors such as EGFR and CD44, to stimulate cell 
proliferation [Kultti et al, 2012]. Meanwhile, HA crosslinks naturally with collagens and fibronectin in 
the ECM to promote cell invasion [Kultti et al, 2012]. Through these interactions, HA activates a focal 
adhesion kinase (FAK), Ras GTPases, and modulates actin cytoskeleton [Kultti et al, 2012] as events that 
are associated with YAP signalling. Therefore, incorporating HA in the culture system could provide a 
highly promising approach to study YAP signalling in these in vitro 3D models of PDAC. 
HA-based hydrogels have been widely used to establish 3D cancer models, most of which utilized 
chemically-modified products. PDAC cells have been shown to be viable in thiol-modified HA and 
models have demonstrated epigenomic and metabolic changes in the stromal compartment of these 
systems [Sherman et al, 2017]. The effects of by-products and residual materials generated by these 
chemical crosslinking reactions can affect genetic changes and protein expression that might alter 
PDAC properties [Burdick et al, 2011]. Such possible events warrant further investigation. Meanwhile, 
HA isolated from microbial fermentation, such as Streptococcus equi, can be used to examine the 
feasibility using unmodified HA to develop 3D models to mimic PDAC tumours. In this section, studies 
were performed to identify optimised condition for using HA and to study the impact of this ECM 





4.2.2 Spheroid expansion in HA 
 
There were limited data on the 3D culture of Capan-2 and PANC-1 cells in HA. HA present in human 
PDAC and human normal pancreas is reported to range from 0.029 ± 0.003 to 0.388 ± 0.032 mg per g 
wet tissue [Ozcelikkale et al, 2017]. Such a large range of potential HA levels did not provide much 
guidance in the selection of HA concentrations to include in the 3D culture format. Thus, an empirical 
approach was taken to select an HA concentration that might be useful in establishing a 3D cancer 
format for future screening of potential anticancer agents. 
3D mono-culture spheroids composed of Capan-2 or PANC-1 cancer cells were formed using the 
hanging-drop protocol. At day 4, these spheroids were dropped into the wells of polyHEMA low-
attachment plates containing 1, 3, or 5 mg/mL HA in PBS. An HA stock solution was prepared at 10 
mg/mL in PBS. It should be noted that the introduction of HA reduced the volume of culture medium 
in the final culture conditions, where the higher HA content correlated with lower levels of nutrients 
coming from the amount of culture media replaced by HA solution. As a result, wells with the same 
volume of PBS as the ones in the highest HA concentration (5 mg/mL) used in the present study served 
as controls, acknowledging this discrepancy in potential nutrient composition.   
As shown in Figure 56 and 57, compared to spheroids dropped into the wells on day 4, there was no 
marked difference between the spheroid expansions over 5 days grown in PBS: medium mixture and 
spheroids grown in standard culture medium (the difference in the size was due to the manual 
variability between independent experiments). Cancer cell mono-culture spheroids in the wells 
containing the PBS without HA (controls) were indistinguishable from those wells with normal culture 
medium as detected by phase-contrast imaging. This indicates that the reduction in nutrients on this 
occasion had no significant impact on gross aspects of these 3D cancer cell spheroids. Of note, small 
clusters of PANC-1 cells could be seen after 1 day in the 3 and 5 mg/mL HA whereas none were 
observed in the 0 and 1 mg/mL HA (Figure 57).  
5 mg/mL HA was chosen for the following sections because it could mimic more challenging barrier for 
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Figure 56. Capan-2 spheroid expansion in hyaluronic acid.  
500 Capan-2 cells were seeded in GravityPLUSTM HangingDrop plates and after 4 days the droplets were pushed 
to the wells containing 0, 1, 3, and 5 mg/mL hyaluronic acid (HA) in polyHEMA low-attachment plates. The wells 
with the same volume of PBS (the solvent used to dissolve HA) as the ones in the highest concentration of HA (5 
mg/mL) were included to examine the reduction of nutrients in the culture environment. Images were acquired 
by Leica DMI4000 B (50x magnification) manually at the time points indicated after dropping Capan-2 spheroids 
into the polyHEMA low-attachment plates. Representative images from six spheroids in the same group from one 
independent experiment were shown. The insert image of Capan-2 with medium on Day 0 was captured in the 
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Figure 57. PANC-1 spheroid expansion in hyaluronic acid.  
500 PANC-1 cells were seeded in GravityPLUSTM HangingDrop plates and after 4 days the droplets were pushed 
to the wells containing 0, 1, 3, and 5 mg/mL hyaluronic acid (HA) in polyHEMA low-attachment plates. The wells 
with the same volume of PBS (the solvent used to dissolve HA) as the ones in the highest concentration of HA (5 
mg/mL) were included to examine the reduction of nutrients in the culture environment. Images were acquired 
by Leica DMI4000 B (50x magnification) manually at the time points indicated after dropping PANC-1 spheroids 
into the polyHEMA low-attachment plates. Representative images from six spheroids in the same group from one 






























4.2.3 YAP subcellular localisation in 3D cultures of cancer cells with hyaluronic acid 
 
YAP expression and localization was investigated in Capan-2 and PANC-1 spheroids grown in the 
presence of hyaluronic acid (HA). 500 Capan-2 or PANC-1 cells were seeded in GravityPLUSTM 
HangingDrop plates for 4 days and spheroids were dropped to 96-well plates containing medium with 
or without 5 mg/mL HA. After 2 days, whole spheroids were fixed in PFA, and immunofluorescence 
staining with anti-YAP antibodies and DAPI followed by optical clearing was performed. 
After 2 days in HA, nuclear and cytoplasmic localisation of YAP, both at the edge and the core of the 
spheroids, changed in the spheroids with HA compared to the ones grown in medium without HA 
(Figure 58). There appeared to be more signals near the core of the spheroids when cultured with HA 
than the ones without HA (Figure 58). Semi-quantification of YAP was conducted in one Capan-2 
spheroid in the presence of HA (Figure 59). Unfortunately, DAPI staining of the spheroids cultured with 
medium was missing during sampling, causing unavailability of semi-quantification of YAP in the 
spheroids without HA. Because the data representing YAP intensities and ratios did not follow normal 
distribution and not have the same shape of distribution, mean ranks of the datasets were compared 
using a non-parametric Mann-Whitney U test in Figure 59. Comparing the total YAP intensities in the 
whole cells near the edge and the core, the cells near the edge exhibited significantly higher YAP 
expression (mean rank of 25.35 for Capan-2 cells near the core and 77.31 for Capan-2 cells near the 
edge, p < 0.001). The ratio of cytoplasmic YAP intensities was significantly lower than the ratio of 
nuclear YAP intensities in the Capan-2 cells near the core of the spheroids (mean rank of 28.17 for ratio 
of cytoplasmic YAP intensity and 68.83 for nuclear intensities of YAP, p < 0.001), and Capan2 cells near 
the edge of the spheroids (mean rank of 44.24 for ratio of cytoplasmic YAP intensity and 74.76 for 
nuclear intensities of YAP, p < 0.001). The data indicated cells with nuclear accumulation of YAP were 



























Figure 58. Subcellular localization of YAP in 3D mono-culture of Capan-2 spheroids and PANC-1 spheroids with 
or without hyaluronic acid.  
500 Capan-2 cells or PANC-1 cells were seeded in GravityPLUSTM HangingDrop plates for 4 days and spheroids 
were dropped to 96-well plates containing medium with or without 5 mg/mL hyaluronic acid (HA). After 2 days, 
immunofluorescence staining with anti-YAP antibodies (yellow) and DAPI (blue) followed by optical clearing was 
performed. Fluorescent images were acquired by confocal laser scanning microscopy using Zeiss LSM880 with 
optical sectioning near the core of each spheroid. Image analysis was performed using Zen 2.3 (blue edition). 





















Figure 59. Semi-quantification of YAP subcellular 
expression in 3D mono-culture of Capan-2 spheroids with 
hyaluronic acid.  
500 Capan-2 cells were seeded in GravityPLUSTM 
HangingDrop plates for 4 days and spheroids were 
dropped to medium with 5 mg/mL hyaluronic acid. After 
2 days, immunofluorescence staining with anti-YAP 
antibodies (yellow) and DAPI (blue) followed by optical 
clearing was performed. Fluorescent images were 
acquired by confocal laser scanning microscopy using 
Zeiss LSM880 with optical sectioning near the core of each 
spheroids. Image analysis was performed using Zen 2.3 
(blue edition). Semi-quantification of YAP expression was 
analysed by CellProfiler. A representative field of view in an 
image processed by CellProfiler was shown, depicting the 
outlined nuclear areas and the cytoplasmic areas labelled 
with numbers (A). Whisker box graph was made from all 
the values of total YAP intensity in the whole cell of each 
individual cell (B) or the intensity ratios of nuclear YAP 
intensity to total YAP intensity in the whole cell of each 
individual cell or cytoplasmic YAP intensity to total YAP 
intensity in the whole cell of each individual cell (C) from 
around 45-60 cells near the core of the spheroid and the 
edge of the spheroid, using Excel. Mean markers were 
shown. Median was exclusive from quartile calculation. 
Dots indicated the values in cells automatically 
generated by Excel. Non-parametric Mann-Whitney U 
test in SPSS was used to calculate the p values. Nu: 
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Rat Collagen I and mouse Matrigel® are biomaterials that have been used to mimic the ECM in 3D PDAC 
models and patient-derived organoids [Baker et al, 2016]. Batch-to-batch differences and the variability 
of animal-derived factors obtained by various isolation methods raise uncertainties to their long-term 
use in in vitro models to the tumour environment in patients with PDAC [Baker et al, 2016]. There is a 
need to reduce the cost of the PDAC models considering the demand for high-throughput assays. In 
this chapter, the feasibility of Myogel and unmodified HA in establishing 3D PDAC models and studying 
YAP signalling was investigated.  
The commonly used commercially available materials to mimic ECM are extractions from rat tails and 
the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. They usually come from companies as solutions so 
they may not be ideal to recapture the 3D structure of tumours because they lose the architecture of 
intact cells. But gelation occurs when they are put in the environment with 5% CO2 at 37 °C, recovering 
certain degree of the ECM structure in cancer microenvironment. The idea of extraction from porcine 
skeletal muscle (PSM) follows similar principles so as to produce ECM macromolecules to form ECM 
structure. 
Since pancreatic cancer originated from the pancreas, assumptions can be made to extract ECM from 
the porcine pancreas as a more feasible approach not only to obtain ECM macromolecules but also 
other factors that may be essential for the growth and maintenance of pancreatic cancer cells than 
from PSM. However, The collagen content was 486.7 ± 133 µg per mg of PSM extract [Abberton et al, 
2008], higher than the one (0.029 µg per mg) in porcine pancreas [Mirmalek-Sani et al, 2013]. 
Compared to the higher amount of skeletal muscle per animal than the pancreas per animal, extraction 
from skeletal muscle may be more efficient than that from the pancreas and compliant with the 
emerging trend of replacement, reduction and refinement of animal use in scientific research [Brown 
et al, 2018; Tannenbaum et al, 2015]. 
There were two commonly used methods to prepare Myogel. One method is to use trypsin and 
detergents such as SDS and Triton™ X-100 to treat the tissue, which requires multiple freeze-thaw steps 
and lengthy incubation of the tissue with SDS solutions and Triton-100 solution to decellularize the 
tissue [DeQuach et al, 2012; Stern et al, 2009; Wolf et al, 2012]. The other method is based on 
homogenization [Abberton et al, 2008], which is tested for reproducibility in this section and 
considered to be more efficient and less harsh for ECM proteins than the first method to preserve the 
ECM macromolecules. The resulting total protein concentration of Myogel could reach about 9 mg/mL, 
which could be close to the commercially available protein concentration in Matrigel®. The serious 
batch variation could be due to the human error. However, collagens, fibronectin and laminin were not 
detected by mass spectrometry whereas peptide signatures following trypsin hydrolysis of the Myogel 
prepared in these studies indicated large amount of myosin proteins. While immunoblotting studies 
detected collagens, fibronectin and laminin in the Myogel preparation isolated for these studies, the 
presence of collagens, fibronectin and laminin could not be verified by mass spectrometry. There are 
three probable reasons why the peptides unique to collagens, fibronectin and laminin were not 
observed by mass spectrometry: 1) the energy used to charge the peptides derived from digested 
Myogel may not have been sufficient to ionize all the peptides from collagens, fibronectin and laminins 
for detection; 2) the shotgun MS could have been overlooked the presence of peptides from collagens, 
fibronectin and laminins due to multiple peptides at much higher content from myosin proteins being 
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eluted at the same time; 3) no collagens, fibronectin and laminin could be extracted using the current 
method.  
Two models to test the biocompatibility of Myogel with pancreatic cancer cells were used in the current 
study. One model is to use the cell suspension in Myogel to test the viability and proliferation of single 
cancer cell in Myogel so as to validate the ability of Myogel to support pancreatic cell growth and 
spheroids formation. The other model is to use the pre-formed spheroids in Myogel so as to test the 
potential of Myogel as a matrix for modelling cell invasion in ECM. Because PANC-1 cells are isolated 
from a patient with metastatic PDAC and possess high invasiveness in ECM [Deer et al, 2010], it was 
expected that the spheroids would expand in Myogel compared to the ones grown in the medium. 
Significant increase could be seen in PANC-1 spheroids in Myogel compared to the ones in medium. 
However, the sizes of PANC-1 spheroids remained the same when cultured with Myogel for 4 days 
compared to 2 days. The data are not consistent with each other, possibly due to an isolated event if 
sufficient independent experiments could be attained. Single Capan-2 cell formed 3D structures in 
Myogel after 2 days whereas it sometimes took 10 days for single PANC-1 cell to form 3D structures. 
Despite that 3D Capan-2 and PANC-1 spheroids were able to expand in Myogel and the cell viability 
increased after 2 days, YAP expression and localisation was not affected by Myogel, which was 
supposed to have the components to induce YAP nuclear translocation [Miroshnikova et al, 2017; Rice 
et al, 2017]. Taken together, purification of Myogel by enrichment of ECM may worth exploring in the 
future. 
It is possible that large molecules of HA could be fragmented during heating. HA is reported to be 
metabolised into small HA fragments to large molecular weight polymers (2,000–25,000 disaccharide 
unit) in the cancer microenvironment, which can bind to cell surface receptors such as EGFR and CD44, 
to stimulate cell proliferation [Kultti et al, 2012]. Weighing the risk of contamination to affect the cell 
growth and considering the reported method of sterilising HA by heating [Madihally et al, 1999], high 
temperature sterilization method was used to ensure the aseptic quality of HA solution because of the 
difficulty during filtering and uncertainty of HA concentration after filtering. After autoclaving, the HA 
solution still maintains the viscosity, creating a viscous environment to test the drug diffusion. Obvious 
spheroid expansion could be seen in both 3D Capan-2 and PANC-1 in unmodified HA derived from 
Streptococcus equi over 5 days. Meanwhile, after semi-quantification of YAP in 3D Capan-2 spheroids, 
more YAP translocated into the nucleus in the presence of HA compared to the ones in the Chapter 3, 
consistent with the findings indicating that HA can activate upstream regulators in YAP signalling to 
promote the nuclear accumulation of YAP [Kultti et al, 2012]. It also recapitulated YAP signalling as a 
driving force for aggressive cell proliferation in PDAC. Thus, the present study offered direct evidence 
on unmodified HA from Streptococcus equi as a biomaterial to recreate PDAC environments. 
One major limitation of the studies described in this chapter is that they only examined YAP signalling 
in the context of cancer cell-ECM interaction, lacking stellate cells and immune cells that are present 
in the PDAC tumour environment. At present, it is unclear which receptors, cell junction proteins, 
growth factors, chemokines, and cytokines that might be provided by stellate cells and immune cells 
are needed to recapitulate the complex networks affecting YAP signalling in PDAC tumours. Another 




Chapter 5.  YAP signalling in 3D co-culture models of pancreatic cancer cells, stellate 
cells and ECM-like materials 
 
Graphical abstract 
























Figure 60. Diagram of YAP signalling in 3D co-culture models of pancreatic cancer spheroids dropping into 
stellate cells suspensions with ECM-like materials. 
  
Cancer spheroid                      SCs suspension in HA 
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Figure 61. Diagram of YAP signalling in 3D co-culture models of pancreatic cancer cells mixing with stellate cells 























Dropping of PDAC spheroids into a stellate cells suspension in HA or HA with collagen I was able to 
establish a 3D co-culture model where only some of the cancer cells contacted with stellate cells 
without the multi-layered stellate cell barrier around the cancer cells core. 
Growing PDAC cells and stellate cells in a collagen I matrix with or without HA formed a single spheroid 
in each well of 96-well plates, resulting in multiple cancer cell cores inside the 3D co-culture models 
that resembled the fibrotic cancer microenvironment in patients with advanced and metastatic PDAC. 
Dynamic YAP subcellular localisation was found in these PDAC and stellate cell 3D co-culture models. 
Reduction of p53 expression correlated with YAP cytoplasmic localisation in the 3D co-culture models 
of PDAC cells and stellate cells. 
Potential anti-cancer compounds Pseudopterosin A-D and Tylophorinine, derived from natural 





Based on our previous work, direct co-culture of PDAC cells and stellate cells in scaffold-free conditions 
failed to form spheroids organized into stellate cells surrounding the cancer cells in each well. 
Additionally, dropping cancer cell mono-culture spheroids into a scaffold-free stellate cells suspension 
was not able to establish this organization where stellate cells could wrap around a cancer cells core. 
Unmodified hyaluronic acid was found to be biocompatible with PDAC cells and able to affect YAP 
signalling. Therefore, in the work reported below, we aimed to build an easy-to-use model for high-
throughput assay by mixing cancer cells, stellate cells, HA, and collagen I in various ways. These studies 
focused on stabilizing 3D spheroids in the desired organization of cancer cells and stellate cells using 
ECM surrogate materials. Only those approaches considered to potentially provide a consistent, 





5.2 Spheroid formation and cell distribution in 3D co-culture models of stellate 
cells to cancer cells at a 10:1 cell ratio with hyaluronic acid 
 
5.2.1 Dropping cancer cell spheroids into hepatic stellate cells suspensions in hyaluronic acid 
 
In our opinion, having a single spheroid per well will benefit the standardization of spheroid size in 
high-throughput assay, consistent with other studies on 3D culture in micropatterning [Hirschhaeuser 
et al, 2010] and forming 3D culture using centrifugation [Friedrich et al, 2009]. In order to determine 
the optimal concentration of hyaluronic acid (HA) to suspend stellate cells to provide conditions for 
attachment to and engulfment of a cancer cells spheroid, we mixed the stellate cells suspension with 
an HA preparation to produce a final concentration of 0, 1, 3, or 5 mg/mL HA in each well in 96-well 
polyHEMA plates. The goal was to identify conditions leading to the formation of multilayers of stellate 
cells surrounding a cancer cells core. Each cancer cell mono-culture spheroid was pushed from a 
hanging drop plate to individual well containing a stellate cells suspension in HA, resulting in dropping 
one spheroid per well.  
As shown in Figure 62, stellate cells in 1 mg/mL HA settled to the bottom of wells approximately 2 hours 
after seeding when being captured by the microscope on day 4, whereas stellate cells in either 3 mg/mL 
or 5 mg/mL HA initiated aggregation into small spheres suspending in the medium 4 hours after seeding 
(Figure 65). As illustrated in Figure 63 and 64, one large spheroid with multiple small spheroids nearby 
could be detected after Capan-2 and PANC-1 spheroids dropped into the HSCs suspension with HA. 
Stellate cells and clusters of stellate cells surrounding the cancer cells spheroid in HA started to attach 
to cancer spheroids 4 hours after seeding into the wells containing 3 mg/mL or 5 mg/mL HA (Figure 
65). We expected the stellate cell spheres would move towards the cancer spheroids to form one single 
spheroid in each well over time. However, there was no single spheroid formed in each well 4 days 
(Day 8) and 8 days (Day 12) after seeding into the wells containing 1 mg/mL or 5 mg/mL HA (Figure 63 
and 64). 
After quantification of the largest spheroid in the field of view, the sizes of the HSCs mono-culture in 1 
mg/mL HA and the co-culture of PANC-1 with HSCs and 1, 3, or 5 mg/mL HA declined whereas the ones 
of the co-culture of Capan-2 with HSCs and 1, 3, or 5 mg/mL HA rose from day 4 to day 5. Sizes of 
spheroids from day 5 to day 12 remained unchanged (Figure 62-64). 
5 mg/mL HA was chosen for the following sections because it could mimic more challenging barrier for 





















Figure 62. Sphere-forming assays in hepatic stellate cells 
with different concentration of hyaluronic acid over time.  
20,000 cells per well of hepatic stellate cells (HSCs) 
suspensions were seeded in the poly-HEMA low-attachment 
96-well plates with either no hyaluronic acid (Medium), 1 
mg/mL hyaluronic acid (HA), 3 mg/mL HA, or 5 mg/mL HA 
respectively. The experiment was done in parallel with 
dropping cancer cell spheroids to HSCs suspensions. Day 4 
indicated the day when cancer cell spheroids pre-formed in 
hanging drops were dropped to the HSCs suspension with 
HA. A. Phase-contrast images were taken by Leica DMI4000 B (50x 
magnification) manually at the time points indicated. 
Representative images from five spheroids in the same group from one independent experiment were shown 
except that representative images of spheroids with 5 mg/mL HA were from two independent experiments. Scale 
bar, 500 μm. B. The percentages of spheroid sizes on Day 4, Day 6 and Day 7 normalized to the ones on day 5. 
The areas were measured using CellProfiler. The mean areas in pixels of spheroids on day 4, day 6 and day 7 were 
divided by the mean areas in pixels of spheroids in the same well on day 5 and then multiplied by 100. Graph was 
created by Excel, using the means of the percentages in 5-6 spheroids. Error bars represented standard deviations 
from the percentages of 5-6 spheroids in one independent experiment. Only one spheroid on day 4 was found 
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Figure 63. Sphere-forming assays in Capan-2 spheroids with different concentration of hyaluronic acid over 
time.  
500 Capan-2 cells were seeded in hanging drops and after 4 days each droplet was pushed into a well containing 
20,000 cells per well of hepatic stellate cells (HSCs) suspensions and either 1 mg/mL hyaluronic acid (HA), 3 mg/mL 
HA, or 5 mg/mL HA respectively. Day 4 indicated the day when cancer cell spheroids pre-formed in hanging drops 
were dropped to the HSCs suspension with HA. A. Phase-contrast images were taken by Leica DMI4000 B (50x 
magnification) manually at the time points indicated. Representative images from five spheroids in the same 
group from one independent experiment were shown except that representative images of spheroids with 5 
mg/mL HA were from two independent experiments. Scale bar, 500 μm. B. The percentages of spheroid sizes on 
Day 4, Day 6 and Day 7 normalized to the ones on day 5. The areas were measured using CellProfiler. The mean 
areas in pixels of spheroids on day 4, day 6 and day 7 were divided by the mean areas in pixels of spheroids in the 
same well on day 5 and then multiplied by 100. Graph was created by Excel, using the means of the percentages 
in 5-6 spheroids. Error bars represented standard deviations from the percentages of 5-6 spheroids in one 
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Figure 64. Sphere-forming assays in PANC-1 spheroids with different concentration of hyaluronic acid over 
time.  
500 PANC-1 cells were seeded in hanging drops and after 4 days each droplet was pushed into a well containing 
20,000 cells per well of hepatic stellate cells (HSCs) suspensions and either 1 mg/mL hyaluronic acid (HA), 3 mg/mL 
HA, or 5 mg/mL HA respectively. Day 4 indicated the day when cancer cell spheroids pre-formed in hanging drops 
were dropped to the HSCs suspension with HA. A. Phase-contrast images were taken by Leica DMI4000 B (50x 
magnification) manually at the time points indicated. Representative images from five spheroids in the same 
group from one independent experiment were shown except that representative images of spheroids with 5 
mg/mL HA were from two independent experiments. Scale bar, 500 μm. B. The percentages of spheroid sizes on 
Day 4, Day 6 and Day 7 normalized to the ones on day 5. The areas were measured using CellProfiler. The mean 
areas in pixels of spheroids on day 4, day 6 and day 7 were divided by the mean areas in pixels of spheroids in the 
same well on day 5 and then multiplied by 100. Graph was created by Excel, using the means of the percentages 
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Figure 65. Sphere-forming assays in different concentration of hyaluronic acid in 12 hours.  
500 Capan-2 cells or 500 PANC-1 cells were seeded in hanging drops and after 4 days each droplet was pushed 
into a well containing 20,000 hepatic stellate cells (HSCs) and 3 mg/mL hyaluronic acid (HA), or 5 mg/mL HA 
respectively. Wells with HSCs only were also included. Phase-contrast images were taken by Leica DMI4000 B 
(50x magnification) manually at the time points indicated. Representative images from five spheroids in the same 




5.2.2 Stellate cells attaching to areas at the edge of 3D cancer cell spheroids 
 
Although the protocol described above resulted in multiple spheroids in each well, it might be possible 
that a thin layer of stellate cells wrapped around each cancer spheroid. In order to evaluate the cell 
type distribution in this co-culture model, the largest spheroid present in each well was fixed in PFA 
and stained with anti-p53 antibodies and DAPI to differentially detect cancer cells and stellate cells. As 
illustrated in Figure 66, areas that stained with only DAPI with indication of HSCs with small nuclei 
constituted a small proportion of these spheroids. The green staining of HSCs with small nuclei was 
found mainly in the cytoplasm, possibly due to non-specific binding of antibodies and autofluorescence 
in the cytoplasm of HSCs. The cancer cells areas illustrated strong nuclear staining of p53 in green. The 
distribution of p53 and DAPI labelling was consistent with only a few stellate cells attaching at the 


























Figure 66. Stellate cells attached at the surface of the cancer cell spheroids.  
500 cancer cells were seeded in hanging drops and after 4 days these droplets were pushed into the wells with 
20,000 stellate cells and 5 mg/mL HA per well. On day 1 and day 2 after dropping, the largest spheroid in each 
well was collected and stained with DAPI (blue), and for p53 (green). Confocal laser scanning microscopy using 
Zeiss LSM880 was used to acquire images. Image analysis was performed using Zen 2.3 (blue edition). Images 









5.3 Spheroid formation, cell distribution and protein expression in 3D co-
culture models of stellate cells to cancer cells at a 10:1 cell ratio with HA and 
COL I    
 
5.3.1 A single spheroid could be formed after dropping a cancer cell spheroid into a stellate cells 
suspension in hyaluronic acid and collagen I 
 
Pre-formed cancer cell spheroids failed to form a single spheroid when dropped into a hepatic stellate 
cells (HSCs) suspension in HA. Further, stellate cells formed only a thin and inconsistent sheet of cells 
at the surface of these cancer spheroids. Based upon this outcome, we explored the formation of a co-
culture system that included collagen I. 500 cancer cells were seeded and cultured using the hanging 
drop protocol. After 4 days, droplets were pushed into wells containing 20,000 stellate cells, 5 mg/mL 
HA and 0.3 mg/mL collagen I per well. As seen in Figure 67 (inserts), there appeared to be collagen fibre 
contraction 4 hours after spheroids were dropped into individual well containing pancreatic stellate 
cells (PSCs). During this time, stellate cells and cancer cells came together to form a single spheroid in 
each well which was reproducible in the case of Capan-2 spheroids with HSCs, Capan-2 spheroids with 
PSCs, PANC-1 spheroids with HSCs, and PANC-1 spheroids with PSCs. No difference could be observed 
between the sizes of spheroids 48 hours after dropping into PSCs and the ones 72 hours after dropping 
into PSCs (Figure 67). 
Of note, as shown in the Figure 67, there were some wells with spheroids attached to the wall that 
appeared to result in a possibly flatten oval shape (red arrow heads). Thus, not all the 3D co-culture 
models of cancer cells, stellate cells and matrices were spheroidal in shape in the current section. Also, 
there were cancer cells spheroids that may have fallen outside the stellate cells spheroids when 
dropped into the wells (red arrows). This may have led to the formation of cancer cell spheroids without 
the surrounding layer of stellate cells. Therefore, it appears that further optimisation is needed to 
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Figure 67. Single spheroid formation after cancer cell spheroids were dropped into a stellate cells suspension 
in hyaluronic acid and collagen I.  
500 cancer cells were seeded in hanging drops and after 4 days the droplets were pushed into wells with 20,000 
pancreatic stellate cells (PSCs) or hepatic stellate cells (HSCs), 5 mg/mL HA and 0.3 mg/mL collagen I per well. 
Images were acquired by Leica DMI4000 B (50x magnification) manually as indicated time points. Representative 
images shown were from five wells in two independent experiments. Red arrow heads: a spheroid attached to 
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5.3.2 Stellate cells fail to engulf whole cancer spheroids and form multi-layered cells surrounding 
cancer spheroids 
 
In the previous sections, stellate cells (SCs) formed small spheres scattered in the wells and distanced 
themselves from the large spheroids in an environment with only hyaluronic acid (HA). Although there 
were some small SCs spheroids attaching to the large spheroids, they remained static in a way that 
they still adhered to themselves without transforming into layers of cells to cover the cancer cells 
spheroids in HA. This is inconsistent with the theory that SCs could be mobilised by cancer cells in the 
tumour microenvironment and the histology reported in PDAC [Dong et al, 2000; Erkan et al, 2008; 
Jeong et al, 2005; Khan et al, 2017; Zhang et al, 2007; Zhao et al, 2016a]. One of the reasons may be 
the lack of protein-based macromolecules such as collagens to provide a scaffold to aid the migration 
of SCs towards the cancer cells spheroids. We next evaluated cell type distribution in the co-culture 
models with HA and collagen I to test the hypothesis that collagens can facilitate the attachment of SCs 
to the cancer cells spheroids. 
On day 2 and 3 after dropping cancer cells spheroids into a SCs suspension in HA and collagen I, whole 
spheroids in each group were fixed in PFA and stained for p53 with DAPI to discriminate SCs from 
cancer cells using confocal microscopy. As demonstrated in Figure 68, a fraction of the large spheroid 
presented with strong p53 staining (red arrows), indicating cells located in the fraction are mostly 
cancer cells. The green staining of SCs with small nuclei was found mainly in the cytoplasm, possibly 
due to non-specific binding of antibodies and autofluorescence in the cytoplasm of SCs. Compared to 
SCs spheroids discontinuously touching the edge of cancer cells spheroids in Figure 66, SCs formed a 
continuous layer around the region of the cancer cells spheroids in Figure 68. However, parts of the 
region of the cancer cells spheroids were devoid of SCs, resulting in direct exposure to medium and 
easy access to oxygen and nutrient for cancer cells located in those parts. This situation is not consistent 
with where cancer cells are grown in patients with PDAC, possibly altering the phenotypes and cell 
signalling in PDAC cells. The attachment of SCs to the cancer cells spheroids has been improved with 
the addition of collagen I; however, no defined cancer cells core surrounded by multi-layered of SCs 









































Figure 68. Stellate cells failed to engulf cancer cells spheroids and form a multi-layered cells surrounding a 
cancer cells core in hyaluronic acid and collagen I. Refer to separate files. Pay attention to lines. 
Spheroids were formed from 500 cancer cells in hanging drops for 4 days and pushed into a hepatic stellate cells 
(HSCs) suspension or a pancreatic stellate cells (PSCs) suspension (20,000 cells per well) with 5 mg/mL hyaluronic 
acid (HA) and 0.3 mg/mL collagen I. On day 2 or 3 after cancer spheroids were dropped into HSCs or PSCs in HA 
and collagen I, whole spheroids in each group were fixed in PFA and then stained with DAPI (blue), and for p53 
(green). Z-stack imaging was performed by confocal microscopy (Zeiss LSM880) to acquire the entire spheroids. 
Image analysis and 3D rendering were done in Zen 2.3 (blue edition). Red arrows: fractions of cancer cells. 
Representative images were from two spheroids in two independent experiments. Scale bars of X, Y, and Z axes: 
200 μm; exception: 50 μm in the Capan-2+PSCs group on day 3.   
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5.3.3 Increased nuclear YAP levels were observed in cancer cells co-cultured with stellate cells, 
hyaluronic acid and collagen I 
 
We next evaluated key components in YAP signalling in this co-culture spheroid model. Whole 
spheroids co-cultured with cancer cells and pancreatic stellate cells (PSCs) were fixed in PFA 3 days 
after dropping cancer spheroids into PSCs and stained for Ocln, TEADs and YAP. As seen in Figure 69-
74, unlike the YAP expression and localization pattern in the section 3.2.4 where YAP staining appeared 
like a ring around the nuclei, high level of YAP could be detected inside p53 positive cancer cell nuclei 
(white arrows) and the elongated nuclei of PSCs (white arrow heads) located at the edge of the 
spheroids or at the core of the spheroids. Cytoplasmic accumulation of YAP could still be detected in 
some PANC-1 cells near the edge of the spheroid in Figure 70. 
Semi-quantification of YAP by CellProfiler was conducted on one optical section of the co-culture 
spheroids with Capan-2 cells or PANC-1 cells with PSCs (Figure 71 and 72). The image exported from 
p53 channel was also used in the module ‘IdentifyPrimaryObjects’ due to signal loss near the core of 
the spheroid in DAPI channel. Because the data representing YAP intensities and ratios did not follow 
normal distribution and not have the same shape of distribution, mean ranks of the datasets were 
compared using a non-parametric Mann-Whitney U test. Comparing the total YAP intensities in the 
whole cancer cells near the edge and the cores, cancer cells near the edge exhibited significantly higher 
YAP expression (mean rank of 4.63 for Capan-2 cells near the core and 9.67 for Capan-2 cells near the 
edge, p = 0.025; mean rank of 10 for PANC-1 cells near the core and 25 for PANC-1 cells near the edge, 
p < 0.001). There was no significant difference between the ratios of cytoplasmic YAP intensity to total 
YAP intensity of the whole cell and the ratios of nuclear YAP intensity to total YAP intensity of the whole 
cell in Capan-2 cells near the core of the spheroids (mean rank of 9.5 for ratios of cytoplasmic YAP 
intensity and 7.5 for nuclear YAP intensity, p = 0.401),  Capan2 cells near the edge of the spheroids 
(mean rank of 2.33 for ratios of cytoplasmic YAP intensity and 4.67 for nuclear YAP intensity, p = 0.127), 
and PANC-1 cells near the edge of the spheroids (mean rank of 12.27 for ratio of cytoplasmic YAP 
intensity and 10.73 for nuclear YAP intensity, p = 0.577). However, the mean ratios of nuclear YAP 
intensities was significantly higher than the one of cytoplasmic YAP intensities in PANC-1 cells near the 
core of the spheroids (mean rank of 10.16 for ratios of cytoplasmic YAP intensity and 28.84 for nuclear 
YAP intensity, p < 0.001). Compared to the data in Figure 47 where a 3D mono-culture spheroid of 
Capan-2 was measured, the overall level of cytoplasmic YAP dropped while the level of nuclear YAP 
increased, suggesting a shift in the subcellular localisation of YAP. The data indicated more cancer cells 
with nuclear localisation of YAP in the core of the spheroid were found in the current optical sections 
of 3D co-culture models. The core of these spheroids was considered to be more hypoxic than the rest 
of the spheroids with reduced nutrient access [Hoarau-Vechot et al, 2018]. These results from analysing 
the co-culture of PANC-1 cells with PSCs, HA and COL I suggest that cancer cells in this environment 
might develop some mechanisms to induce nuclear accumulation of YAP to sustain cell growth and 
survival, possibly through overcoming reduced oxygen and/or nutrient access [Enzo et al, 2015; Mo et 
al, 2015; Wang et al, 2015]. 
Ocln is found to interact with YAP in the cytoplasm and the membrane of cancer cells [Cravo et al, 
2015]. Interestingly, Ocln was not only found in cancer cells but also in PSCs in the current section 
(Figure 69 and 70). Ocln is reported to be undetectable in fibroblasts [Dorfel et al, 2012]. One of the 
reasons for the Ocln expression in PSCs was that the antibodies against Ocln used in the present study 
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were able to bind to certain proteins in PSCs non-specifically, similar to the situation of the green signals 
from p53 in the cytoplasm of stellate cells. Moreover, Ocln was detected in the nucleus and the 
cytoplasm of cancer cells and co-localized with YAP in both location (Figure 69 and 70), possibly 
indicating the destruction of tight junctions during EMT in PDAC cells causing fragments of TJ proteins 
scattering in the nucleus and cytoplasm that happened to be in the same location with YAP distribution 
if the unspecific staining was not taken into account.  
TEADs are the binding partners of YAP in the nucleus to promote cell growth [Abylkassov et al, 2016]. 
As shown in Figure 73 and 74, TEADs could be detected in both cancer cells and PSCs, co-localizing with 
nuclear YAP.  
The data in the current section was obtained in only one optical section in one spheroids from one 






Blue: DAPI; green: p53; Red: Ocln; yellow: YAP.   






















Figure 69. Ocln and YAP expression and co-localisation in 3D co-culture models of Capan-2 with PSCs, HA and 
COL I.  
Spheroids were formed from 500 Capan-2 cells in hanging drops for 4 days and pushed into the pancreatic stellate 
cells (PSCs) suspension (20,000 cells per well) with HA and COL I. On day 3 after cancer spheroids were dropped 
into PSCs with HA and COL I, whole spheroids in each group were fixed in PFA and stained with DAPI (blue), anti-
Ocln antibodies (red), anti-YAP antibodies (yellow), and anti-p53 antibodies (green). Confocal microscopy with 
multitracking scanning using Zeiss LSM880 was performed. Image analysis was done in Zen 2.3 (blue edition). 
White arrows: nuclear localisation of YAP in cancer cells; white arrow heads: nuclear localisation of YAP in PSCs. 




Blue: DAPI; green: p53; Red: Ocln; yellow: YAP. 






















Figure 70. Ocln and YAP expression and co-localisation in 3D co-culture models of PANC-1 with PSCs, HA and 
Col I.  
Spheroids were formed from 500 PANC-1 cells in hanging drops for 4 days and pushed into the pancreatic stellate 
cells (PSCs) suspension (20,000 cells per well) with HA and COL I. On day 3 after cancer spheroids were dropped 
into PSCs with HA and COL I, whole spheroids in each group were fixed in PFA and stained with DAPI (blue), anti-
Ocln antibodies (red), anti-YAP antibodies (yellow), and anti-p53 antibodies (green). Confocal microscopy with 
multitracking scanning using Zeiss LSM880 was performed. Image analysis was done in Zen 2.3 (blue edition). 
White arrows: nuclear localisation of YAP in cancer cells; white arrow heads: nuclear localisation of YAP in PSCs. 
























Figure 71. Semi-quantification of YAP subcellular expression in 3D co-culture models of Capan-2 with PSCs, HA 
and Col I.  
Spheroids were formed from 500 Capan-2 cells in hanging drops for 4 days and pushed into the pancreatic stellate 
cells (PSCs) suspension (20,000 cells per well) with HA and collagen I. On day 3 after cancer spheroids were 
dropped into PSCs with HA and Col I, whole spheroids in each group were fixed and stained with anti-YAP 
antibodies (yellow), and anti-p53 antibodies (green). Confocal microscopy with multitracking scanning using Zeiss 
LSM880 was performed. Image analysis was done in Zen 2.3 (blue edition). Quantification of YAP was performed 
by CellProfiler. A. A representative field of view in an image processed by CellProfiler, depicting the outlined 
nuclear areas and the cytoplasmic areas labelled with numbers. Whisker box graph was made from all the values 
of total YAP intensity in the whole cells (B) or the intensity ratios of nuclear YAP intensity to total YAP intensity in 
the whole cell or cytoplasmic YAP intensity to total YAP intensity in the whole cell (C) from around 3-8 cells near 
the core of the spheroid and the edge of the spheroid, using Excel. Mean markers were shown. Median was 
exclusive from quartile calculation. Dots indicated the values in cells automatically generated by Excel. Non-
parametric Mann-Whitney U test in SPSS was used to calculate the p values. Nu: nucleus, Cy: cytoplasm, W: whole 
cell.  
p = 0.025 
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Figure 72. Semi-quantification of YAP subcellular expression 
in 3D co-culture models of PANC-1 with PSCs, HA and Col I.  
Spheroids were formed from 500 PANC-1 cells in hanging 
drops for 4 days and pushed into the pancreatic stellate cells 
(PSCs) suspension (20,000 cells per well) with HA and 
collagen I. On day 3 after cancer spheroids were dropped into 
PSCs with HA and Col I, whole spheroids in each group were 
fixed and stained with DAPI (blue), anti-Ocln antibodies (red), 
anti-YAP antibodies (yellow), and anti-p53 antibodies (green). 
Confocal microscopy with multitracking scanning using Zeiss 
LSM880 was performed. Image analysis was done in Zen 2.3 
(blue edition). Quantification of YAP was performed by 
CellProfiler. A. A representative field of view in an image 
processed by CellProfiler, depicting the outlined nuclear areas 
and the cytoplasmic areas labelled with numbers. Whisker box 
graph was made from all the values of total YAP intensity in the 
whole cells (B) or the intensity ratios of nuclear YAP intensity to 
total YAP intensity in the whole cell or cytoplasmic YAP intensity 
to total YAP intensity in the whole cell (C) from around 3-8 cells 
near the core of the spheroid and the edge of the spheroid, 
using Excel. Mean markers were shown. Median was exclusive 
from quartile calculation. Dots indicated the values in cells 
automatically generated by Excel. Non-parametric Mann-Whitney U test in SPSS was used to calculate the p 

























































Nu/W     Cyto/W      Nu/W        Cyto/W 
 
 





Blue: DAPI; green: p53; Red: TEADs; yellow: YAP. 























Figure 73.  TEADs and YAP expression and co-localisation in 3D co-culture models of Capan-2 with PSCs, HA and 
Col I.  
Spheroids were formed from 500 Capan-2 cells in hanging drops for 4 days and pushed into the pancreatic stellate 
cells (PSCs) suspension (20,000 cells per well) with HA and COL I. On day 3 after cancer spheroids were dropped 
into PSCs with HA and COL I, whole spheroids in each group were fixed in PFA and stained with DAPI (blue), anti-
pan-TEADs antibodies (red), anti-YAP antibodies (yellow), and anti-p53 antibodies (green). Confocal microscopy 
with multitracking scanning using Zeiss LSM880 was performed. Image analysis was done in Zen 2.3 (blue edition). 
Two spheroids were scanned in one independent experiment. Scale bar, 100 μm. 
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Blue: DAPI; green: p53; Red: TEADs; yellow: YAP.  PANC-1 + PSCs 























Figure 74. TEADs and YAP expression and co-localisation in co-culture models of PANC-1 with PSCs, HA and Col 
I.  
Spheroids were formed from 500 PANC-1 cells in hanging drops for 4 days and pushed into the pancreatic stellate 
cells (PSCs) suspension (20,000 cells per well) with HA and COL I. On day 3 after cancer spheroids were dropped 
into PSCs with HA and COL I, whole spheroids in each group were fixed in PFA and stained with DAPI (blue), anti-
pan-TEADs antibodies (red), anti-YAP antibodies (yellow), and anti-p53 antibodies (green). Confocal microscopy 
with multitracking scanning using Zeiss LSM880 was performed. Image analysis was done in Zen 2.3 (blue edition). 
Two spheroids were scanned in one independent experiment. Scale bar, 100 μm. 
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5.4 Spheroid formation, cell distribution and protein expression in 3D co-
culture models of stellate cells to cancer cells at a 2:1 cell ratio with COL I 
 
5.4.1 Sphere-forming assays and cancer cell distribution in different amount of collagen I with or 
without HA  
 
Efforts were undertaken to explore the direct mixture of a stellate cells suspension with a cancer cells 
suspension at a 2:1 ratio of stellate cells to cancer cells at several collagen I contents per well with or 
without HA. The following matrix conditions were tested: a) 0.3 mg/mL collagen I and 3.5 mg/mL HA in 
100 μL; b) 0.3 mg/mL collagen I and 3.5 mg/mL HA in 50 μL; c) 0.3 mg/mL collagen I in 50 μL; d) 0.1 
mg/mL collagen I in 50 μL. 
As shown in Figure 75 and 76, spheroids were larger in 0.3 mg/mL collagen I when cultured in 100 μL 
compared to those cultured in 50 μL. Spheroids were smaller in 0.1 mg/mL collagen I than in 0.3 mg/mL 
of the same volume. There was no marked difference in spheroid size when cultured in 0.3 mg/mL 
collagen I with or without HA. Quantification of the sizes by CellProfiler was not appropriate due to the 
incomplete areas of the whole spheroids using the current microscope. Based on the clear distinct 
brightness and contrast in the areas of the spheroids in the wells, these studies suggested that collagen 
I is the key factor to determine 3D co-culture spheroid size. 
As seen in Figure 77 and 78, multiple cancer cell cores/clusters with positive staining of p53 were 
formed in the spheroids with 0.3 mg/mL collagen I and 0.1 mg/mL collagen I after 4 days of culture. We 
had intended to use a CellTiter-GLO 3D assay to assess cell viability in these spheroids as a way to assess 
the impact of potential anti-cancer compounds in high-throughput assay. According to the 
manufacturer of this commercial method, 3D spheroids larger than 500 μm in diameter may not be 
accurately assessed. For this reason, the condition of 50 μL of 0.1 mg/mL collagen I per well was chosen 

































Figure 75. Spheroid formation in 3D co-culture spheroids with Capan-2 cells, stellate cells, different amount of 
collagen I with or without HA.  
500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) were mixed in 100 μL or 50 μL of collagen I with or 
without HA as indicated. Phase-contrast images were acquired by Leica DMI4000 B (50x magnification) manually 
at the indicated time points for 4 days. Data shown were representative images from two independent 



































PANC-1 and HSCs in 0.1 mg/mL collagen I (50 μL) 
 
 
Figure 76. Spheroid formation in 3D co-culture spheroids with PANC-1 cells, stellate cells, different amount of 
collagen I with or without HA.  
500 PANC-1 cells and 1,000 hepatic stellate cells (HSCs) were mixed in 100 μL or 50 μL of collagen I with or without 
HA as indicated. Phase-contrast images were acquired by Leica DMI4000 B (50x magnification) manually at the 
indicated time points for 4 days. Data shown were representative images from two independent experiments 
with three spheroids in each experiment. Scale bar, 500 μm. 
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Figure 77. Expression of p53 in 3D co-culture spheroids of Capan-2 cells with stellate cells, different amount of 
collagen I.  
500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) were mixed in 50 μL of 
0.3 or 0.1 mg/mL collagen I as indicated. On day 4, whole spheroids were fixed in PFA and stained with anti-p53 
antibodies (green) and DAPI (blue). Z-stacking was performed using confocal microscope Zeiss LSM880 and 3D 
rendering was done in Zen 2.3 (blue edition). Insert: representative area of cancer cells cores/clusters with 








































Figure 78. Expression of p53 in 3D co-culture spheroids of PANC-1 cells with stellate cells, different amount of 
collagen I. 
500 PANC-1 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) were mixed in 50 μL of 
0.3 or 0.1 mg/mL collagen I as indicated. On day 4, whole spheroids were fixed in PFA and stained with anti-p53 
antibodies (green) and DAPI (blue). Z-stacking was performed using confocal microscope Zeiss LSM880 and 3D 
rendering was done in Zen 2.3 (blue edition). Insert: representative area of cancer cells cores/clusters with 
positive staining of p53. Scale bars of X, Y, and Z axes: 100 μm. 
  














5.4.2 Stellate cells could be seen scattered in the 3D co-culture models with 0.1 mg/mL collagen 
I 
 
Although αSMA was found to be present in 3D mono-culture of Capan-2 and PANC-1 cells grown in a 
scaffold-free condition, we would like to test whether the expression of αSMA in a 3D co-culture system 
with collagen I would be consistent with its expression pattern in a 3D mono-culture system. The 
morphology of stellate cells in 2D observed by phase-contrast microscopy is drastically different from 
the one of Capan-2 and PANC-1 cells in 2D. However, phase-contrast imaging is not able to capture the 
cell distribution in 3D thick specimen due to the limited penetration of visible lights. The fluorescent 
staining of αSMA analysed by confocal microscopy would allow deeper detection of different cell types 
in thick specimen after optical clearing with BABB. 
Expression of αSMA was evaluated in 3D co-culture spheroids prepared from 500 cancer cells and 1,000 
stellate cells in 50 μL of media containing 0.1 mg/mL collagen I. Whole spheroids grown for 4 days were 
fixed in PFA and stained with DAPI, and for αSMA and p53. CLSM Z-stack imaging was performed. 3D 
rendering is used to reconstruct the 3D co-culture models from the Z-stack images. 3D rendering has 
been performed to provide 3D structure of blood and lymphatic vessels [Oren et al, 2018], to 
reconstruct thick mouse inner ears [Kopecky et al, 2012], and analyse 3D cancer microenvironment in 
a whole mouse tumour [Lee et al, 2017]. The integrated 3D rendering module in the software Zen (blue 
edition) developed by an optical and optoelectronic company Zeiss, together with a software company 
arivis AG, allows fast processing of multiple optical slicing images acquired using Z-stacking scanning 
(https://blogs.zeiss.com/microscopy/news/en/solutions-for-the-visualization-and-analysis-of-big-
image-data-in-life-sciences/?doing_wp_cron=1544695322.6736040115356445312500 ). Hundreds of 
2D images resulting from optical sectioning of an intact spheroid using the CLSM with multiple channels 
can be displayed and handled in the module and the reconstruction of the spheroids can be presented 
with scaled axes. 
As shown in Figure 79 and 80, there were regions with high levels of p53 expression or strong DAPI 
staining with enlarged nuclei, indicating clusters of cancer cells in the core of the spheroids. Consistent 
with studies described in section 3.2.3, αSMA expression could be found in the cytoplasm of cancer 
cells. There were also αSMA-positive fibre-like cells with long stretches of cytoplasm and small nuclei 
that did not stain for p53, indicating the presence of stellate cells.   
Among three independent experiments, around 50% of the time, spheroids formed a big cancer core 


































Figure 79. Orthogonal view of stellate cells distributed throughout co-culture spheroids with cancer cells, 
stellate cells and collagen I.  
Spheroids from 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days. The whole spheroids were fixed in PFA and then stained with DAPI 
(blue), and for αSMA (red) and p53 (green). After optical clearing with BABB, Z-stack imaging using confocal laser 
scanning microscopy was performed. Image analysis of orthogonal view was done in Zen 2.3 (blue edition). Yellow 
arrows indicated stellate cells. Scale bar, 100 μm. 
 






























Figure 80. 3D rendering of stellate cells 
distributed throughout co-culture 
spheroids with cancer cells, stellate cells 
and collagen I.  
Spheroids from 500 cancer cells and 1,000 
hepatic stellate cells (HSCs) or pancreatic 
stellate cells (PSCs) in 50 μL of 0.1 mg/mL 
collagen I were grown for 4 days. The whole 
spheroids were fixed in PFA and then stained 
with DAPI (blue), and for αSMA (red) and p53 
(green). After optical clearing with BABB, Z-
stack imaging using confocal laser scanning 
microscopy was performed. Image analysis 
of 3D rendering was done in Zen 2.3 (blue 
edition). Yellow arrows indicated stellate 
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5.4.3 Initial test of potential anti-cancer agents on p53, Ki67 and YAP expression in 3D co-culture 
models 
 
The data presented above suggest that we have developed a 3D co-culture spheroid model that 
resembles the organization of cancer cells and stellate cells present in the pancreatic cancer 
microenvironment. Also, the protocol for building the models is reproducible in our collaborators’ lab 
where the natural products are being investigated as potential anti-cancer agents, two of which are 
Pseudopterosin A-D (PsA-D) and Tylophorinine. PsA-D are a mixture of four amphilectane-containing 
compounds, each of which is acetylated at different locations in one attached xylose sugar. PsA-D 
possess growth-inhibitory activity and can reduce invasiveness in triple negative breast cancer by 
targeting NF-κB signalling and glucocorticoid receptor alpha in vitro [Sperlich et al, 2017; Sperlich et al, 
2018]. Tylophorinine and tylophorine are two interesting natural products that have drawn medicinal 
chemists’ attention on biosynthesis and extraction [Gantait et al, 2017; Govindachari et al, 1965]. A 
tylophorine analogue, DCB-3503, can inhibit pancreatic cancer cell growth by targeting the abnormal 
cell-cycle signalling in PANC-1 and HPAC pancreatic cancer cell lines, providing a promising new 
compound to be tested in PDAC [Shiah et al, 2006]. Thus, we carried out an initial investigation using 
this model to examine its capacity to screen potential anti-cancer agents, PsA-D and Tylophorinine, 
with collaboration across different labs. 
According to the cell viability results from our collaborators Janina Betz, Julia Sperlich, and Nicole 
Teusch from Technische Hochschule Köln, University of Technology, Arts and Sciences in Germany, 70 
μM Pseudopterosin A-D (PsA-D) or 0.1 μM Tylophorinine were added to the spheroids on day 4. 100 
μM gemcitabine was used as a positive control and 0.7% DMSO was used as a solvent control. After 3 
days, phase-contrast imaging and immunofluorescence with CLSM were performed to evaluate the 
effects of these agents on the phenotypic changes of the spheroids. 
As illustrated in Figure 81, phase-contrast images showed no striking differences in co-culture 
spheroids after 3 days in any of the treatment or control groups other than the PsA-D treatment group 
where the surface of these spheroids became less organized, indicating possible cell damage. 
Spheroids were then stained with DAPI, and for p53, Ki67 and YAP. CLSM Z-stack imaging was 
performed to detect the distribution of p53 and Ki67 expression in the entire spheroid (Figure 82). Due 
to limitations of the microscope being used, the 10x objective lens was not able to acquire clear and 
reliable images for anti-YAP antibodies incubated with secondary antibodies conjugated to Alexa Fluo 
647. Airyscan with super-resolution was required to localize YAP definitely in the nuclei and the 
cytoplasm of these cells (Figure 84, 86, and 88). Meanwhile, multi-coloured imaging with Airyscan was 
also performed to detect Ki67 and p53 in the spheroids simultaneously to validate the expression of 
Ki67 and p53 using higher resolution imaging compared to conventional CLSM (Figure 83, 85, and 87). 
As shown from 3D rendering of the entire intact spheroids from all the 2D images from the whole 
spheroids in Figure 82, obvious reduction of Ki67 and p53 expression could be detected after 
treatments with PsA-D and Tylophorinine on the spheroids, without the aid for quantification. Data 
from 3D reconstruction of spheroids stained for p53 and Ki67 provided sufficient information to draw 
conclusions and thereby further quantification by CellProfiler was not conducted at this point. It was 
observed that 70 μM PsA-D or 0.1 μM Tylophorinine both reduced the p53 and Ki67 to a greater extent 
in co-culture models with Capan-2 cells than with PANC-1 cells, using the conventional CLSM (Figure 
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82),  and CLSM with Airyscan (Figure 83, 85, and 87). These data indicated that cancer cells having 
similarities to Capan-2 cells may be more sensitive to PsA-D and Tylophorinine treatment than those 
similar to PANC-1 cells. At this time it is unclear what genotypic/phenotypic characteristic(s) is critical 
to the discrimination made by these two potential anti-cancer agents.  
In these studies, we observed cells with nuclear localisation of YAP near the edge of the untreated 
spheroids (Figure 86 and 88). Meanwhile, cells with cytoplasmic localisation of YAP were also detected, 
both near the edge and the core of the untreated spheroids (Figure 86 and 88). Homogenous YAP 
expression in the nucleus and the cytoplasm seemed to be the main event, indicating a dynamic YAP 
signalling in the 3D co-culture models of PDAC cells, stellate cells and collagen I. Factors that might 
regulate this dynamic nuclear and cytoplasmic localisation of YAP in this 3D co-culture models, such as 
hypoxia or nutrient limitation, is presently unclear. Treatments with 70 μM PsA-D for 3 days, however 
markedly reduced YAP nuclear and cytoplasmic expression (Figure 84, 86, and 88). Cells with nuclear 
localization with YAP after treatment of 100 μM Gemcitabine 0.1 μM Tylophorinine for 3 days were 
also observed (Figure 84, 86, and 88). However, only one optical section could be acquired with 
Airyscan for each spheroid during the limited time possible, which failed to represent a true and 








































Figure 81. Phase-contrast imaging of the 3D co-culture models with or without treatments.  
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a solvent 
control. After 3 days with or without treatments, phase-contrast imaging by Leica DMI4000 B (50x magnification) 
was performed to evaluate the effects of the anti-cancer agents on spheroid sizes and morphological changes. 
Representative images from three independent experiments with three spheroids in each experiment were 
shown in the spheroids treated with 70 μM PsA-D, 0.1 μM TYLO, and 0.7% DMSO. Representative images from 
one independent experiments with three spheroids in each experiment were shown in the spheroids treated with 
































































Figure 82. 3D rendering of entire spheroids showing p53 and Ki67 staining. 
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a solvent 
control. After 3 days with or without treatments, whole spheroids were fixed in PFA and immunofluorescence of 
DAPI (not shown), p53 (green), Ki67 (red) and YAP (not shown) was used to assess co-localization events. CLSM 
with Zeiss LSM880 was performed using a 10x objective lens. Image analysis and 3D rendering were done in Zen 
2.3 (blue edition). Representative images from three independent experiments with three spheroids in each 
experiment were shown in the spheroids treated with 70 μM PsA-D, 0.1 μM TYLO, and 0.7% DMSO. 
Representative images from one independent experiments with three spheroids in each experiment were shown 
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Figure 83. Effect of potential anti-cancer agents on Ki67 and p53 expression in 3D co-culture models: Airyscan 
imaging on whole spheroids. 
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a 
solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging on intact 
spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. DAPI (blue) and 
YAP (orange) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images from 
three independent experiments with three replicates in each experiment were shown in spheroids treated with 
PsA-D, TYLO, and DMSO. Representative images from one independent experiment with three replicates in each 
experiment were shown in spheroids treated with GEM and medium. Scale bar, 100 μm.  





























Figure 84. Effect of potential anti-cancer agents on YAP expression in 3D co-culture models: Airyscan imaging 
on whole spheroids. 
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) used as a positive control. 0.7% DMSO was 
used as a solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging 
on intact spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. DAPI 
(blue) and YAP (orange) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images 
from three independent experiments with three replicates in each experiment were shown in spheroids treated 
with PsA-D, TYLO, and DMSO. Representative images from one independent experiment with three replicates in 
each experiment were shown in spheroids treated with GEM and medium. Scale bar, 100 μm. 




























Figure 85. Effect of potential anti-cancer agents on Ki67 and p53 expression in 3D co-culture models of PDAC: 
Airyscan imaging near the core of intact spheroids.  
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a 
solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging on intact 
spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. Ki67 (red) and 
p53 (green) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images from three 
independent experiments with three spheroids treated with PsA-D, TYLO, and DMSO in each experiment were 
shown. Representative images from one independent experiment with three spheroids treated with GEM and 
medium in each experiment were shown. Scale bar, 10 μm. 
 




























Figure 86. Effect of potential anti-cancer agents on YAP expression in 3D co-culture models of PDAC: Airyscan 
imaging near the core of intact spheroids.  
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) used as a positive control. 0.7% DMSO was 
used as a solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging 
on intact spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. DAPI 
(blue) and YAP (orange) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images 
from three independent experiments with three replicates in each experiment were shown in spheroids treated 
with PsA-D, TYLO, and DMSO. Representative images from one independent experiment with three replicates in 
each experiment were shown in spheroids treated with GEM and medium. Scale bar, 10 μm. 
 





























Figure 87. Effect of potential anti-cancer agents on Ki67 and p53 expression in 3D co-culture models of PDAC: 
Airyscan imaging near the edge of intact spheroids.  
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a 
solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging on intact 
spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. Ki67 (red) and 
p53 (green) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images from three 
independent experiments with three spheroids treated with PsA-D, TYLO, and DMSO in each experiment were 
shown. Representative images from one independent experiment with three spheroids treated with GEM and 
medium in each experiment were shown. Scale bar, 10 μm. 





























Figure 88. Effect of potential anti-cancer agents on YAP expression in 3D co-culture models of PDAC: Airyscan 
imaging near the edge of intact spheroids.  
Spheroids with 500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 50 μL 
of 0.1 mg/mL collagen I were grown for 4 days and then treated with medium, 70 μM Pseudopterosin A-D (PsA-
D) and 0.1 μM Tylophorinine (TYLO), or 100 μM gemcitabine (GEM) as a positive control, and 0.7% DMSO as a 
solvent control. After 3 days with or without treatments, immunofluorescence with Airyscan imaging on intact 
spheroids was performed with Zeiss LSM880 using a 10x objective lens and four fluorescent dyes. DAPI (blue) and 
YAP (orange) were illustrated. Image analysis was done in Zen 2.3 (blue edition). Representative images from 
three independent experiments with three spheroids treated with PsA-D, TYLO, and DMSO in each experiment 
were shown. Representative images from one independent experiment with three spheroids treated with GEM 
and medium in each experiment were shown. Scale bar, 10 μm. 





5.5 Spheroid formation, cell distribution and protein expression in 3D co-
culture models of stellate cells to cancer cells at a 2:1 cell ratio with HA and COL 
I 
 
5.5.1 Correlation of spheroid size with collagen content in hyaluronic acid 
 
Efforts were also undertaken to explore the direct mixture of stellate cells suspension with cancer cells 
suspension at a 2:1 ratio of stellate cells to cancer cells with 0.03 mg/mL, 0.05 mg/mL, 0.1 mg/mL, and 
0.3 mg/mL collagen I (COL I) with 3.5 mg/mL hyaluronic acid (HA) to form 3D co-culture models in a 50 
μL volume.  
As seen in Figure 89-92, after cells, HA and COL I were mixed and grown for 1 day, dark areas could be 
detected in the wells with 0.1 mg/mL and 0.3 mg/mL COL I. At the same time, irregular spheroids could 
be found in the wells with 0.03 mg/mL and 0.05 mg/mL COL I. On day 3, spheroids with smooth edge 
could be formed in the wells with 0.03 mg/mL, 0.05 mg/mL, and 0.1 mg/mL COL I. On day 4, the areas 
of spheroids in the wells with 0.3 mg/mL COL I were smaller compared to the ones on day 3. After 
measuring the sizes on day 4 by CellProfiler, the mean areas of spheroids to the concentration of COL 
I were plotted in Figure 89-92. The R2 of the plots were 1 for Capan-2 cells with hepatic stellate cells 
(HSCs), 0.985 for Capan-2 cells with pancreatic stellate cells (PSCs), 0.9962 for PANC-1 cells with HSCs 
and 0.9988 for PANC-1 with PSCs combinations (Figure 89-92). The data indicated the correlation of 
spheroid size with collagen content in the current study. 
Consistent with data presented in section 5.4.1, higher amounts of collagen resulted in a larger 
spheroid size. This observation was consistent for studies performed on Capan-2 cells with HSCs, 
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Figure 89. Correlation of spheroid size with collagen I 
content in 3D co-cultures of Capan-2 cells, hepatic stellate 
cells, collagen I and hyaluronic acid. 
500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) 
were mixed in 50 μL of 0.03 mg/mL, 0.05 mg/mL, 0.1 
mg/mL and 0.3 mg/mL collagen I with 3.5 mg/mL 
hyaluronic acid as indicated. A. Images were acquired by 
Leica DMI4000 B (50x magnification) manually and daily for 
4 days. Data shown were representative images from two 
independent experiments with three spheroids in each 
experiment. Scale bar, 500 μm. B. Spheroid sizes on day 4 
were measured using CellProfiler. The areas (µm2) of 
spheroids cultured in different concentrations of collagen I 
on day 4 were graphed. Error bars represented standard 
deviations from three spheroids from one independent 
experiment. The R2 used to measure linearity of was 
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Figure 90. Correlation of spheroid size with collagen I 
content in 3D co-cultures of Capan-2 cells, pancreatic 
stellate cells, collagen I and hyaluronic acid. 
500 Capan-2 cells and 1,000 pancreatic stellate cells (PSCs) 
were mixed in 50 μL of 0.03 mg/mL, 0.05 mg/mL, 0.1 
mg/mL and 0.3 mg/mL collagen I with 3.5 mg/mL 
hyaluronic acid as indicated. A. Images were acquired by 
Leica DMI4000 B (50x magnification) manually and daily 
for 4 days. Data shown were representative images from 
two independent experiments with three spheroids in 
each experiment. Scale bar, 500 μm. B. Spheroid sizes on 
day 4 were measured using CellProfiler. The areas (µm2) 
of spheroids cultured in different concentrations of 
collagen I on day 4 were graphed. Error bars represented 
standard deviations from three spheroids from one 
independent experiment. The R2 used to measure linearity 
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Figure 91. Correlation of spheroid size with collagen I 
content in 3D co-cultures of PANC-1 cells, hepatic stellate 
cells, collagen I and hyaluronic acid. 
500 PANC-1 cells and 1,000 hepatic stellate cells (HSCs) 
were mixed in 50 μL of 0.03 mg/mL, 0.05 mg/mL, 0.1 mg/mL 
and 0.3 mg/mL collagen I with 3.5 mg/mL hyaluronic acid as 
indicated. A. Images were acquired by Leica DMI4000 B (50x 
magnification) manually and daily for 4 days. Data shown 
were representative images from two independent 
experiments with three spheroids in each experiment. Scale 
bar, 500 μm. B. Spheroid sizes on day 4 were measured 
using CellProfiler. The areas (µm2) of spheroids cultured in 
different concentrations of collagen I on day 4 were 
graphed. Error bars represented standard deviations from 
three spheroids from one independent experiment. The R2 
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Figure 92. Correlation of spheroid size with collagen I 
content in 3D co-cultures of PANC-1 cells, pancreatic 
stellate cells, collagen I and hyaluronic acid. 
500 PANC-1 cells and 1,000 pancreatic stellate cells (PSCs) 
were mixed in 50 μL of 0.03 mg/mL, 0.05 mg/mL, 0.1 
mg/mL and 0.3 mg/mL collagen I with 3.5 mg/mL 
hyaluronic acid as indicated. A. Images were acquired by 
Leica DMI4000 B (50x magnification) manually and daily 
for 4 days. Data shown were representative images from 
two independent experiments with three spheroids in 
each experiment. Scale bar, 500 μm. B. Spheroid sizes on 
day 4 were measured using CellProfiler. The areas (µm2) 
of spheroids cultured in different concentrations of 
collagen I on day 4 were graphed. Error bars represented 
standard deviations from three spheroids from one 
independent experiment. The R2 used to measure linearity 
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5.5.2 FAP and p53 expression in 3D co-culture models in collagen I and hyaluronic acid 
 
Previously in section 3.2.3 and section 5.4.2, αSMA was demonstrated not to be a specific marker for 
stellate cells because Capan-2 and PANC-1 were also positively stained by anti-αSMA antibodies. 
Fibroblast activation protein (FAP) has also been regarded as a marker for CAFs in PDAC [Brennen et 
al, 2012; Lo et al, 2017], thus being selected for testing to determine if it could be specifically expressed 
in stellate cells but not in Capan-2 and PANC-1 cells. 
As seen in Figure 93-95, FAP was detected in hepatic stellate cells, pancreatic stellate cells and cancer 
cells, although the stellate cells could be distinguished by their stretched cytoplasm. The staining 
pattern of DAPI, FAP and p53 was similar to the one of DAPI, αSMA and p53 in section 5.4.2. There was 
no marked difference in stellate cell distribution between all the experiment groups. Higher level of 
p53 expression was seen near the edge of the spheroids than the core of the spheroids.  
Currently it is unknown whether growing Capan-2 and PANC-1 cells in 2D, either with or without 
stellate cells could affect FAP expression. Further explorations are required to test the expression of 
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Figure 93. FAP and p53 
expression in the 3D co-
culture models with 0.1 
mg/mL collagen I and 
hyaluronic acid.  
500 cancer cells and 1,000 
hepatic stellate cells 
(HSCs) or pancreatic 
stellate cells (PSCs) were 
mixed in 50 μL of 0.1 
mg/mL collagen I with 3.5 
mg/mL hyaluronic acid, 
grown for 4 days and then 
stained with DAPI (blue), 
and for FAP (red) and p53 
(green). Images were 
acquired by CLSM using 
Zeiss LSM880 with 10x or 
20x objective lens and 
image analysis was done 
in Zen 2.3 (blue edition). 



























Figure 94. FAP and p53 expression in the 3D co-culture models with 0.05 mg/mL collagen I and hyaluronic acid.  
500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) were mixed in 50 μL of 
0.05 mg/mL collagen I with 3.5 mg/mL hyaluronic acid, grown for 4 days and then stained with DAPI (blue), and 
for FAP (red) and p53 (green). Images were acquired by CLSM using Zeiss LSM880 with 10x or 20x objective lens 





























Figure 95. FAP and p53 expression in the 3D co-culture models with 0.03 mg/mL collagen I and hyaluronic acid.  
500 cancer cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) were mixed in 50 μL of 
0.03 mg/mL collagen I with 3.5 mg/mL hyaluronic acid, grown for 4 days and then stained with DAPI (blue), and 
for FAP (red) and p53 (green). Images were acquired by CLSM using Zeiss LSM880 with 10x or 20x objective lens 





5.5.3 Effects of different amounts of collagen I with or without hyaluronic acid on YAP subcellular 
localisation 
 
Next we also explored various factors such as hyaluronic acid (HA) and different types of stellate cells 
on YAP expression and localisation by multi-coloured imaging with confocal microscopy. As shown in 
Figure 96-97, co-localisation of YAP and p53 could be detected near the edge of the spheroids with 
different concentration of collagen I (COL I), indicating nuclear localisation of YAP. In particular, co-
localisation of YAP and p53 was more commonly seen in 3D co-culture spheroids with Capan-2 cells 
and 0.1 mg/mL COL I than the ones with Capan-2 cells and 0.03-0.05 mg/mL COL I, or the ones with 
PANC-1 cells. The core of spheroids with 0.03 or 0.05 mg/mL COL I presented with cytoplasmic 
accumulation of YAP, indicating the translocation of YAP out of the nucleus. 
As demonstrated in Figure 98 and 99, semi-quantification of YAP by CellProfiler was conducted on one 
optical section of the 3D co-culture spheroids with Capan-2 cells with pancreatic stellate cells (PSCs) 
and hepatic stellate cells (HSCs). Because the data representing YAP intensities and ratios did not follow 
normal distribution and not have the same shape of distribution, mean ranks of the datasets were 
compared using a non-parametric Mann-Whitney U test.  
Comparing all the total YAP intensities in the whole cancer cell of each individual cell near the edge and 
the cores, there was no significant difference between the cancer cells near the core of the spheroids 
and the edge in the spheroids in HA and 0.1 mg/mL COL I (mean rank of 82.94 for Capan-2 cells near 
the core and 79.99 for Capan-2 cells near the edge of the spheroids co-cultured with HSCs, p = 0.689; 
mean rank of 105.60 for Capan-2 cells near the core and 112.39 for Capan-2 cells near the edge of the 
spheroids co-cultured with PSCs, p = 0.449), regardless of the cell type of stellate cells. However, 
significantly reduction of total YAP intensities was found in the cancer cells near the core of the 
spheroid compared with the ones near the edge of the spheroids co-cultured with 0.1 mg/mL COL I 
only (mean rank of 61.73 for Capan-2 cells near the core and 84.86 for Capan-2 cells near the edge, p 
= 0.002), suggesting the possible role of HA to induce YAP expression in Capan-2 cells in the current 3D 
co-culture models.  
We hypothesized that the differential expression of YAP in the cells near the core and the edge of the 
spheroids would correlate with the concentration of COL I. When the concentration of COL I was 
reduced to 0.05 mg/mL COL I, there was no significant difference between the cancer cells near the 
core of the spheroids and the edge in the spheroids co-cultured with HA and 0.05 mg/mL COL I (mean 
rank of 73.70 for Capan-2 cells near the core and 82.77 for Capan-2 cells near the edge of the spheroids 
co-cultured with HSCs, p = 0.231). However, cancer cells near the core exhibited significantly lower YAP 
expression than the ones near the edge of the spheroids co-cultured with HA and 0.03 mg/mL COL I 
(mean rank of 39.77 for Capan-2 cells near the core and 86.32 for Capan-2 cells near the edge, p < 
0.001), indicating the amount of COL I in the spheroids could affect YAP signalling. 
Next, we also test the hypothesis that HA and the concentration of COL I could affect the subcellular 
localisation of YAP. Both the ratios of nuclear YAP intensity to total YAP intensity of the whole cell near 
the edge of the spheroids were significantly higher than the ones of cytoplasmic YAP intensity, 
regardless whether the spheroids were cultured with HA or without HA (p < 0.001).  
There was no significant difference in the ratios of nuclear YAP intensity to total YAP intensity of the 
whole cell and the ratios of cytoplasmic YAP intensity to total YAP intensity of the whole cell near the 
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core of the spheroid co-cultured with PSCs without HA (p = 0.16) whereas the ratios of nuclear YAP 
intensity to total YAP intensity of the whole cell decreased significantly compared to the ratios of 
cytoplasmic YAP intensity to total YAP intensity of the whole cell near the core of the spheroid co-
cultured with PSCs in presence of HA (p < 0.001). Nevertheless, there was a significant increase in the 
ratios of nuclear YAP intensity to total YAP intensity of the whole cell compared to the ratios of 
cytoplasmic YAP intensity to total YAP intensity of the whole cell in Capan-2 cells near the core of the 
spheroids cultured with HSCs in presence of HA (p = 0.005). Meanwhile, there was no significant 
difference in the ratios of nuclear YAP intensity to total YAP intensity of the whole cell and the ratios 
of cytoplasmic YAP intensity to total YAP intensity of the whole cell near the edge of the spheroid co-
cultured with HSCs and HA (p = 0.217). It may be possible that different cell type of stellate cells can 
affect the overall outcomes of interaction between stellate cells and cancer cells on YAP signalling.  
Opposing to the data in 0.1 mg/mL COL I in the presence of HSCs and HA, there was a significant 
decrease in the ratios of nuclear YAP intensity to total YAP intensity of the whole cell compared to the 
ratios of cytoplasmic YAP intensity to total YAP intensity of the whole cell in Capan-2 cells near the core 
of the spheroids cultured with 0.03 mg/mL and 0.05 mg/mL COL I in the presence of HSCs and HA (p < 
0.001), indicating higher amount of COL I can induce YAP nuclear translocation near the core of the 
spheroids.   
Compared to the data in Figure 47 where a 3D mono-culture spheroid of Capan-2 was measured, the 
overall level of cytoplasmic YAP dropped while the level of nuclear YAP increased, suggesting a shift in 
the subcellular localisation of YAP in the current models. Consistent with the data in Figure 59 when 
Capan-2 cells were cultured with HA, inclusion of ECM in the 3D co-culture models can cause increased 
nuclear localisation of YAP.    
To summarize, spheroids grown in 0.1 mg/mL COL I exhibited a greater fraction of cancer cells with 
nuclear YAP localisation than spheroids grown in 0.05 mg/mL and 0.03 mg/mL COL I. More nuclear 
accumulation of YAP could be found in the core of spheroids cultured in 0.1 mg/mL COL I. The addition 
of 3.5 mg/mL HA induced YAP expression in the core of spheroids co-cultured with PSCs. However, 
more independent experiments are needed to validate this observation. Cytoplasmic YAP could also 
be detected in those cells with nuclear YAP expression, suggesting accumulation of both nuclear and 
cytoplasmic YAP, consistent with the dynamic YAP signalling in section 5.4. Cells with cytoplasmic 
accumulation of YAP were more often detected near the core of the spheroids than near the edge of 


























Figure 96. YAP expression and subcellular localisation in intact spheroids co-cultured with Capan-2 cells and stellate 
cells.  
Spheroids prepared from 500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) in 
50 μL of 0.1 mg/mL, 0.05 mg/mL, 0.03 mg/mL of collagen I (COL I) and 3.5 mg/mL hyaluronic acid were grown for 4 
days, fixed with PFA and then stained with DAPI (blue) and for p53 (green) and YAP (orange). Images were acquired by 
CLSM using Zeiss LSM880 and image analysis was done in Zen 2.3 (blue edition). Representative images from two 




























  Figure 97. YAP expression and subcellular localisation in intact spheroids co-cultured with PANC1 cells and 
stellate cells.  
Spheroids prepared from 500 PANC-1 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells (PSCs) 
in 50 μL of 0.1 mg/mL, 0.05 mg/mL, 0.03 mg/mL of collagen I (COL I) and 3.5 mg/mL hyaluronic acid were grown 
for 4 days, fixed with PFA and then stained with DAPI (blue) and for p53 (green) and YAP (orange). Images were 
acquired by CLSM using Zeiss LSM880 and image analysis was done in Zen 2.3 (blue edition). Representative 























Figure 98. Identification of YAP localisation in image processing by CellProfiler. 
Spheroids prepared from 500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells 
(PSCs) in 50 μL of 0.1 mg/mL, 0.05 mg/mL, 0.03 mg/mL of collagen I (COL I) with or without 3.5 mg/mL hyaluronic 
acid as indicated were grown for 4 days, fixed with PFA and then stained with DAPI (blue) and for p53 (green) and 
YAP (orange). Images were acquired by CLSM using Zeiss LSM880 and image analysis was done in Zen 2.3 (blue 
edition). Representative images from two spheroids in one independent experiment were shown. Representative 
images processed by CellProfiler was shown, depicting the outlined nuclear areas and the cytoplasmic areas 
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Figure 99. Semi-quantification of YAP subcellular expression near the edge and the core of 3D co-culture 
spheroids.  
Spheroids prepared from 500 Capan-2 cells and 1,000 hepatic stellate cells (HSCs) or pancreatic stellate cells 
(PSCs) in 50 μL of 0.1 mg/mL, 0.05 mg/mL, 0.03 mg/mL of collagen I and 3.5 mg/mL HA were grown for 4 days 
and then stained with DAPI (blue) and for YAP (orange). Images were acquired by CLSM using Zeiss LSM880 and 
image analysis was done in Zen 2.3 (blue edition). Representative images from 2 spheroids in one independent 
experiment were shown. Intensities of YAP in single cell on one optical slide were generated by CellProfiler. 
Whisker box graph was made from all the values of total YAP intensity in the whole cells (A) or the intensity ratios 
of nuclear YAP intensity to total YAP intensity in the whole cell or cytoplasmic YAP intensity to total YAP intensity 
in the whole cell (B) from around 50-150 cells near the core of the spheroid and the edge of the spheroid, using 
Excel. Mean markers were shown. Median was exclusive from quartile calculation. Dots indicated the values in 
cells automatically generated by Excel. Non-parametric Mann-Whitney U test was used to calculate the p values, 
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There are three major strengths and merits of this chapter. Firstly, imaging methods combining optical 
clearing with ethanol and BABB, Z-stack and Airyscan using the Zeiss LSM880 with a 10x objective lens 
are validated to be robust for future phenotypic analysis in thick cancer models with approximately 
500 μm diameter without disturbing the samples, leading to higher efficiency comparing with the 
traditional histology methods such as tissue processing using paraffin. This is the vital step to 
characterize the 3D co-culture models in order to get a clear and defined cell distribution in larger 
volume and more cell layers than single-layered 2D culture. Secondly, compared with commonly used 
of PDAC models using 1-2 mg/mL collagen I concentration [Coleman et al, 2014a; Froeling et al, 2009; 
Kadaba et al, 2013], our study provides evidence of building PDAC models with reduced concentration 
of collagen I. YAP nuclear translocation could be seen in the 3D co-culture models with 0.1 mg/mL 
collagen I, a phenomenon relevant to the PDAC microenvironment in patients. Thirdly, compounds 
PsA-D and Tylophorinine derived from natural products are able to reduce p53, Ki67 and YAP 
expression in the 3D co-culture models with HSCs and PSCs, indicating the potentials of the two 
compounds to inhibit pancreatic cancer growth in the pancreas and the liver.  
Initially, we attempted to develop a 3D co-culture model with PDAC cells and stellate cells without 
animal-derived materials to reduce the cost and the variability of PDAC models. However, the approach 
with PDAC spheroids in stellate cells suspension with pure HA was not able to form a single spheroid. 
One possible reason could be that the distances between stellate cells are too large for them to migrate 
towards the centre of the well. Also, stellate cells might need a scaffold to form a single spheroid in the 
well. As collagen I was added in the model, a single spheroid was formed within 24 hour. The main 
reason for the failure of dropping the spheroid into HA with collagen I to form a models with multilayers 
of stellate cells surrounding the cancer cells core was probably because cancer cells did not 
communicate with stellate cells sufficiently through chemoattractant and stellate cells were prone to 
attach to the same cell type in 3D conditions. 
When we analysed the protein expression in the 3D co-culture models, we have the following questions 
in mind: why is p53 expression reduced at the core of the spheroids/at high cell density? Does p53 
reduction happen before or after cytoplasmic retention of YAP?  
As seen in chapter 3 when studying 3D mono-culture models of PDAC cells without ECM, p53 
expression was high but YAP still mainly retained in the cytoplasm of the majorities of cancer cells. 
However, reduction of p53 expression correlates with YAP cytoplasmic localisation in the 3D co-culture 
models of PDAC in this chapter. Unfortunately, 3D mono-culture of PDAC cells with ECM failed to form 
spheroids within the same period of time as the 3D co-culture models. Even when we attempted to 
perform the immunofluorescence on the fractions of 3D mono-culture of PDAC cells with collagen I 
collected from the wells, they disappeared during the process and thus this experiments were stopped. 
Based on the data from other research groups and the data from section 4.2 where HA was shown to 
induce YAP nuclear translocation, the role of ECM has been considered mainly to facilitate YAP entering 
the nucleus [Miroshnikova et al, 2017; Rice et al, 2017]. Wild-type p53 is a tumour suppressor as a pro-
apoptotic inducer whereas mutant p53 has anti-apoptotic and tumour-promoting function, 
contributing to cancer progression [Muller et al, 2014; Ozaki et al, 2011]. The YAP localisation pattern 
was the same in Capan-2 cells that express a wild-type p53 and in PANC-1 cells that express a mutant 
p53 [Deer et al, 2010]. In the case of mutant p53, this protein could bind to YAP and promote its nuclear 
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accumulation, as suggested by Ferraiuolo et al [Ferraiuolo et al, 2017]. However, some PANC-1 cells 
presented with mutant p53 expression and cytoplasmic YAP expression, indicating other mechanisms 
may need to be explored to link p53 signalling with YAP signalling in these 3D co-culture spheroids. In 
the beginning, we were convinced by the reported data on the existence of wild-type p53 in Capan-2 
cell lines [Deer et al, 2010] and confused by our data indicating the possible binding of wild-type p53 
with YAP which is inconsistent with the proposed crosstalk between p53 signalling and YAP signalling 
[Ferraiuolo et al, 2017]. Thus, more efforts were used to investigate the p53 status in Capan-2 cell lines. 
A review was found and more papers were read carefully. As reviewed by Berglind et al., three different 
p53 statuses in Capan-2 cell line have been reported: wild-type, mutated at p.R273H or p53 gene 
deletion [Berglind et al, 2008]. In 1992, sequence analysis of exons 5-8 of the p53 gene in Capan-2 cells 
revealed point mutation at Arg273His [Ruggeri et al, 1992]. In 1994, Japanese researchers reported 
that Capan-2 cells showed a 200-bp deletion of the 3’ side of exon 4 and a frame shift using PCR, a G-T 
base pair substitution at the third nucleotide of codon 125 using direct sequencing and were weakly 
positive for p53 using anti-p53 antibody (DO7) that recognized both wild-type and mutant p53 in 
immunocytochemistry [Suwa et al, 1994], concluding that Capan-2 cells expressed mutant p53. 
However, in the same year, mutant p53 protein was reported to be undetectable in Capan-2 cells by 
immunocytochemistry and immunoblotting using both anti-p53 antibodies (pAB421) that bind to  wild-
type and mutant p53 and anti-p53 antibodies (pAB240) that bind to mutant p53 while mutant p53 gene 
was also not detected using PCR for amplification of exons 5-9 of the p53 gene by German researchers 
[Simon et al, 1994], leading to the opposite conclusion as the one in 1992 and drawn by the Japanese 
research group. Two research groups reported mutant p53 in exon 4 while one group could not detect 
the amplification of exons 5-9 of the p53 gene. We wonder if using the same PCR protocol would have 
produced the same result. In the same group, mutant p53 gene was detected but weak staining of 
mutant p53 protein was found. We wonder if using another antibodies against mutant p53 would have 
detected p53 expression. Since our data indicated possible binding of p53 to YAP in Capan-2 cells, we 
postulated that the Capan-2 cell lines in our lab express mutant p53, which needs further verification 
using other antibodies specific for mutant p53. Therefore, reduction of mutant p53 in Capan-2 cells 
and PANC-1 cells could cause the disassociation of YAP with mutant p53, leading to the lack of binding 
partner of YAP in the nucleus that could retain nuclear localisation of YAP.  
Alternatively, hypoxia and depletion of nutrients such as glucose occurring at the core of the spheroids 
may cause the imbalance of mechanisms to promote YAP nuclear accumulation and the ones to 
promote YAP cytoplasmic accumulation, independent of p53 signalling. Immunoprecipitation to study 
the binding of p53 to endogenous YAP is necessary to elucidate the interaction of YAP signalling and 
P53 signalling. More specific antibodies against wild-type p53 and mutant p53 or other gene 
sequencing methods were helpful to distinguish the isoforms of p53 in the current co-culture models. 
Factors that affect YAP localisation include: 
 The stellate cells can be in close contact with a portion of cancer cells, as seen in section 5.3 
where stellate cells attached to certain regions of the edge of cancer spheroids. However, some 
stellate cells are not in a close cell-cell contact with cancer cells, as noted in section 5.4 and 
5.5, so the influence of stellate cells on YAP signalling based on the cell-cell contact which 
associated with nuclear exclusion of YAP [Gumbiner et al, 2014] may be minimal. 
 Spheroid volume increased in relation to higher amounts of collagen I which associated with 
nuclear accumulation of YAP [Rice et al, 2017].   
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 The distance of cancer cells to the spheroid surface determine the oxygen level and nutrient 
level which related to cytoplasmic retention of YAP [Mo et al, 2015; Wang et al, 2015]. 
 Higher amounts of collagen may affect the density and the tension sensed by cancer cells which 
could change from the edge to the core [Aragona et al, 2013; Butcher et al, 2009; Dupont et 
al, 2011].  
 High cancer cell-cell contact at the core could lead to nuclear exclusion of YAP [Gumbiner et al, 
2014]. 
Quantification of YAP expression and the location of cancer cells in the spheroids will need to be 
delineated in order to get a better understanding of how different factors affecting YAP signalling in 
the current 3D co-culture PDAC models, which will contribute to untangling the similar complex 
networks also expected for cancer cells to encounter in PDAC. 
The strengths and limitations of the 2:1 ratio of stellate cells to cancer cells is that the cancer model 
closely resembled the pathophysiological barriers as ECM organization, where a few stellate cells 
scattered, wrapping around cancer cell clusters; however, the insufficient number of stellate cells 
shown in the Figure 79, 80, and 93-85 comparing to clinical biopsies reported [Coleman et al, 2014b; 
Erkan et al, 2007; Gopinathan et al, 2015; Hwang et al, 2016; Logsdon et al, 2015; Whatcott et al, 2015; 
Yen et al, 2002] made the models less ideal to recapitulate the intense interaction between stellate 
cells and cancer cells found in patients with late-stage PDAC. Nevertheless, based on the data 
presented in this chapter, future work could easily be built on choosing the highe ratio of stellate cells 
to cancer cells such as 5:1 or 10:1 to carry on refining the 3D co-culture models. 
Another major drawback of the models described in this chapter is the lack of immune cells that are 
abundant in the PDAC tumour environment. At present, it is unclear which receptors and cytokines 
that might be provided by immune cells are needed to recapitulate the complex networks affecting 










In the current studies, direct mixture of cancer cells and stellate cells co-cultured in a scaffold-free 
environment recreates a model with cancer cells wrapping around a sphere of stellate-cells. Thus, this 
format fails to establish a model emulating the organization observed in PDAC tumours where clusters 
of cancer cells are surrounded by and intermingle with multiple layers of stellate cells. Higher level of 
endogenous YAP is found in the cytoplasm than in the nucleus of the majority of cancer cells in the 
direct mixture of cancer cells and stellate cells co-cultured in a scaffold-free environment, indicating 
that a small amount of YAP might be sufficient to drive pancreatic cancer growth.  
Collagen I, collagen IV, fibronectin and laminin can be detected in Myogel. Myogel may be 
biocompatible with certain subtypes of pancreatic cancer cells. Unmodified hyaluronic acid (HA) 
derived from Streptococcus equi is biocompatible with pancreatic cancer cells and promotes nuclear 
accumulation of YAP.  
Dropping of PDAC mono-culture spheroids into a stellate cells suspension in HA or HA with collagen I 
is able to establish a 3D co-culture model where only fractions of the cancer cells have contacted with 
stellate cells without the multi-layered stellate cells barrier around the cancer cells core.  
Mixing PDAC cells and stellate cells in a collagen I matrix with or without HA can result in the formation 
of multiple cancer cells cores inside the 3D co-culture models that resemble the fibrotic cancer 
microenvironment in patients with advanced and metastatic PDAC. Dynamic YAP subcellular 
localisation is found in these 3D co-culture models of PDAC cells and stellate cells. Reduction of p53 
expression correlates with YAP cytoplasmic localisation in these 3D co-culture models of PDAC cells 
and stellate cells. Potential anti-cancer compounds Pseudopterosin A-D and Tylophorinine, derived 
from natural products, can reduce p53, Ki67 and YAP expression in these 3D co-culture models of PDAC 
cells and stellate cells. 
Imaging methods combining optical clearing with ethanol and BABB, Z-stack and Airyscan using the 
Zeiss LSM880 with a 10x objective lens are validated to be robust for future phenotypic analysis in thick 
cancer models with approximately 500 μm diameter without disturbing the samples, leading to higher 
efficiency comparing with the traditional histology methods such as tissue processing using paraffin.  
  
6.2 Future direction for developing biomaterials from porcine species for 
modelling pancreatic cancer 
 
Porcine species has been regarded to share a number of similarities such as physiology and metabolic 
profile with humans [Gutierrez et al, 2015], thereby positioning themselves as better models than 
rodents in some research areas. Recently, pancreata from mice [Goh et al, 2013], rats [Yu et al, 2018] 
and pigs [Elebring et al, 2017; Mirmalek-Sani et al, 2013] have been attempted be developed into a 
novel extracellular matrix scaffold for pancreas bioengineering. For modelling pancreatic cancer 
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microenvironment, one of the research themes is finding a cost-effective way to recapitulate an 
environment for tumour cells and stromal cells grown in vitro to preserve their phenotypes and 
genotypes as close as the ones in patients with PDAC [Baker et al, 2016]. Conventional biomaterials 
such as rat tail collagen I and Matrigel® derived from rodents have been a standard of components in 
building 3D culture models using cancer cell lines and organoids from patients. It is still debatable to 
what degree that the rodents-derived materials could affect the biological properties of cancer cells. 
Meanwhile, experts in the research field have also raised the question of whether the cost of modelling 
PDAC could be reduced by novel biomaterials [Baker et al, 2016]. The main reason to choose rat tail 
collagen I and Matrigel® derived from rodents is that they contain the major components in ECM that 
are abundant in PDAC microenvironment. If a biomaterial could facilitate the cancer models achieve 
the similar levels of ECM in PDAC, initial attempts could be made to test its feasibility for modelling 
pancreatic cancer. 
For the purpose of reducing animal use for addressing public sensitivities and moral obligations [Brown 
et al, 2018], porcine pancreas will be better than the ones from mice and rats due to the difference in 
weight. The mean weight of the whole porcine pancreas was 347±103 g, with a range from 190 to 698 
g per pig [Ferrer et al, 2008]. The wet weight of pancreas in 3, 12 and 18 months old rats was reported 
to be 0.8-1 g per rat [Jiang et al, 2013]. The total weight of the dry pancreas in 11-week-old and 12-
month-old male and female rats was reported to be around 0.3 – 0.5 g per rat [Reaven et al, 1987]. 
Among rodent species and porcine species, the size of mice is the smallest, making the weight of the 
pancreas less than the one in rats. Complying with the same principle, the amount of porcine skeletal 
muscle (PSM) per pig is higher than that of pancreas. Besides, collagens content of the muscle extract 
is reported to be higher than the one in pancreas. The collagens content was 486.7 ± 133 µg per mg of 
the skeletal muscle extract [Abberton et al, 2008]. The collagens content in porcine pancreas was 
reported to be 0.029 µg per mg [Mirmalek-Sani et al, 2013] and 40 µg collagens per mg wet tissue was 
detected by another research group [Elebring et al, 2017]. Those three research groups all used Sirius 
Red dye to measure the collagens content. Beside, fibronectin and laminins are also found in extract 
from skeletal muscle [Abberton et al, 2008; Wolf et al, 2012]. Although the high ECM content was not 
found in the current study, the lack of purification and the detection methods could affect the 
reproducibility. Also, the strain of pigs may also be important to keep a record of in term of the ECM 
content. Therefore, further exploration to refine the protocols for extracting ECM from PSM in the 
future is needed. 
Indeed, maintaining the biological properties of cancer cells should be the priority in choosing the right 
biomaterial so that effective treatments could be developed using the novel in vitro cancer models 
[Baker et al, 2016]. More studies will need to be undertaken to compare genotypes and phenotypes of 
tumour cells and stromal cells grown in the extract from porcine muscle and porcine pancreas with the 
ones in patients. If no significant difference of genotypes and phenotypes of tumour cells and stromal 
cells could be found when they culture in the extract from porcine muscle and porcine pancreas, 
together with accuracy in matching clinical samples, then the porcine muscle would worth being 





6.3 Future direction for refinement of the current 3D co-culture models 
 
In order to develop an in vitro biological model mimicking PDAC in patients, it is imperative to delineate 
the components as the building blocks with the accurate ratios and distribution. It is well-known that 
around 10% of cells within PDAC microenvironment are pancreatic cancer cells [Neesse et al, 2011]. 
Compared to primary tumours in the pancreas site, more cancer cells are detected at metastatic site 
in the liver of patients with PDAC [Whatcott et al, 2015]; however, the exact percentage of cancer cell 
regions in the liver has not yet been confirmed in large cohort of patients with metastatic PDAC. The 
animal models of human PDAC have not been able to recreate the highly fibrotic microenvironment 
[Logsdon et al, 2015]. The 3D co-culture models with human cancer cell lines, patient-derived stellate 
cells and ECM possess the potential to be manipulated in vitro to create a more realistic model with 
cell ratios and distribution resembling the situation in patients with PDAC than the animal models. 
Although the current 3D co-culture models of stellate cells to cancer cells at a 2:1 cell ratio have 
recreated a microenvironment where cancer cells located near the core of the models, surrounded by 
collagen I and stellate cells, there are a few improvements could be made.  
Firstly, the area of stellate cells within the models shown in Figure 79, 80, and 93-95 was not the same 
as the one detected by histology and immunochemistry [Coleman et al, 2014b; Erkan et al, 2007; 
Gopinathan et al, 2015; Hwang et al, 2016; Logsdon et al, 2015; Whatcott et al, 2015; Yen et al, 2002], 
making them less ideal to recapitulate the intense interaction between cancer cells and stellate cells. 
The areas of stellate cells within the models of stellate cells to cancer cells at a 10:1 cell ratio illustrated 
in Figure 68 represented a closer situation to the ones in patients compared to the models with a 2:1 
cell ratio of stellate cells to cancer cells. Although the 2:1 ratio of stellate cells to cancer cells were used 
commonly [Coleman et al, 2014b; Fujiwara et al, 2016; Lee et al, 2018a; Ware et al, 2016], higher ratios 
of stellate cells to cancer cells, which is feasible based on data presented in the current section 5.3, 
could have the potential to make the cancer models recapitulate the realistic ratio of 10% cancer cells 
in the microenvironment as found in PDAC patients. 
Secondly, the current 3D co-culture models lack the characterisation of ECM. The phase-contrast 
images shown in the Figure 75-78 and 89-92 suggested the strong likelihood of collagen I present in 
the models; however, the solid evidence should be obtained by specific detection using antibodies 
against collagen I. Likewise, detection of fibronectin, hyaluronic acid and laminins using antibodies is 
also required to provide as parameters to adjust the initial ECM concentrations. 
Thirdly, inclusion of immune cells is also critical for modelling PDAC. Tumour-infiltrating immune cells 
in PDAC tumours are commonly detected [Bailey et al, 2016; Seo et al, 2017]. Immunotherapeutic 
strategies have provided novel approaches to treat PDAC [Neoptolemos et al, 2018], which required 
realistic models to test their efficacy and effectiveness. Recently, immune cells have been successfully 
incorporated into an organoid model of PDAC [Tsai et al, 2018]. Therefore, further exploration adding 
immune cells into in vitro PDAC models will be achievable. 
Fourthly, more specific and stable markers for cancer cells are needed in the current models. In the 
Figure 27-28 and 93-95, cancer cells presented with negative staining for p53 were found. While it may 
create an opportunity to study the p53 signalling in the models, p53 expression level might not be a 
good indicator for cell growth in terms of testing the therapeutic agents to inhibit cancer cell 
proliferation. Alternatively, construction of pancreatic cancer cell lines with fluorescent proteins has 
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been successfully established [Hiroshima et al, 2014; Katz et al, 2003; Park et al, 2015]. For instance, 
green fluorescent protein expressing PANC-1 cell lines and MIA-PaCa-2 cell lines have been used in 
xenograft models [Hiroshima et al, 2014; Park et al, 2015]; red fluorescent protein expressing MIA-
PaCa-2 cells have been visualized to study tumour growth and metastasis in vivo [Katz et al, 2003]. 
Thus, the feasibility of using genetic modified cancer cell lines with fluorescent protein could be tested 
in the 3D co-culture models with the protocol developed in the current study.  
 
6.4 Future direction for application of the current 3D co-culture models in 
screening anti-cancer agents 
 
In 1980s, the US National Cancer Institute (NCI) 60 tumour cell line anticancer drug screen was 
established, using 96-well plates to culture leukaemia, colon, lung, CNS, renal, melanoma, ovarian, 
breast and prostate cancer cell lines as 2D cancer models and screen for cytotoxic compounds 
[Shoemaker, 2006]. This kind of screening contributes to the translational examples such as eribulin 
mesylate to treat late-stage breast cancer and bortezomib to treat myeloma [Shoemaker, 2006]. 2D 
culture has the advantages for scalable high-throughput screening such as low cost and fast 
establishment. However, the unrealistic cell-cell spatial organization, cell proliferation and growth, cell 
polarity and tumour progression, migration and response to therapies have been acknowledged to be 
the limitations of 2D culture [Hoarau-Vechot et al, 2018; Yamada et al, 2007]. In recent year, 3D co-
culture models have been refined to be more easy-to-use than before. The protocol of the current 
study is based on other established protocols with minor modification such as reduction of use of 
centrifugation [Friedrich et al, 2009; Kota et al, 2018], which provides evidence that 3D co-culture 
models are suitable to use in a 96-well plate for screening of anti-cancer agents. It is predicted to be 
applicable in 384-well plates, both of which will fit the automatic drug screening equipment currently 
developed for conventional 2D culture in the future. 
With the development of bio-printing, 3D co-culture models can be built in an accurate, defined, 
consistent, fast and precise manner. Cancer cells, fibroblasts, immune cells and ECM can be mixed with 
various approaches and spatially dispensed in a microscale within seconds, aided by state-of-art 
equipment [Zhang et al, 2016]. This kind of automation will also increase the efficiency of establishing 
the models and reduce the unavoidable human error during manual handling large numbers of 
samples. 
However, it is also imperative to compare the accuracy and effectiveness of the 3D co-culture models 
with the conventional animal models and biopsies from patients. Researchers have been gathering 
data on the accuracy of organoids to mimic cancer microenvironment in patients by comparing with 
clinical specimen and xenografts [Boj et al, 2015; Gao et al, 2014]. Clinical trials may need to be 
conducted to compare the outcomes of drug treatment among animal models, 3D co-culture models 






6.4 Future direction for semi-quantification of YAP expression  
 
In the current study, semi-quantification of YAP expression with image processing software CellProfiler 
has been conducted on one optical section. Measurement of YAP intensities in hundreds of cells was 
aided by machine learning, reducing the burden of manual identification. However, there are a few 
modifications should be made in the future. 
Firstly, more evidence for efficient antibody penetration in the whole spheroids processed using the 
current protocol should be collected. The experiment on p53 quantification was only performed once, 
which is insufficient for testing the reproducibility. Conventional methods for detecting cancer markers 
should also be conducted on the same batch of 3D co-culture spheroids to produce histology slides, 
which should be analysed with the similar immunofluorescence protocol in the current study. If there 
is no statically significant difference in certain protein expression patterns and protein intensities 
between the cells near the edge and the core of the spheroids, or the differential expression patterns 
and protein intensities are statically comparable between the detection on staining the whole spheroid 
and the histology slide, then concrete evidence on efficient antibody penetration in whole spheroids 
will be attained.   
Secondly, there is a need for membrane markers on PDAC cells to aid the identification of cell borders. 
In the current study, the borders used to separate individual cells were processed using the images 
with YAP staining. However, YAP distributes homogenously in the nucleus and the cytoplasm in the 3D 
models without a defined membrane localisation. Therefore, after verification of the accuracy of the 
module ‘IdentifySecondaryObjects’, there were a number of cells with inaccurate identification of the 
cytoplasmic YAP, which were excluded from the final calculation. It is uncertain that to what degree 
this elimination of data will affect the outcomes of the measurements. Undoubtedly, counting as many 
cells as possible should be one of the effective strategies to get the accurate overview of the protein 
expression in the 3D models. There are a few membrane proteins in the PDAC cell lines could be tested 
in the future, such as EGFR, E-cadherin and TGF-β type I receptors in both Capan-2 cells and PANC-1 
cells [Kimple et al, 2010; Subramanian et al, 2004; Toyoda et al, 2005] and CD44 in PANC-1 cells [Zhao 
et al, 2016b]. 
Thirdly, in order to increase the efficiency to a greater extent, high-content microscope with 
programming is required to acquire and process a large number of optical sections from 3D co-culture 
models. 3D voxel measurement of Ki67 and YAP could be conducted in CellProfile. However, the 
immense workload requires more than one researcher to draw the conclusion quickly and accurately. 
Artificial intelligent will certainly speed up the process. 
 
6.5 Future direction for studying the crosstalk between p53 signalling and YAP 
signalling  
 
In the current study, p53 expression was high but YAP still mainly retained in the cytoplasm of the 
majorities of cancer cells in the 3D mono-cultures of PDAC cells without ECM. However, reduction of 
p53 expression correlated with YAP cytoplasmic localisation in the 3D co-culture models of PDAC. 
Based on the data from other research groups and the data from section 4.2 where HA is shown to 
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induce YAP nuclear translocation, the role of ECM is considered mainly to facilitate YAP entering the 
nucleus [Miroshnikova et al, 2017; Rice et al, 2017]. However, in the presence of HA and collagen I, a 
group of cells still presented with cytoplasmic accumulation of YAP and negative staining of p53. We 
postulated that disassociation with p53 may cause translocation of YAP from the nucleus to the 
cytoplasm. Consistent with the proposed role of mutant p53 in YAP signalling, mutant p53 could bind 
to YAP and promote its nuclear accumulation, as suggested by Ferraiuolo et al [Ferraiuolo et al, 2017]. 
This could be the case for PANC-1 cells in the current co-culture models. As for the Capan-2 cells, the 
first step should be the validation of p53 status using specific antibodies against mutant p53, which are 
available as commercial ones and self-produced ones [Hwang et al, 2018]. Meanwhile, advanced 
sequencing analysis should be used together with PANC-1 cells as positive controls. Correlation of p53 
expression and nuclear YAP expression needs to be quantified using CellProfiler to measure the p53 
intensity. Immunoprecipitation to study the p53 binding to endogenous YAP is necessary to elucidate 
the interaction of YAP and p53. However, immunoprecipitation may disrupt the binding of p53 to YAP 
during the experimental procedure, leading to false findings indicating p53 may not bind to YAP. Long-
term searching for the suitable antibodies to perform the immunoprecipitation may be required. 
Development of Förster resonance energy transfer and fluorescence lifetime imaging microscopy to 
detect protein interaction in intact spheroids may be helpful in the future without disturbing the 3D 
structure [Margineanu et al, 2016]. 
 
6.6 Future direction for Pseudopterosin A-D and Tylophorinine 
 
The current studies have shown the potential of Pseudopterosin A-D (PsA-D) and Tylophorinine to 
inhibit PDAC growth in the liver and the pancreas, using a 3D co-culture PDAC model. There is still a 
long way to go for PsA-D and Tylophorinine from bench to bedside in terms of cancer treatment. Two 
successful natural products, irinotecan (camptothecin analogue) and paclitaxel that have been 
translated from discovery to clinic, provide excellent examples for the development of PsA-D and 
Tylophorinine [Wall et al, 1996]. Irinotecan and paclitaxel have been used in as parts of combinatory 
treatments for several cancers including PDAC [Neoptolemos et al, 2018; Wall et al, 1996]. 
Similar to paclitaxel [Cragg, 1998], the issue of the limited supply of the two compounds needs to be 
addressed [Berrue et al, 2011; Gantait et al, 2017]. PsA-D are originally derived from the gorgonian 
coral Pseudopterogorgia elisabethae [Mydlarz et al, 2003]. Tylophorinine is extracted from a perennial 
vine called Tylophora indica (Burm. f.) Merrill [Gantait et al, 2017]. Currently, researchers are 
optimising the synthesis of PsA-D and Tylophorinine for sustainable supplies due to environmental 
concerns [Gantait et al, 2017; Mydlarz et al, 2003]. Once the synthesis protocols are standardized, the 
residues from chemical reaction will be controllable to prevent potential harm to the patients.  
Both of irinotecan and paclitaxel first exhibited anti-tumour activity against human tumour xenograft 
models and then were further investigated to uncover mechanism of actions during early years [Wall 
et al, 1996]. This kind of phenotypic screening has been considered with insufficient knowledge of the 
molecular mechanisms of disease, thereby being used less than the screening approach based on 
molecular mechanism of action [Swinney et al, 2011]. Therefore, mechanism of actions of PsA-D and 
Tylophorinine are being investigated across labs. The mechanism of PsA-D has been elicited to block 
the glucocorticoid receptor alpha signalling and NF-κB Signalling in breast cancer cell lines grown as 2D 
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and 3D [Sperlich et al, 2017; Sperlich et al, 2018]. A tylophorine analogue, DCB-3503, can inhibit 
pancreatic cancer cell growth by reducing cell cycle regulatory proteins and inhibiting NF-κB signalling 
in pancreatic cancer cell lines [Shiah et al, 2006]. The current study demonstrated PsA-D and 
Tylophorinine can attenuate expression of p53, Ki67 and YAP in a 3D co-culture PDAC models. However, 
whether targeting p53 and YAP is a direct or indirect effect of PsA-D and Tylophorinine in pancreatic 
cancer cells needs further exploration. Incubation of normal cells without mutant p53 expression or 
nuclear accumulation of YAP in 3D with the same concentration of PsA-D and Tylophorinine may be 
also able to test the specificity of those compounds.  
Another issue that needs to be addressed is related to drug-like properties, such as solubility. The poor 
solubility of paclitaxel in water and its relatively high dose requirements led to a surfactant formulation 
with Cremophor EL, causing serious allergic reactions including anaphylaxis in patients [Cragg, 1998]. 
PsA-D and Tylophorinine require DMSO to be dissolved. In particular, the IC50 of PsA-D is high, 
indicating the possible high dose to be used in clinic. How to increase solubility of PsA-D and 
Tylophorinine without affecting potency may needs exploration. 
After addressing the aforementioned issues, attention should be drawn to the safety-related issue. The 
adverse effects of drugs have led to high attrition rate in the drug discovery and development process 
[Bowes et al, 2012]. Therefore, a panel of targets that cause potential hazard in human body have been 
proposed, such as the GPCRs, ion channels, neurotransmitter transporters, two nuclear hormone 
receptors, to guide the assessments of the safety of compounds [Bowes et al, 2012]. Toxicology based 
on those targets will need to be assessed on PsA-D and Tylophorinine to come up with preventative 
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